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CHAPTER I 
 
VOLTAGE-GATED SODIUM CHANNELS ASSOCIATED WITH EPILEPSY 
 
Introduction 
Epilepsy is a widespread and complex brain disease characterized by abnormal 
neuronal signaling. To help clinicians diagnose and treat patients, the epilepsies have 
been divided into epilepsy syndromes based on age of onset, types of seizures, duration 
of symptoms, severity, and etiology. These groupings allow clinicians to utilize the most 
effective treatment plan for a particular epilepsy. Channelopathies encompass a subset 
of genetic epilepsy syndromes with associated mutations in genes encoding various 
voltage-gated and ligand-gated ion channels such as potassium and sodium channels 
(George, Jr., 2005). Commonly used anticonvulsant agents including phenytoin, 
carbamazepine, valproate, lamotrigine and topiramate target voltage-gated sodium 
channels (Ragsdale and Avoli, 1998). Investigating the molecular basis underlying 
inherited epilepsy disorders is essential for proper identification and treatment. 
 
Epidemiology of genetic forms of epilepsy 
 The prevalence of epilepsy in the general population is 0.5% with a lifetime 
prevalence of 3%. Over 2.7 million Americans suffer from epilepsy (Centers for Disease 
Control). Epidemiological studies of Western populations have revealed that 5% of first-
degree relatives of patients with epilepsy also have epilepsy, suggesting a moderate 
genetic component (Beaussart and Loiseau, 1969; Bianchi et al., 2003; Vestergaard et 
al., 2007). Although inherited epilepsy syndromes represent a small subset of all 
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epilepsy, genetic risk factors have been increasingly identified and implicated in forms of 
epilepsy not initially labeled as genetic.  
In the 1930s, William Lennox became the first to apply the scientific method to 
inherited seizure disorders through examining twin cohorts. Monozygotic twins showed a 
high concordance (40-50%) whereas dizygotic twins had a moderate concordance (10-
15%) suggesting a strong genetic component in epilepsy (Lennox, 1951; Berkovic et al., 
1998; Kjeldsen et al., 2003). Subsequent twin studies have not always resulted in 
reproducible genetic risk factors for specific genetic epilepsy phenotypes. Instead most 
of the advances in the molecular mechanisms underlying epilepsy were discovered 
through multiplex family or family aggregation studies (Helbig et al., 2008). 
 In the late 1980s to 1990s, attempts to isolate epilepsy-associated mutations 
identified large candidate chromosomal regions through linkage analysis in large families 
with a single epilepsy syndrome. The positional cloning technique was employed to 
narrow down the candidate region by isolating overlapping DNA fragments until discrete 
genes associated with the phenotype were identified (Frankel, 1999). Candidate genes 
typically encode proteins thought to be important in neuronal excitability. The candidate 
gene is then directly sequenced in affected family members to search for a rare mutation 
or a single nucleotide polymorphism (SNP). Once identified, nonsense, frameshift, or 
splice site mutations can easily be postulated to have deleterious effects on the protein, 
but missense mutations often require functional data to be distinguished from common 
benign SNPs (George, Jr., 2004). 
 
Genetics of inherited epilepsy 
Idiopathic and symptomatic epilepsies are two broad categories into which 
epilepsy syndromes can be divided. Idiopathic epilepsies are those occurring in the 
absence of brain lesions or neurological deficits, and without any known external 
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causes. Most cases of Idiopathic generalized epilepsy (IGE) are thought to have 
polygenic inheritance but this is the category of epilepsy disorders most commonly 
thought to be caused by mutations in a single gene. In contrast to IGE, symptomatic 
epilepsies have underlying brain abnormalities or neurological insults. A subset of 
symptomatic epilepsies is caused by complex genetic syndromes. As genetic factors are 
increasingly implicated in all types of epilepsy, divisions between the categories are 
becoming less distinct. Now epilepsy is more commonly postulated to be a spectrum of 
disorders with those entirely caused by a mutation in a single gene at one end and those 
with no identifiable genetic susceptibility at the other (Figure 1) (Berkovic et al., 2006; 
Helbig et al., 2008). 
Studying rare monogenetic epilepsy syndromes increases understanding of 
general epilepsy pathophysiology. Monogenic epilepsies are easier to study than those 
with polygenic inheritance, a combination of acquired and genetic factors, or no known 
genetic risk factors (Figure 1). Often the genes affected in Mendelian epilepsies have 
altered function in more common epilepsy syndromes. By understanding how 
dysfunction of these genes modulates neuronal excitability, we may be able to better 
understand more genetically complex forms of epilepsy. Rare monogenetic epilepsies 
may also contribute to our understanding of genes involved in normal brain function and 
the diversity of mechanisms contributing to altered excitability. Also studying Mendelian 
epilepsies can aid with discovery of avenues for novel therapeutic treatments.  
Most of the genes known to be mutated in genetic epilepsies encode for voltage-gated 
or ligand-gated ion channels, though there are recent examples of non-ion channel 
proteins increasing susceptibility for or causing certain forms of epilepsy. Examples of 
mutations identified in monogenetic epilepsy syndromes are described below: first the 
epilepsy syndromes related to defective ion channels will be explored and secondly a 
few novel genes will be discussed (Table 1). 
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Figure 1. Neurobiological spectrum of epilepsy. Idiopathic epilepsies are commonly associated with monogenetic mutations in ion 
channels. Mutant ion channels can lead to altered neuronal excitability. Some epilepsy syndromes result from polygenic inheritance 
or from the interplay between genetic and acquired factors. These syndromes may be the result of differential gene regulation or 
post-transcriptional modifications to ion channels. Symptomatic epilepsies result from congenital malformations, stroke, trauma, or 
neoplasia. Rarely, symptomatic epilepsies may be caused by genetic syndromes. Increasing evidence also shows that symptomatic 
epilepsies, especially those without an identifiable brain lesion, have underlying alterations of ion channel function. Epilepsies used to 
be easily categorized as genetic or acquired, but the distinctions between these have now become less distinct. Adapted from 
(Berkovic et al., 2006; Helbig et al., 2008). 
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Table 1. Genes involved in inherited forms of epilepsy 
Genes Syndrome§ Chromosome 
   
Sodium channel   
SCN1A GEFS+ type 2 2q24.3 
 ICEGTC  
 SMEI  
 IS (West Syndrome)  
 TLE  
SCN2A BFNIS 2q23-q24 
 BFIS  
 GEFS+  
 SMEI  
SCN3A Cryptogenic pediatric partial 
epilepsy 
2q24 
SCN1B GEFS+ type 1 19q13.1 
Potassium channel   
KCNQ2 BFNC type 1 20q13.3 
KCNQ3 BFNC type 2 8q24 
KCNA1 Partial epilepsy / Episodic 
ataxia 
12p13.32 
   
Calcium channel   
CACNA1A IGE / Episodic ataxia type 2 19p13.2-p13.1 
CACNA1H CAE 16p13.3 
CACNB4 IGE / JME 2q22-q23 
  7
Chloride channel   
CLCN2 CAE / juvenile absence 
epilepsy/ JME / Epilepsy with 
grand mal seizure on 
wakening 
3q27-q28 
GABA Receptor   
GABRA1 JME / CAE type 4 5q34-q35 
GABRG2 GEFS+ type 3 / CAE type 2/ 
SMEI 
5q31.1-q33.1 
GABRD GEFS+ 1p36.3 
Acetylcholine Receptor   
CHRNA4 ADNFLE type 1 20q13.2-q13.3 
CHRNB2 ADNFLE type 3 1q21.3 
Novel genes   
LGI1 TLE 10q24 
MASS1/VLGR1/GPR98 FS with afebrile seizures 5q13 
EFHC1 JME 6p12.3 
BRD2 JME 6p21.3 
ME2 IGE 18q21 
CNTNAP2 Focal epilepsy/ developmental 
delay / cortical migration 
abnormalities 
7q35-q36 
ARX X-linked West Syndrome (IS) Xp21 
ATP1A2 BFIS 1q21-q23 
§ GEFS+ – generalized epilepsy with febrile seizures plus, ICEGTC – intractable 
childhood epilepsy with generalized tonic-clonic seizures, SMEI – severe 
myoclonic epilepsy of infancy, IS – infantile spasms, TLE – temporal lobe 
epilepsy, BFNIS – benign familial neonatal-infantile seizures, BFIS – benign 
familial infantile seizures, BFNC – benign familial neonatal convulsions, IGE – 
idiopathic generalized epilepsy, CAE – childhood absence epilepsy, JME – 
juvenile myoclonic epilepsy, ADNFLE – autosomal dominant nocturnal frontal 
lobe epilepsy, FS – febrile seizures 
  8
In 1995, a large Australian family was identified with several members affected 
by autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Onset of ADNFLE is 
in middle childhood and is characterized by clustered seizures at night during dozing or 
before awakening (Berkovic and Scheffer, 1997). The ADNFLE phenotype was linked to 
20q13.2 (Phillips et al., 1995), and further studies found the putative disease causing 
missense mutation in the α4 neuronal nicotinic acetylcholine receptor (nAChR) encoded 
by CHRNA4 (Steinlein et al., 1995). Additional ADNFLE mutations were identified 
several years later in the β2 nAChR subunit encoded by CHRNB2 (De et al., 2000).   
Next defects in voltage-gated potassium channels were associated with a 
Mendelian form of epilepsy. In 1998, mutations in the KCNQ2 and KCNQ3 genes 
encoding KV7.2 and KV7.3 were linked to benign familial neonatal convulsions (BFNC) 
(Singh et al., 1998; Charlier et al., 1998). BFNC is an autosomal dominant disorder that 
causes seizures in the neonatal period that spontaneously remit within the first few 
months of life (Singh et al., 1998). BFNC mutations in KV7.2 and KV7.3 lead to aberrant 
neuronal M current, a slowly activating and deactivating current responsible for 
regulating neuronal excitability.  
Generalized epilepsy with febrile seizures plus (GEFS+) is a mild epilepsy 
syndrome that has autosomal dominant inheritance. Patients initially experience febrile 
seizures (FS), seizures that are provoked by fever. Typical FS occur in children younger 
than six years old, and are relatively common affecting about 3% of children (Wallace et 
al., 2001), but are not necessarily predictive of future seizures or development of 
epilepsy. In GEFS+ patients, the seizures progress to febrile seizures plus (FS+). FS+ is 
characterized by febrile seizures after the age of six with or without the presence of 
afebrile seizures (Scheffer and Berkovic, 1997) and has been thought to be a 
predisposing factor for later development of epilepsy. A diagnosis of GEFS+ is made 
when patients experience generalized convulsions as well as FS+. The first mutation 
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identified in a GEFS+ family was found in the SCN1B gene that encodes the auxiliary 
voltage-gated sodium channel β1 subunit (Wallace et al., 1998). The β1 mutation C121W 
was the first time a voltage-gated sodium channel mutation was implicated in epilepsy. 
Now there are a total of four mutations in SCN1B associated with GEFS+ type 1 and 
there is functional data for three of the four mutations (Meadows et al., 2002; Audenaert 
et al., 2003; Scheffer et al., 2007; Xu et al., 2007a). Next a new locus for GEFS+ was 
mapped to 2q21-q33 (Baulac et al., 1999). This locus was refined revealing mutations in 
SCN1A, the α1 voltage-gated sodium channel that became known as GEFS+ type 2 and 
will be further discussed below with other neuronal epilepsy sodium channel mutations.  
GABAA receptors are another ion channel that is mutated in several genetic 
forms of epilepsy. In 2001, the first evidence for dysfunctional GABAA receptors in 
epilepsy was elucidated when another GEFS+ locus was narrowed down to the GABAA 
receptor γ2 subunit encoded by GABRG2 (Baulac et al., 2001a). GEFS+ type 3 refers to 
cases where GABRG2 receptor mutations are identified. Variants in the GABAA receptor 
δ subunit have also been implicated to increase susceptibility to GEFS+ (Dibbens et al., 
2004; Macdonald et al., 2004). Mutations in GABRG2 were also found in patients with 
childhood absence epilepsy (CAE) type 2 and febrile convulsions (Kananura et al., 2002; 
Marini et al., 2003). An early truncation of the GABRG2 subunit has been implicated as a 
rare cause of severe myoclonic epilepsy of infancy (SMEI) (Macdonald et al., 2004). 
GABRA1 encodes the α1 subunit of GABAA receptors. Mutations in GABRA1 were 
identified in autosomal dominant juvenile myoclonic epilepsy (JME) (Cossette et al., 
2002) and also in CAE type 4 (Maljevic et al., 2006). 
 Other forms of absence and myoclonic epilepsy are also associated with 
disturbances in other ion channels. CAE type 1 has been mapped to 8q24 but no 
specific gene has been identified (Fong et al., 1998). And a variety of IGE phenotypes 
including CAE type 3, juvenile absence epilepsy, and JME are associated with mutations 
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in the voltage-gated chloride channel encoded by CLCN2 (Haug et al., 2003), though 
epilepsy-associated mutations are rarely identified in this gene. Mutations in CACNA1H 
encoding the CaV3.2 T-type voltage-gated calcium channel are also associated with 
CAE (Chen et al., 2003). Variants in the α1a subunit of the P/Q type voltage-gated 
calcium channel, encoded by CACNA1A, result in increased susceptibility for IGE 
(Chioza et al., 2001). Mutations in CACNB4 encoding the β4 subunit of the P/Q type 
voltage-gated calcium channel are associated with JME and IGE with episodic ataxia 
(Escayg et al., 2000a). Many of the epilepsy-associated mutations in ion channels have 
been functionally characterized to elucidate mechanisms of altered neuronal excitability. 
 Now non-ion channel proteins have been implicated in the pathogenesis of 
certain forms of epilepsy, but how mutations in these proteins alter neuronal excitability 
is largely unknown. For example, autosomal dominant lateral temporal lobe epilepsy 
(ADLTLE) is associated with mutations in leucine-rich glioma inactivated 1 (LGI1I) 
(Kalachikov et al., 2002; Morante-Redolat et al., 2002). Recent evidence showed that 
LGI1 complexes with presynaptic KV1 channels and modifies the N-type inactivation 
caused by KVβ1 (Schulte et al., 2006), but how this relates to epilepsy has still not been 
explored. Monogenic audiogenic seizure susceptibility (MASS1) is part of a larger gene 
called VLGR1 which contains a structural motif similar to LGI1. The MASS1/VLGR1 
gene product resides within the FEB4 FS locus, but no mutations have been positively 
linked to FS. There have been heterozygous mutations in MASS1/VLGR1 reported in 
Japanese families with febrile and afebrile seizures (Nakayama et al., 2002).  
Studies now indicate that mutations in proteins as varied as EF-hand domain 
containing protein (EFHC1), malic enzyme 2 (ME2), bromodomain containing protein 2 
(BRD2), and contactin-associated protein-like 2 (CNTNAP2) are associated with various 
epilepsy syndromes (George, Jr., 2004; Gurnett and Hedera, 2007). Rarely infantile 
spasms (IS) are associated with an X-linked form of West Syndrome due to mutant 
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Aristaless-related homeobox (ARX) (Stromme et al., 2002). Determining the function of 
these proteins and the continual search for other novel proteins involved in epilepsy 
pathogenesis will provide new avenues for studying the genetics of epilepsy. An 
additional direction this field is moving towards is to understand the role of susceptibility 
genes that contribute to complex inheritance of epilepsy when multiple proteins are 
involved in producing a seizure phenotype. Overall studying the dysfunctional proteins 
implicated in epilepsy helps to better define normal brain excitability and identify specific 
perturbations underlying epilepsy that may be better targeted with a different therapeutic 
approach. 
 
Structure and function of voltage-gated sodium channels 
 Neuronal voltage-gated sodium channels are responsible for the rapid membrane 
depolarization that characterizes the initial “upstroke” of the action potential. Although no 
crystal structure exists, mammalian neuronal sodium channels have been well 
characterized. Channels consist of multiple interacting subunits: a large (~ 260 kDa) α 
subunit, which forms the channel pore, and smaller (~ 33-36 kDA) β accessory subunits 
that appear to modulate the activity, expression, and localization of the α subunit (Isom 
et al., 1994; Kazen-Gillespie et al., 2000; Malhotra et al., 2000). The human pore-
forming α subunits exist in nine isoforms with varying degrees of amino acid 
conservation as shown in Figure 2 (Plummer and Meisler, 1999). Structurally, α subunits 
consist of four homologous domains (DI-DIV). The membrane topology of a typical α 
subunit is depicted in Figure 3. Each domain has six putative transmembrane-spanning 
segments (S1-S6) along with a reentrant hydrophobic pore loop (P-loop) between S5 
and S6. Ion selectivity through the pore is conferred by the selectivity filter located in the 
P-loop. For voltage-gated sodium channels, the DEKA residues in each domains P-loop  
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Figure 2. Evolutionary diversity of voltage-gated sodium channels. Adapted from 
(Plummer and Meisler, 1999) showing phylogenetic relationships of the rodent and 
drosophila voltage-gated sodium channel α isoforms. The percentage conservation 
between protein sequences is shown as is the chromosomal location for the human 
orthologs.  
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Figure 3. Schematic of a voltage-gated sodium channel. One sodium channel α isoform is shown with key structural elements 
including the intracellular amino (N) and carboxy (C) termini. The main pore-forming α subunit has four domains (D1-D4) that have 
homologous elements and are comprised of six transmembrane-spanning segments (S1-S6) each. The S4 segment contains 
positively charged residues that allow it to act as the voltage sensor by moving through the lipid bilayer in response to changes in 
voltage. The reentrant loop between each S5 and S6 are pore loops (P-loop) with the selectivity filter to determine what ion species 
can pass. For voltage-gated sodium channels, the important selectivity filter residues are the DEKA residues. The fast inactivation 
gate is on the D3-D4 linker with critical IFM residues. On either side of the α subunit are the β1 and β2 subunits which are single 
transmembrane domain proteins. The extracellular amino terminus has an immunoglobulin (Ig) fold and the intracellular carboxy 
terminus has several important regulatory sites. 
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are important for preferential Na+ conductance through the channel pore (Figure 3). The 
voltage sensor of the sodium channel is comprised of the four S4 helices, which contain 
arginine (R) or lysine (K) residues (basic amino acids) at every third position (Figure 3). 
These positively charged residues are thought to move through the lipid bilayer in 
response to voltage changes allowing the sodium channel to change conformations 
(Stühmer et al., 1989). 
Neuronal sodium channels are thought to be formed by one α subunit along with 
the β1 and β2 subunits as shown in Figure 3 (Catterall, 2000). The role of voltage-gated 
sodium channel complexes with β3 and β4 in vivo is still largely undetermined. The β 
subunit structure consists of a large extracellular amino-terminal domain, one 
transmembrane domain, and a small cytoplasmic carboxy-terminal domain (Figure 3) 
(Hanlon and Wallace, 2002). The amino terminus has a large immunoglobulin (Ig) 
domain with critical cysteine residues. The carboxy terminus has many regulatory sites. 
There are four known β subunits encoded by the genes SCN1B-SCN4B. In heterologous 
expression systems, co-expression of the β1 subunit increases current density and 
accelerates both activation and inactivation (Isom et al., 1992). Similarly, co-expression 
of the β2 subunit increases current amplitude and modulates gating (Isom et al., 1995). 
The β1 and β2 subunits also regulate localization of α subunits through interactions with 
cytoskeletal proteins (Malhotra et al., 2000; McEwen et al., 2004). The β3 and β4 
subunits are less well characterized than the originally identified β1 and β2 isoforms 
leading to a largely unknown role for these subunits in the brain (Morgan et al., 2000; Yu 
et al., 2003). 
Voltage-gated sodium channels open and close in response to changes in 
membrane potential. According to the classical model developed by Hodgkin and Huxley 
(Hodgkin and Huxley, 1952b; Hodgkin and Huxley, 1952c; Hodgkin and Huxley, 1952d; 
Hodgkin and Huxley, 1952a), two kinetic processes control changes in ionic permeability 
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in excitable membranes: activation and inactivation. Membrane depolarization that 
opens (activates) sodium channels will result in a rapid, localized rise in sodium 
permeability. The increased sodium permeability is short-lived due to a rapid inactivation 
process, which is thought to be coupled to activation. Fast inactivation serves to limit the 
total amount of Na+ that enters the cell and is critical for action potential repolarization at 
nodes of Ranvier (Ulbricht, 2005). A cytoplasmic linker between domains III and IV with 
the critical IFM residues acts as a hinge, docking to the S4-S5 loops of domains III and 
IV to mediate fast inactivation (Figure 3) (Stühmer et al., 1989; West et al., 1992). Upon 
repolarization, sodium channels enter the closed state and release the fast inactivation 
gate in preparation for the next cycle of depolarization and action potential initiation. A 
distinct slower form of inactivation has been described, but this mechanism remains less 
clear than fast inactivation (Ruben et al., 1992; Vilin et al., 1999). Slow inactivation is 
likely important in vivo because it has been observed in mammalian neurons. Channel 
availability following prolonged depolarization or repetitive stimulation and regulation of 
excitability are thought to be determined by slow inactivation (Ulbricht, 2005). 
 
Localization of neuronal voltage-gated sodium channels 
 The nine isoforms of voltage-gated sodium channel α subunits have distinct 
expression patterns within the brain, peripheral nerves, ganglia, heart, skeletal muscle, 
glia, and certain neuroendocrine tissues shown in Table 2 (Noda et al., 1986) (Trimmer 
et al., 1989; Gautron et al., 1992; George, Jr. et al., 1992; Klugbauer et al., 1995). 
Mutations in many of the human voltage-gated sodium channel α isoforms have been 
identified in a wide variety of diseases (Table 2). SCN1A, SCN2A, SCN3A, and SCN8A 
encoding NaV1.1, NaV1.2, NaV1.3, and NaV1.6 respectively, are found at high levels in 
the central nervous system (CNS). Several groups have used antibodies directed 
against the four brain isoforms to determine the cellular and subcellular localization in 
  17
both rodent and human brains. Subtype specific antibodies have also been employed to 
study the developmental expression patterns of neuronal voltage-gated sodium 
channels. Regarding the primarily neuronal subunits, several genetic epilepsy 
syndromes are associated with mutations in human SCN1A and SCN2A. There were 
recently reported epilepsy mutations in human SCN3A but currently there are no known 
mutations in human SCN8A that are associated with genetic epilepsy. The epilepsy 
phenotypes associated with neuronal voltage-gated sodium channels will be explored 
below in detail. SCN1A and SCN2A share 87% amino acid identity (Plummer and 
Meisler, 1999), have distinct expression patterns in the CNS, and most likely have 
different functional roles within neurons. The goal of this thesis research is to understand 
the molecular basis of inherited epilepsy disorders through studying SCN1A and SCN2A 
mutations in multiple model systems. 
In rodent and human brains, NaV1.1 is generally found on the soma or dendritic 
trees of neurons, whereas NaV1.2 mostly localizes to axons and fiber tracts. NaV1.1 is 
expressed at moderate levels in the hippocampus. Dentate granule cells and 
interneurons in the dentate hilus show strong immunoreactivity to NaV1.1. Somatic and 
proximal dendrites of pyramidal cells within the CA1, CA2, and CA3 subregions of the 
hippocampus also express NaV1.1 (Gong et al., 1999; Whitaker et al., 1999; Whitaker et 
al., 2000; Whitaker et al., 2001). Recent studies also show NaV1.1 at the axon initial 
segment of parvalbumin (PV) interneurons in the developing mouse cortex and at the 
somata and axon initial segment of PV interneurons in the developing hippocampus 
(Ogiwara et al., 2007). 
Early in development NaV1.2 is highly expressed in areas destined to become 
nodes of Ranvier but are developmentally replaced by NaV1.6 in adult rat brains (Kaplan 
et al., 2001). NaV1.2 is enriched at axon initial segments in developing neurons and 
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Table 2. Mammalian voltage-gated sodium channel genes 
Gene Protein Major 
expression 
Minor 
expression 
Disorders 
     
SCN1A NaV1.1 CNS, PNS Cardiac 
muscle 
Epilepsy, FHM 
SCN2A NaV1.2 CNS, PNS  Epilepsy 
SCN3A NaV1.3 CNS, PNS  Epilepsy 
SCN4A NaV1.4 Skeletal 
muscle 
 Myotonia, 
periodic paralysis 
SCN5A NaV1.5 Cardiac 
muscle 
Skeletal 
muscle, brain 
LQTS, Brugada 
syndrome, SIDS 
SCN8A NaV1.6 CNS, PNS Cardiac 
muscle 
 
SCN9A NaV1.7 PNS  Primary 
erythermalgia 
SCN10A NaV1.8 PNS   
SCN11A NaV1.9 PNS   
     
SCN1B β1 CNS Skeletal 
muscle, 
cardiac muscle 
Epilepsy 
SCN2B β2 CNS   
SCN3B β3 CNS   
SCN4B β4 CNS   
 
Abbreviations as follows: CNS – central nervous system, PNS – peripheral nervous 
system, FHM – familial hemiplegic migraine, LQTS – long QT syndrome, SIDS – sudden 
infant death syndrome. 
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unmyelinated axons in the adult brain (Boiko et al., 2003; Garrido et al., 2003b; Garrido 
et al., 2003a; Westenbroek et al., 1989; Westenbroek et al., 1992). In contrast to NaV1.1, 
NaV1.2 is located on axons and terminals of many hippocampal pathways including the 
perforant path that arises from the entorhinal cortex and projects through the middle third 
of the molecular layer of the dentate gyrus. NaV1.2 is associated with dentate granule 
cell axons called mossy fibers located just above the pyramidal neurons in region CA3. 
Additionally, NaV1.2 is expressed near the termination of the Schaffer collaterals, which 
are projections from CA3 to CA1. An exception to the usual expression pattern of NaV1.2 
is the somatodendritic expression of NaV1.2 on CA1 pyramidal neurons (Gong et al., 
1999; Whitaker et al., 1999; Whitaker et al., 2000; Whitaker et al., 2001).  
In the cerebellum, NaV1.1 is moderately expressed somatodendritically in granule 
cells, Purkinje cells, other cells within the molecular layer, and cells of the deep 
cerebellar nuclei. Surprisingly, NaV1.1 was also expressed along distal axons of 
developing mouse cerebellar fibers (Ogiwara et al., 2007). Unlike NaV1.1, NaV1.2 
immunoreactivity is diffusely seen throughout the molecular layer of the cerebellum 
probably associated with terminals and axons such as the parallel fibers of granule cells 
(Gong et al., 1999; Whitaker et al., 1999; Whitaker et al., 2000; Whitaker et al., 2001).   
Northern blot and in situ hybridization experiments examining the distribution of β 
subunit mRNAs have shown distinct regional expression patterns within human and 
rodent brains. In the hippocampus, both β1 and β2 are highly expressed in the CA 
regions and dentate gyrus and are weakly expressed in hilar neurons. In the cerebellum, 
the β1 subunit is highly expressed in the granular layer, in Purkinje cells, and deep 
cerebellar nuclei and moderately expressed in the molecular layer. The β2 subunit is also 
strongly expressed in the granular layer and in Purkinje cells, but is only weakly 
associated with the molecular layer and deep cerebellar nuclei (Whitaker et al., 1999; 
Whitaker et al., 2000). In contrast to β1, the β3 subunit expression begins early in 
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development and is maintained at a high level of expression in the adult brain (Shah et 
al., 2001). The β3 subunit in the adult rat brain is highly expressed in forebrain structures 
of the olfactory system, layers II and III of the neocortex, and CA subfields of the 
hippocampus (Morgan et al., 2000). β4 is expressed in pyramidal neurons of the cortex 
and hippocampus, a subset of hilar neurons, and highly expressed in dorsal root ganglia 
(DRG), Purkinje cells and deep cerebellar nuclei (Yu et al., 2003). 
 
Neuronal voltage-gated sodium channels associated with epilepsy 
Throughout the central nervous system, voltage-gated sodium channels are 
critical for the initiation and propagation of action potentials. Voltage-gated sodium 
channels are important pharmacological targets for anticonvulsant therapeutics 
(Macdonald and Greenfield, Jr., 1997; Catterall, 1999) and over 300 mutations have 
been linked to some forms of genetic epilepsy (Mulley et al., 2005; Meisler and Kearney, 
2005; Harkin et al., 2007; Herlenius et al., 2007; Holland et al., 2008; Zucca et al., 2008). 
One genetic epilepsy syndrome with encephalopathic features is SMEI, formerly known 
as Dravet Syndrome. SMEI causes FS during the first year of life followed by 
progression to intractable epilepsy, impaired psychomotor development, and ataxia 
(Scheffer et al., 2001). In this rare convulsive disorder, the seizures are typically 
resistant to anticonvulsant therapeutics. Greater than 70% of SMEI patients have a 
mutation in SCN1A in some populations (Zucca et al., 2008), whereas other studies 
have identified NaV1.1 mutations in only one-third of SMEI cases (Wallace et al., 2003). 
Over 180 heterozygous mutations in SCN1A have been reported in SMEI patients. Many 
of the SMEI mutations are nonsense mutations leading to premature truncation, or 
insertions or deletions that shift the open reading frame. Many of the nonsense or 
frameshift mutations would encode non-functional sodium channels. Other SMEI alleles 
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are missense mutations that more likely are functional and may exhibit a mix of gain- or 
loss-of-function (Mulley et al., 2005; Harkin et al., 2007; Zucca et al., 2008).   
  GEFS+ is a less severe form of genetic epilepsy. GEFS+ patients experience FS 
and other types of afebrile seizures beyond six years of age. The inheritance of GEFS+ 
is autosomal dominant with incomplete penetrance and a high rate of phenocopy. 
Mutations in genes encoding voltage-gated sodium channel α (SCN1A, SCN2A) 
(Escayg et al., 2000b; Sugawara et al., 2001) or β1 (SCN1B) (Wallace et al., 1998) and 
the GABAA receptor subunit (GABRG2) (Baulac et al., 2001a; Wallace et al., 2001) have 
been associated with GEFS+. In many cases of GEFS+ there is no identifiable mutation 
in one of the four genes listed above. It is thought that about 17% of all GEFS+ cases 
are due to mutations in a voltage-gated sodium channel gene (Nakayama and Arinami, 
2006). Common clinical characteristics and similar genetic etiologies suggest that 
GEFS+ and SMEI, may represent a spectrum of the same disease (Singh et al., 2001).   
 Intractable childhood epilepsy with generalized tonic-clonic seizures (ICEGTC) is 
an epilepsy syndrome that is also hypothesized to reside in the GEFS+ and SMEI 
spectrum with an intermediate severity (Stafstrom, 2003). The seizures begin prior to 
one year of age often during fever and are accompanied with mental decline. Another 
distinguishing feature of ICEGTC is the presence of diffuse theta waves on 
electroencephalogram (EEG). Mutations in SCN1A are the only known cause of 
ICEGTC (Fujiwara et al., 2003; Osaka et al., 2007). 
 Other epilepsy phenotypes are uncommonly linked to alterations in SCN1A. The 
triad of symptoms associated with West Syndrome include IS, hypsarrythmia and 
developmental regression. West Syndrome is often found in the presence of metabolic 
or structural brain abnormalities. About one-third of cases have a positive family history 
of FS or idiopathic epilepsy. Two missense point mutations in SCN1A were identified in 
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IS patients with West Syndrome, but only one alters a highly conserved residue (Wallace 
et al., 2003). Temporal lobe epilepsy (TLE), one of the most common forms of partial 
epilepsy, initially was primarily considered to be an acquired disorder with little known 
about its inheritance (Baulac et al., 2001b). Now there are two reports in the literature of 
SCN1A mutations in either FS or GEFS+ families and one SCN1B mutation in a GEFS+ 
family that had a few family members who subsequently developed TLE (Abou-Khalil et 
al., 2001; Colosimo et al., 2007; Scheffer et al., 2007). Recently, mutations in SCN1A 
have also been identified in cryptogenic epilepsy syndromes (Zucca et al., 2008). 
Interestingly, a few mutations in NaV1.1 have also been identified in familial hemiplegic 
migraine (FHM), a rare headache disorder with concomitant epilepsy in some family 
members. The relationship between migraine and epilepsy is a novel source for 
investigation (Dichgans et al., 2005; Thomsen et al., 2007; Vanmolkot et al., 2007; 
Gargus and Tournay, 2007). 
Rarely dysfunction of NaV1.2 is found in severe epilepsy cases. There has been 
one report of a GEFS+ phenotype segregating with a mutation in SCN2A (Sugawara et 
al., 2001). A nonsense mutation in SCN2A that disables channel function has been 
associated with an unclassified, malignant epilepsy similar to SMEI (Kamiya et al., 
2004). Epilepsy syndromes linked to neuronal sodium channel mutations may also have 
benign phenotypes causing seizures only during infancy and early childhood before 
spontaneous remission. Rarely a mutation in NaV1.2 has resulted in benign familial 
infantile seizures (BFIS) (Striano et al., 2006a). BFIS is an epilepsy syndrome that 
affects children in the first few months of life but resolves within one year. BFIS is more 
commonly associated with dysfunction of the ATP1A2 gene (Striano et al., 2006b). Eight 
missense mutations in SCN2A are associated with a mild form of epilepsy known as 
benign familial neonatal-infantile seizures (BFNIS). The clinical characteristics of BFNIS 
are slightly distinct from BFNC but may share some overlapping features with BFIS 
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(Striano et al., 2006b). BFNIS is an autosomal dominant disorder with onset during early 
infancy that remits by one year of age and has no known long-term neurological 
sequelae. Afebrile secondarily generalized partial seizures and rare febrile seizures 
characterize BFNIS (Kaplan and Lacey, 1983; Heron et al., 2002; Berkovic et al., 2004; 
Herlenius et al., 2007). The factors that distinguish benign from malignant epilepsy 
syndromes caused by sodium channel mutations are currently unknown. One important 
goal of this thesis research is to understand the functional consequences of SCN2A 
mutations in the mild BFNIS phenotype for comparison with other brain sodium channel 
defects associated with more severe epilepsy phenotypes. 
Screening SCN1A and SCN2A for genetic mutations in familial epilepsy 
syndromes has become more common, but the other sodium channels predominantly 
expressed in brain, SCN3A and SCN8A, had not been as widely investigated or 
implicated in inherited epilepsies. Recently children with pharmacoresistant cryptogenic 
pediatric partial epilepsy were screened for mutations in SCN3A. The diagnosis was 
made when partial epilepsy was confirmed and was labeled cryptogenic when other 
structural abnormalities, neurological disorders, or idiopathic epilepsy syndromes were 
ruled out. One mutation and 12 novel SNPs in SCN3A were identified thereby 
implicating NaV1.3 dysfunction as a cause of epilepsy (Holland et al., 2008). 
 
Functional studies of epilepsy-associated voltage-gated sodium channel mutants 
 The fastest approach to obtain functional data from epilepsy mutations has been 
through electrophysiological experiments of heterologously expressed mutant sodium 
channel. Functional studies of epilepsy mutations in voltage-gated sodium channels 
primarily make use of heterologous expression in a transformed mammalian cell line, 
commonly tsA201 or CHO-K1 cells. The recombinant sodium channel may be transiently 
transfected alone or in combination with auxiliary β subunits. Earlier studies introduced 
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the mutation into a non-neuronal voltage-gated sodium channel isoform or a rodent 
ortholog of SCN1A or SCN2A that is more amenable to site-directed mutagenesis. The 
transfected cells are subjected to whole-cell voltage clamp recording with relatively 
standard protocols to assess current-voltage (I-V) relationship, voltage dependence of 
activation, fast inactivation, and other parameters. Another heterologous expression 
model system that some researchers utilized was two-electrode voltage clamp (TEVC) in 
Xenopus oocytes injected with cRNA encoding the wild-type (WT) or mutant sodium 
channel. One major goal of heterologous expression studies is to make genotype-
phenotype correlations where multiple mutations linked to one epilepsy syndrome may 
cause similar disturbances in sodium current explaining the common disease phenotype. 
 To date functional studies of NaV1.1 mutations associated with GEFS+, SMEI, 
ICEGTC, TLE and NaV1.2 mutations associated with GEFS+, SMEI, and BFNIS have 
been performed (Alekov et al., 2000; Sugawara et al., 2001; Lossin et al., 2002; Lossin 
et al., 2003; Rhodes et al., 2004; Spampanato et al., 2004b; Kamiya et al., 2004; 
Rhodes et al., 2005; Mantegazza et al., 2005; Ohmori et al., 2006; Barela et al., 2006; 
Scalmani et al., 2006; Xu et al., 2007b). The biophysical function of each mutation differs 
slightly based on which heterologous expression system was used. Biophysical 
phenotypes run a large range from nonfunctional sodium currents to small differences in 
comparison to WT. Below biophysical defects affecting different parameters identified by 
experiments using heterologous expression systems are highlighted (Table 3).  
Perturbations in the voltage dependence of activation lead to a change in the 
magnitude of depolarization needed for the channel to open and conduct sodium ions. A 
few GEFS+ mutations, including I1656M and R1657C, caused positive shifts in the 
voltage dependence of activation in comparison to WT-NaV1.1. These two mutations 
disrupt conserved residues in the D4/S4 segment and may alter neuronal excitability by 
requiring a greater membrane depolarization for the channel to activate (Lossin et al., 
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2003). A different SCN1A GEFS+ mutation, W1204R caused a negative shift in 
activation allowing the channel to open at more negative membrane potentials (Lossin et 
al., 2002; Spampanato et al., 2003). Opposing shifts in the voltage dependence of 
activation by GEFS+ mutations exemplifies the difficulty with making generalizations 
about how biophysical defects are causing disease. 
Whole-cell current decay, voltage dependence of fast inactivation and recovery 
from fast inactivation are important for determining the duration of sodium conductance 
and the ability of the channel to reset for subsequent depolarizations. The GEFS+ 
mutation in NaV1.2, R188W, delayed whole-cell current decay. R188W also caused a 
negative shift in the voltage dependence of fast inactivation. The impairments in fast 
inactivation caused by R188W predict an increased sodium conductance that could 
cause hyperexcitability (Sugawara et al., 2001). The T875M mutation in NaV1.1 was 
identified in GEFS+ patients and exhibited a delayed recovery in fast inactivation. 
Alternatively, the NaV1.1 mutations R1648H, R1648C, and F1661S all accelerated 
recovery from fast inactivation (Lossin et al., 2002; Lossin et al., 2003). The recovery 
from fast inactivation findings are another example of one parameter that is altered in 
opposing ways by mutations associated with the same Mendelian epilepsy. 
Slow inactivation is thought to regulate channel availability following prolonged 
depolarization or repetitive stimulation. The SCN1A GEFS+ mutation R1657C 
accelerated recovery from slow inactivation (Lossin et al., 2003).  On the other hand, the 
NaV1.1 mutations F1661S and R859C delayed recovery from slow inactivation (Rhodes 
et al., 2004; Barela et al., 2006). Thus deficits in slow inactivation appear to cause 
dysfunctional sodium channels leading to alterations in neuronal excitability.  
Many other defects in sodium channel function have been linked to the 
pathogenesis of monogenetic epilepsies. GEFS+ and SMEI NaV1.1 mutations, including 
R1648H and R1648C, exhibited increased persistent sodium current that can be
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Biophysical abnormality Mutation Syndrome
   
Depolarized voltage dependence of activation (hSCN1A, tsA201 cells) 
(rScn1a, Xenopus oocytes) 
I1656M, R1657C 
R859C 
GEFS+ 
Hyperpolarized voltage dependence of activation (rScn1a, Xenopus oocytes / hSCN1A, 
tsA201 cells) 
W1204R GEFS+ 
Delayed whole-cell current decay / Hyperpolarized voltage dependence of fast inactivation 
(rScn2a, HEK293 cells) 
R188W* GEFS+ 
Delayed recovery from fast inactivation (hSCN1A, tsA201 cells) T875M GEFS+ 
Accelerated recovery from fast inactivation (hSCN1A, tsA201 cells) R1648H 
R1648C, F1661S 
GEFS+ 
SMEI 
Delayed recovery from slow inactivation (hSCN1A, tsA201 cells)  
(rScn1a, Xenopus oocytes) 
F1661S 
R859C 
SMEI, 
GEFS+ 
Accelerated recovery from slow inactivation (hSCN1A, tsA201 cells) R1657C GEFS+ 
Increased persistent current (hSCN1A, tsA201 cells) R1648H 
R1648C 
F1808L 
GEFS+ 
SMEI 
ICEGTC 
Increased late openings, longer mean open time by single channel analysis (hSCN1A, 
tsA201 cells) 
R1648H GEFS+ 
Table 3. Biophysical defects from heterologous expression systems 
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Decreased interaction with β1 (rScn1a, Xenopus oocytes) D1866Y GEFS+ 
Decreased use-dependent channel behavior (hSCN1A, tsA201 cells) V893A, F1808L ICEGTC 
Decreased current density (hSCN1A, tsA201 cells)  
(hSCN1A, HEK293 cells) 
G1749E 
R712X, G979R 
SMEI 
 
Dominant negative effect on WT channel (hSCN2A, HEK293 cells) R102X* SMEI 
Nonfunctional sodium channels (hSCN1A, tsA201 cells) A1685V, V1353L 
T1902I 
L986F, F902C, G1647R 
GEFS+ 
ICEGTC 
SMEI 
 
* denotes mutation in SCN2A.  All other mutations were identified in SCN1A. The heterologous expression system used is in 
parentheses. The h denotes human and r denotes rat for the sodium channel α isoform characterized in the study.
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observed during the end of a depolarizing voltage step. Increased late sodium current is 
hypothesized to increase sodium conductance leading to a more depolarized resting 
membrane potential (Lossin et al., 2002; Lossin et al., 2003). Single channel recordings 
have rarely been performed on WT or mutant NaV1.1, but can provide information that is 
unattainable through whole-cell methods. The R1648H GEFS+ mutation was found to 
have increased late openings and longer mean open time compared to WT-NaV1.1. 
These findings are thought to explain the increase in persistent current seen at the 
whole-cell level (Vanoye et al., 2006). A weakened interaction between α and β1 
subunits leading to a less hyperpolarized voltage dependence of inactivation in the 
presence of β1 was observed for D1866Y, a GEFS+ mutation in SCN1A (Spampanato et 
al., 2004b). Interaction with β subunits is critical for proper sodium channel function, 
localization, and expression levels so loss of this interaction could result in epilepsy 
(Isom et al., 1995; Malhotra et al., 2000; McEwen et al., 2004). 
Many SMEI mutations encode nonsense or frameshift mutations that are 
predicted to encode nonfunctional sodium channels. However, some SMEI, ICEGTC, 
and GEFS+ missense mutations also result in nonfunctional sodium channels (Table 3). 
Two possible explanations for nonfunctional sodium channels are that the proteins have 
aberrant trafficking or that the channel is unable to conduct Na+ (Lossin et al., 2003; 
Rhodes et al., 2004; Rhodes et al., 2005; Ohmori et al., 2006). Other SMEI mutations 
result in significantly reduced sodium current but are not entirely nonfunctional 
(Sugawara et al., 2003; Ohmori et al., 2006). One interesting NaV1.2 mutation identified 
in a SMEI patient encodes a premature stop codon before the first transmembrane 
segment and is nonfunctional when expressed alone. When R102X is coexpressed with 
WT-NaV1.2, it acts in a dominant negative fashion to decrease sodium current (Kamiya 
et al., 2004). 
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 Recently there has been recognition that overexpression in non-neuronal cell 
lines may not be providing enough information to determine mechanisms underlying the 
epilepsy pathology or to reconcile the varied biophysical defects with clinical phenotype. 
Some groups have been trying to transfect acutely isolated neurons with recombinant 
sodium channels in the hope that the neuronal background will more closely resemble 
the physiological state (Scalmani et al., 2006). Unfortunately homogenous populations of 
neurons are difficult to isolate, transfect, maintain, and use in whole-cell voltage clamp 
experiments. Distinguishing mutant sodium current from the endogenous current can 
also be difficult depending on what electrophysiological methods are employed. Also 
overexpression of the sodium channel may overwhelm the endogenous interacting 
proteins that would regulate expression under normal physiological conditions. Below 
two other avenues of investigation for mutant voltage-gated sodium channels are 
discussed. 
  
Computational models of voltage-gated sodium channels 
 Initial attempts to utilize computational modeling to simulate WT and mutant 
sodium channel function have followed the Hodgkin-Huxley (HH) mechanism of 
independent gating processes (Hodgkin and Huxley, 1952a). These computational 
models have been able to approximate some aspects of sodium channel function, 
especially the activation properties of the channel. NaV1.1 channel models were created 
to hypothesize the effect of epilepsy-associated mutations on neuronal excitability 
parameters including action potential threshold and firing patterns (Spampanato et al., 
2004a; Spampanato et al., 2004b; Barela et al., 2006). But the HH type models do not 
adequately recapitulate the fast inactivation and slow inactivation properties in part 
because activation and fast inactivation processes are coupled (Cha et al., 1999; Kuhn 
and Greeff, 1999). This makes it difficult to evaluate conclusions about neuronal 
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excitability derived from HH NaV1.1 models. Empirical and thermodynamic models have 
also been made to try and generate sodium channel behavior, but these models are also 
unable to simulate all aspects of sodium current (Patlak, 1991).  
A newer approach to computational investigation of voltage-gated sodium 
channels utilizes Markov chain models. Markov chain models are based upon the idea of 
stochastic processes such that transitioning from one state to the next depends upon a 
probabilistic transition. The Markov chain models are better suited for replicating the 
sodium channel properties and for examining the contribution of the sodium channel to 
neuronal excitability (Vedantham and Cannon, 1998; Irvine et al., 1999). Computational 
models of NaV1.1 using the Markov chain model more accurately emulate biophysical 
data and will hopefully suggest mechanisms for altered sodium current causing epilepsy 
(Clancy and Kass, 2004; Kahlig et al., 2006b). The sodium channel models should be 
validated by comparing the model to empirically derived biophysical data of many 
sodium channel parameters including activation, fast inactivation, slow inactivation, and 
persistent current. 
Once accurate channel models exist, they can be inserted into different sized 
modeling environments including a simple cylindrical unit, singular cells, or complex 
neuronal networks. A simple cylindrical unit would allow one to refine the sodium 
channel model and test channel function or mutation effects without competing ion 
channel conductances. Inserting the NaV1.1 model into a single neuron or neuronal 
network would provide a more realistic representation of how the model functions in vivo 
(Xu and Clancy, 2008). Freely accessible databases contain models of multiple neuron 
types that have incorporated data from morphology and physiology experiments. In 
addition to simulating a neuronal environment, another avenue for investigation is in 
silico pharmacology where the channel models can be tested against theoretical drugs 
to aid in rational drug design.  
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The major downside to computational modeling is the large amount of user 
control over a wide array of parameters. Some of these parameters have no supporting 
data so the user must make decisions about what values to use. A few of these 
parameters that are difficult to determine include sodium channel expression levels, 
subcellular localization of sodium channels, effects of auxiliary subunits, and similar 
considerations for other ion channels within the same compartment. Single neuron or 
neuronal network modeling environments are improving constantly, but cannot yet 
compete with using a biological model system derived from animal brain. Even with 
these potential disadvantages, computational modeling provides a robust way for us to 
better understand empirically derived data as well as guide future experiments. 
  
Animal models of epilepsy with defective sodium channels 
 One way to obtain relevant physiological and behavioral data on sodium channel 
mutations is through the use of animal models of epilepsy. Early models involved 
inducing seizures through chemical or electrical means as in the case of kindling. Other 
models were obtained through spontaneous random mutations in inbred rat or mouse 
strains. As techniques for engineering genetically altered animals have become refined, 
several mouse models focused on sodium channel dysfunction have been developed 
(Table 4). Here we will discuss in detail only those mouse models that are relevant to 
later chapters. 
 In 2000, a characterization of mice with targeted disruption of SCN2A was 
published. The homozygous knockout mice exhibited perinatal lethality, or death by 
postnatal day (P) 2. The sodium currents from cultured hippocampal pyramidal cells 
showed a dramatic reduction in maximum conductance for the homozygous knockout 
and a modest reduction in maximum conductance for the hemizygous mice. No seizure 
activity was measured in either the homozygous knockout or hemizygous animals. The  
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Table 4. Mouse models of sodium channel mutations with neurological disorders 
Gene Channel Mutation Disorder 
    
SCN1A NaV1.1 Targeted null Homozygous lethal at P15, 
seizures and ataxia 
  R1407X Homozygous lethal after 
P18, seizures and ataxia 
SCN2A NaV1.2 Q54 Transgene 
(GAL879-881QQQ) 
Dominantly inherited TLE 
  Targeted null Homozygous lethal at P2 
SCN8A NaV1.6 Spontaneous null Paralysis, lethal 
  Null heterozygote Learning deficits 
  A1071T Ataxia, tremor 
  Hypomorph (medJ) Dystonia 
  Conditional null CRE-dependent lethal 
SCN9A NaV1.7 Targeted null Lethal 
  Conditional null Pain resistant 
SCN10A NaV1.8 Targeted null Pain resistant 
SCN1B β1 Targeted null Homozygous lethal by P26,  
seizures 
  Conditional null Not lethal 
SCN2B β2 Targeted null Homozygote susceptible to 
seizures 
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homozygous knockout animals lost weight during the first two days of life and appeared 
to have hypoxia that was presumed to be the cause of death. Homozygous knockout 
animals had normal neuroanatomy, but at the ultrastructural level mitochondrial 
disruptions and increased vacuolization were visualized. The heterozygous animals had 
normal life spans and no difficulty breeding (Planells-Cases et al., 2000). 
 The next mouse model was developed prior to identification of human mutations 
in voltage-gated sodium channels. A mutation in rat Scn2a, GAL879-881QQQ, caused 
impaired fast inactivation and increased persistent current when examined by TEVC in 
Xenopus  oocytes. The GAL879-881QQQ mutation was inserted as a transgene into the 
mouse genome. The transgenic mice called Q54 exhibited spontaneous seizures of 
hippocampal origin similar to a dominantly inherited TLE within the first two months of 
life. Hippocampal CA1 pyramidal neurons isolated from the Q54 mice had significantly 
increased persistent sodium current compared with WT littermates and transgenic mice 
overexpressing WT Scn2a (Kearney et al., 2001). 
 Mice with targeted knockout of the auxiliary β1 and β2 subunits have also been 
characterized. Knockout of the β2 subunit resulted in decreased sodium current density 
and a negatively shifted voltage dependence of inactivation in acutely isolated 
hippocampal neurons. Additionally the SCN2B null mice displayed an increase in seizure 
susceptibility by pilocarpine induction (Chen et al., 2002). Knockout of the β1 subunit 
resulted in decreased NaV1.1 and increased NaV1.3 expression in a subset of pyramidal 
neurons in the CA2/CA3 regions of the hippocampus despite normal sodium currents. 
These mice had spontaneous generalized seizures and appeared ataxic (Chen et al., 
2004). Recently mice with a floxed allele of Scn1b were made to study conditional 
inactivation of the β1 subunit to allow for more specific investigation of the mechanism 
underlying the epilepsy phenotype (Chen et al., 2007). 
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 In 2006, a study was published characterizing knockout of Scn1a in mice by 
disrupting the last coding exon (exon 26). Mice with only one NaV1.1 allele were 
predicted to be a model for SMEI because many SMEI mutations lead to nonfunctional 
channels causing a haploinsufficiency. Hemizygous mice had spontaneous behavioral 
seizures and sporadic death beginning between P21 and P27. The hemizygous mice 
were often found dead from a presumed status epilepticus episode. EEG recordings 
showed the hemizygous mice having both clonic and tonic-clonic seizures. Homozygous 
knockout mice developed spontaneous seizures and ataxia around P9. Initially 
homozygous knockout animals lost postural control but by P15 had spontaneous 
generalized clonic and forelimb convulsive seizures. The null animals died on P15 from 
starvation or dehydration. Both hemizygous and homozygous null mice had decreased 
sodium currents specifically in acutely isolated bipolar neurons of the hippocampus and 
altered action potential amplitude and width. Acutely isolated hippocampal pyramidal 
neurons had normal sodium current leading to the hypothesis that the SMEI phenotype 
was the result of dysfunctional GABAergic interneurons (Yu et al., 2006). 
 Another mouse model of SMEI was made by targeted insertion of R1407X (RX) 
into Scn1a. The RX mutation was identified in multiple unrelated SMEI patients 
(Sugawara et al., 2002; Fujiwara et al., 2003; Fukuma et al., 2004) and was 
nonfunctional when heterologously expressed in HEK293 cells (Sugawara et al., 2003). 
The RX/RX mice became ataxic by P10 with increased difficulty for feeding and 
developed spontaneous, recurring clonic and tonic-clonic seizures between P12 to P16. 
Homozygous animals all died within the first three weeks of life. The heterozygous mice 
began having spontaneous recurring seizures and sporadic death after P18. Neurons 
from heterozygous mice showed increased spike amplitude decrement and an I-V 
relationship with more rectification at negative potentials (Ogiwara et al., 2007). 
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 Now that mouse models with varying severity of epilepsy syndromes exist, and 
more are being developed including conditional and tissue-specific targeted insertions, 
physiologically relevant mechanistic data are on the horizon. Experiments with the 
mouse models should provide better genotype-phenotype correlations than heterologous 
expression experiments have given. The mouse models may also provide a new way to 
investigate therapeutic strategies for the pharmacoresistant severe epilepsy syndromes.  
The disadvantages of using animal models include the difficulty and expense 
associated with making and maintaining the models. The result is that only a few distinct 
animal lines for each epilepsy syndrome are created and some benign forms of epilepsy 
may never be investigated with an animal model. Also there are differences between 
rodents and humans leading to difficulty discerning what the differences are and how 
they affect the conclusions. In all likelihood, multiple experimental paradigms with the 
animal models will provide the most useful data to guide alterations therapeutic 
management of patients. 
 
Research goals 
Mutations in neuronal voltage-gated sodium channels lead to several genetic 
epilepsy syndromes.  These genetic forms of epilepsy differ in phenotype with regards to 
age of onset, severity, presence of seizures in adulthood, and responsiveness to 
anticonvulsant therapeutics. This suggests that inter-individual genetic differences 
causing changes in the properties of the neuronal voltage-gated sodium channels may 
modulate epilepsy severity or determine the epilepsy syndrome. We pursued a series of 
experiments designed to understand the functional effects of epilepsy-associated 
mutations in brain voltage-gated sodium channels and the relationship with epilepsy 
severity. In order to try and form better genotype-phenotype correlations, the three 
model systems described above were utilized. Thus the primary goal of this dissertation 
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research has been to examine epilepsy-associated voltage-gated sodium channel 
mutations in multiple model systems to gain a deeper understanding of the molecular 
mechanism underlying these disorders. 
 
Specific Aims 
 As described above, there is a lot known about the structure-function relationship 
of large structural regions of voltage-gated sodium channels. However, there still remain 
many avenues of discovery because we cannot predict the functional outcomes of a 
particular disease-associated mutation. Additionally, we do not know why some 
missense mutations cause benign epilepsy syndromes while others cause severe or 
intractable forms of epilepsy. 
 One of the main ways to study epilepsy-associated mutations in voltage-gated 
sodium channels has been to overexpress the mutation in a heterologous expression 
system and perform whole-cell patch clamp studies. These studies have provided a 
large amount of information about kinetic and voltage dependent alterations in channel 
function. Problems with these studies include that the mutations are overexpressed in 
cells of non-neuronal origin and may not be associating with proper auxiliary subunits. 
Recent studies from mutations overexpressed in neurons or studies from animal models 
have shown that mutant channels may have different functional consequences in each 
model system. Future experiments will have to reconcile data from different experimental 
paradigms in order to move the field forward. Here we describe investigation of epilepsy-
associated mutations in NaV1.1 and NaV1.2 using multiple model systems to gain a 
deeper understanding of the molecular mechanism underlying these disorders through 
the following specific aims: 
 Specific Aim I:  Prediction of the impact of a neuronal sodium channel biophysical 
defect on neuronal excitability 
  37  
 
 Specific Aim II:  Functional characterization of neuronal sodium channel 
mutations associated with genetic epilepsy syndromes  
 
 Specific Aim III:  Characterization of neuronal sodium channels in cultured 
neurons from mutant Scn2a transgenic mice with differing seizure 
susceptibility 
  
In Specific Aim I, we utilized previously recorded data from tsA201 cells 
heterologously expressing WT-NaV1.1 to construct a model NaV1.1. We hypothesized 
that the biophysical parameters of WT sodium channels could be generated in silico to 
create an accurate model of WT-NaV1.1. Once a WT-NaV1.1 model was created, we 
constructed a model of the well characterized GEFS+ mutant R1648H. Disruption of a 
highly conserved arginine residue in NaV1.1 caused increased persistent sodium current 
when R1648H is heterologously expressed. We hypothesized that our computational 
models could be used to predict how the persistent sodium current caused by R1648H 
might alter neuronal excitability. The results of these experiments are described in more 
detail in Chapter Two. 
 In Specific Aim II, we sought to determine genotype-phenotype correlations for 
the benign epilepsy syndrome BFNIS associated with missense mutations in NaV1.2 and 
for a novel MTLE mutation identified in SCN1A. We hypothesized that we would be able 
to identify biophysical parameters that differed between WT and mutant neuronal sodium 
channels. We predicted that mutant sodium channels would be functional but could 
cause alterations in peak sodium current density. We hypothesized that peak current 
density disturbances could be due to altered cell surface expression or channel 
trafficking. Experiments examining WT and BFNIS-associated NaV1.2 mutations are 
described in Chapters Three and Four. Descriptions of experiments performed with the 
novel MTLE mutation in NaV1.1 are in Chapter Five. 
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 In Specific Aim III we moved out of heterologous expression systems and into a 
previously established mouse model of epilepsy. We utilized the Q54 transgenic mice on 
two different background strains that had significantly different seizure susceptibilities. 
Our collaborator had performed a genome wide scan and identified two modifier loci 
within the mouse genome that accounted for the majority of the differing seizure 
susceptibility. Although our collaborator has identified candidate genes in the modifier 
loci, the final modifier genes and corresponding functions are not yet known. Our 
hypothesis was that one of the modifier genes would directly affect the sodium channel 
transgene function. We performed whole-cell voltage clamp recordings on acutely 
isolated neurons to identify differences in voltage-gated sodium channel properties. We 
also used western blot analysis of membrane preparations isolated from whole brain of 
mice from the two different background strains to examine expression levels. Chapter 
Six describes the optimization steps and preliminary results from utilizing a mouse model 
of epilepsy studies. 
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CHAPTER II 
 
IMPAIRED INACTIVATION GATE STABILIZATION PREDICTS        
INCREASED PERSISTENT CURRENT FOR AN EPILEPSY-ASSOCIATED 
SCN1A MUTATION 
 
Introduction 
 Mutations in genes encoding voltage-gated sodium channel subunits have been 
linked to several inherited disorders of membrane excitability including defects in skeletal 
muscle contraction, cardiac arrhythmias and epilepsies (George, Jr., 2005). Currently, 
more than 300 SCN1A mutations have been associated with various genetic epilepsies 
(Mulley et al., 2005; Meisler and Kearney, 2005; Harkin et al., 2007; Herlenius et al., 
2007; Holland et al., 2008; Zucca et al., 2008). Functional studies of these SCN1A 
mutants in heterologous systems have revealed an array of biophysical abnormalities 
that are difficult to fully reconcile with the observed clinical phenotype. In vivo NaV1.1 
generates and propagates action potentials within an integrative environment consisting 
of multiple ionic conductances, thus establishing correlations between genotypes and 
biophysical phenotypes will likely require examination of NaV1.1 mutant behavior within 
such a context using either animal or computational models. 
 The majority of efforts to simulate sodium channel behavior using computational 
models (including NaV1.1 (Spampanato et al., 2004b; Spampanato et al., 2004a; Barela 
et al., 2006)) have utilized the classic Hodgkin-Huxley (HH) formalism (Hodgkin and 
Huxley, 1952b). These equations define sodium permeability in terms of multiple 
identical gates operating independently. However, this approach is unable to account for 
all channel behaviors (Hille, 2001). For instance, although voltage-gated sodium 
channels are constructed of four homologous domains (DI-DIV), each domain does not 
contribute identically to channel gating (Hille, 2001). In addition, inactivation and 
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activation are coupled because channel inactivation preferentially immobilizes the DIII 
and DIV associated activation gating movements (Cha et al., 1999; Kuhn and Greeff, 
1999). Additional discrepancies between HH-predicted and experimentally observed 
sodium channel behavior have also been described including gating currents, current 
fluctuation analysis, single channel activity and activation kinetics (Baranauskas and 
Martina, 2006; Patlak, 1991; Hille, 2001; Naundorf et al., 2006). 
 Attempts to reconcile the experimental voltage-gated sodium channel behavior to 
a mathematical description of channel activity have produced numerous thermodynamic 
and empirical models (see reviews by Patlak (Patlak, 1991) and Hille (Hille, 2001)). More 
recently, Markov chain models have been developed for excitability simulation studies 
that more faithfully approximate the biophysical activity of sodium channels (Irvine et al., 
1999; Clancy and Rudy, 1999; Clancy and Rudy, 2002; Vedantham and Cannon, 1998; 
Clancy and Kass, 2004). Computational investigations with accurate sodium channel 
models promise to guide empirical experimentation and to predict novel mechanisms of 
abnormal excitability (Clancy and Kass, 2003). 
 In this chapter we utilize an expanded Markov model for NaV1.1 to better define 
molecular mechanisms for an epilepsy-associated mutation. The model accurately 
reproduces all the measured whole-cell biophysical characteristics of the human wild-
type (WT) channel co-expressed with the human β1 and β2 accessory subunits, and can 
be modified to simulate the behavior observed for the GEFS+ mutant R1648H. 
Moreover, both models provide theoretical insight into NaV1.1 gating. Our models predict 
that NaV1.1 open state inactivation occurs by a biphasic mechanism that can be 
conceptualized by docking of the inactivation gate to the cytoplasmic face of the pore 
followed immediately by gate stabilization (“latching”). Importantly, the increased 
persistent current exhibited by R1648H can be predicted by introducing a selective 
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impairment of the latching mechanism, a heretofore unrecognized molecular mechanism 
for sodium channel dysfunction in epilepsy. 
 
Materials and Methods 
 
Electrophysiology 
 All heterologously expressed WT-NaV1.1 and R1648H data used for the 
generation of the computational models has been previously reported by our laboratory 
(Lossin et al., 2002; Rhodes et al., 2004; Rhodes et al., 2005; Vanoye et al., 2006). 
Briefly, biophysical characterization of WT-NaV1.1 and R1648H was performed using 
human tsA201 cells (HEK293 cells stably expressing the SV40 large T antigen). Cells 
transiently co-expressed human WT-SCN1A  or R1648H cDNA as well as the human β1 
and β2 accessory subunits. Specific voltage-clamp protocols assessing channel 
activation, inactivation and recovery from inactivation were employed. Representations 
of all voltage protocols are included as figure insets and all recordings were performed at 
room temperature. The average current recorded from multiple cells was used as a 
calibration standard to guide optimization of an accurate computational model response. 
NaV1.1 persistent current measurements were obtained by digital subtraction of currents 
recorded in the presence and absence of 10 μM tetrodotoxin (TTX, Sigma, St. Louis, MO, 
USA). Heterologously expressed NaV1.1 data is presented as mean ± SEM (Lossin et al., 
2002; Rhodes et al., 2004; Rhodes et al., 2005; Vanoye et al., 2006). 
 
Computational Modeling 
 The computational modeling was done as a collaborative project with Kristopher 
M. Kahlig, a postdoctoral fellow in the laboratory. The computational model reported 
here for NaV1.1 is based on voltage-gated sodium channel modeling efforts by Clancy 
  42  
and Kass (Clancy and Kass, 2004), Clancy and Rudy (Clancy and Rudy, 2002; Clancy 
and Rudy, 1999) and Horn and Vandenberg (Vandenberg and Horn, 1984; Horn and 
Vandenberg, 1984). Figure 4 illustrates the Markov model for NaV1.1 that includes states 
for the conditions: closed (C), open (O, conducting; Ø, non-conducting), fast inactivated 
(F) and slow inactivated (S). Transitions between states are reversible and described by 
continuous equations whose instantaneous solution depends on the membrane voltage. 
In response to a voltage change, the channel distribution shifts to a new equilibrium over 
a time course determined by the new values of the rate constants. Alteration of a single 
transition effects channel occupancy for each state. During NaV1.1 model optimization, 
the rate equations were constrained by the average whole-cell current recorded from 
heterologously expressed NaV1.1.  
 Voltage-gated ion channels do not exist at thermodynamic equilibrium at 
membrane voltages other than 0 mV (i.e., the imposed voltage gradient influences 
channel conformation) (Colquhoun et al., 2004; Finkelstein and Peskin, 1984). Violations 
of the thermodynamic principle of detailed balance (microscopic reversibility) have been 
described previously for ion channels due to the influence of outside energies (ion 
electrochemical gradient or voltage gradient) on channel gating (Finkelstein and Peskin, 
1984; Richard and Miller, 1990; Schneggenburger and Ascher, 1997; Wyllie et al., 
1996). Thus, detailed balance was not imposed on the model for NaV1.1 for the following 
reasons: 1) non thermodynamic equilibrium of NaV1.1 resulting from membrane voltage 
(Colquhoun et al., 2004; Finkelstein and Peskin, 1984; Lauger, 1995); 2) microscopic 
reversibility has not been demonstrated for NaV1.1; 3) the absorbing nature of NaV1.1 
inactivated states (low number of channel re-openings) limits the available information 
for assessing detailed balance (Vanoye et al., 2006); and 4) statistical tests for detailed 
balance lack sufficient power to test our complex and highly cyclic NaV1.1 model  
 
  43  
 
 
 
 
 
 
 
 
 
Figure 4. Diagram of NaV1.1 Markov model. The NaV1.1 Markov model consists of 21 
states connected by 37 reversible transitions. The model includes states for the 
conditions: closed (C), open (O), fast inactivated (F) and slow inactivated (S). The only 
ion conducting state is O (Ø states are non-conducting due to inactivation gate closure). 
Table 5 includes a complete list of the voltage-dependent rate equations.  
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(Rothberg and Magleby, 2001; The et al., 2002). Rate equations for all transitions are 
reported in Table 5. 
The state O represents the conducting state and the occupancy of O determines 
the sodium current by:  INa = GNa_bar* O * (V - ENa), where INa is the sodium current, GNa_bar 
is the maximum sodium current density, O is the fractional occupancy of the open state, 
V is the membrane voltage and ENa is the sodium reversal potential. For whole-cell 
simulations, the computational NaV1.1 model was expressed at a GNa_bar of 0.02 S/cm2. 
This corresponds to previously utilized sodium channel GNa_bar values of between 0.01 
and 0.2 S/cm2 (Clancy and Kass, 2004; Spampanato et al., 2004b; Spampanato et al., 
2004a; Barela et al., 2006). For single channel simulations, a single model NaV1.1 
channel was expressed with a conductance (GNa) of 17 pS. This value corresponds to 
the single channel conductance previously reported for WT-NaV1.1 (17.2 ± 0.5 pS, n = 
10) and R1648H (16.9 ± 0.9 pS, n = 7) (Vanoye et al., 2006). The average empirically 
calculated reversal potential observed for NaV1.1 was used for all simulations (ENa = 71.3 
± 1.5 mV, N = 14) (Rhodes et al., 2005).  
 Computational modeling was performed using NEURON (www.neuron.yale.edu; 
(Hines and Carnevale, 2001). All simulations were performed using the default 
integration strategy (Backward Euler) with an implicit fixed time step of 25 μs to maintain 
temporal accuracy and efficiency. Simulations were implemented on either a PC 
workstation employing two parallel Intel Xeon dual-core 2.8 GHz processors or a PC 
desktop employing an Intel Pentium 4, 3.0 GHz processor. All simulations were 
performed in Windows XP. 
 For whole-cell simulations we constructed an in silico single compartment model 
of a tsA201 cell with a length of 20.0 μm, diameter of 12.1 μm and membrane 
capacitance of 1 μf/cm2. The resulting computational surface area is equivalent to the 
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Table 5. Transition rates for NaV1.1 models 
Transition Forward Rate:   α (ms-1) Reverse Rate:    β (ms-1)
(1) C4 ↔ C3 77.149 * exp(v / 16.056) + 1.3181 5.63 * exp(-v / 47.619) + 2.6 
(2) C3 ↔ C2 48.115 * exp(v / 16.12) + 0.8 6.3137 * exp(-v / 73.692) 
(3) C2 ↔ C1 39.634 * exp(v / 44.236) + 5.3197 6.4559 * exp(-v / 28.947) 
(4) C1 ↔ O 4.25 * exp(v / 43.478) + 0.76 3.8617 * exp(-v / 44.028) 
(5) O ↔ FØ 5.2639 * exp(v / 31.779) + 3.8922e-4 0.033189 * exp(v / 11.34) + 0.22802 
(6) FØ ↔ FØL 0.4437 * exp(v / 48.1) 0.007 * exp(v / 5e4) 
(7) C4 ↔ FC4 3.0e-8  * exp(-v / 5e5) 4.592e-4 * exp(-v / 25.873) + 0.01957 
(8) C3 ↔ FC3 0.003 * exp(-v / 52.632) 5.8e-10 * exp(-v / 6.41) + 8.87e-4 
(9) C2 ↔ FC2 0.1888 * exp(-v / 50.582) 3.642e-4 * exp(-v / 16.276) 
(10) C1 ↔ FC1 0.8635 * exp(-v / 121.181) 3.1e-6 * exp(-v / 10.101) 
(11) FC4 ↔ FC3 0.02 * exp(v / 5e4) 0.0186 * exp(-v / 36.456) 
(12) FC3 ↔ FC2 0.0098053 * exp(v / 10.258) + 0.03 0.00546 * exp(-v / 33.445) 
(13) FC2 ↔ FC1 0.24 * exp(v / 9.09) 0.0082 * exp(-v / 20.92) 
(14) FC1 ↔ FØL 0.19 * exp(v / 15.151) 0.022 * exp(-v / 25.641) 
(15) C4 ↔ SC4 1.23285e-6 * exp(v / 47.772) 4.70479e-8 * exp(-v / 13.263) 
(16) C3 ↔ SC3 1.23285e-6 * exp(v / 47.772) 5.01079e-8 * exp(-v / 14.472) 
(17) C2 ↔ SC2 1.23285e-6 * exp(v / 47.772) 5.3367e-8 * exp(-v / 15.924) 
(18) C1 ↔ SC1 1.23285e-6 * exp(v / 47.772) 5.3367e-8 * exp(-v / 15.924) 
(19) O ↔ SØ 1.23285e-6 * exp(v / 47.772) 5.3367e-8 * exp(-v / 15.924) 
(20) FC4 ↔ SFC4 1.23285e-6 * exp(v / 47.772) 3.51119e-8 * exp(-v / 9.555) 
(21) FC3 ↔ SFC3 1.23285e-6 * exp(v / 47.772) 4.32876e-8 * exp(-v / 11.943) 
(22) FC2 ↔ SFC2 5.49e-4 * exp(v / 104.932) 3.65143e-8 * exp(-v / 9.926) 
(23) FC1 ↔ SFC1 1.23285e-6 * exp(v / 47.772) 9.38931e-8 * exp(-v / 158.697) 
(24) FØL ↔ SFØL 5e-4 * exp(v / 74.627) 5.97425e-5 * exp(-v / 63.111) 
(25) SC4 ↔ SC3 0.385745 *exp(v / 16.056) + 0.00659 0.02815 * exp(-v / 47.619) + 0.013 
(26) SC3 ↔ SC2 0.240575 * exp(v / 16.12) + 0.004 0.0315685 * exp(-v / 73.692)  
(27) SC2 ↔ SC1 0.19817 * exp(v / 44.236) + 0.026599 0.0322795 * exp(-v / 28.947)  
(28) SC1 ↔ SØ 0.02125 * exp(v / 43.478) + 0.0038 0.0193085 * exp(-v / 44.028)  
(29) SØ ↔ SFØL 0.026769 * exp(v / 32.146) 2.6567e-4 * exp(v / 50) + 8.8025e-4 
(30) SC4 ↔ SFC4 1.5e-10 * exp(-v / 5e5) 2.296e-6 * exp(-v / 25.873) + 9.785e-5 
(31) SC3 ↔ SFC3 1.5e-5 * exp(-v / 52.632) 2.9e-12 * exp(-v / 6.41) + 4.435e-6 
(32) SC2 ↔ SFC2 9.44e-4 * exp(-v / 50.582) 1.821e-6 * exp(-v / 16.276)  
(33) SC1 ↔ SFC1 0.0043175 * exp(-v / 121.181) 1.55e-8 * exp(-v / 10.101)  
(34) SFC4 ↔ SFC3 1e-4 * exp(v / 5e4) 9.3e-5 * exp(-v / 36.456)  
(35) SFC3 ↔ SFC2 4.90265e-5 * exp(v / 10.258) + 1.5e-4 2.73e-5 * exp(-v / 33.445)  
(36) SFC2 ↔ SFC1 1.2e-3 * exp(v / 9.091) 4.1e-5 * exp(-v / 20.921)  
(37) FSC1 ↔ SFØL 9.5e-4 * exp(v / 15.152) 1.1e-4 * exp(-v / 25.641) 
Modifications for R1648H Model  
(6) FØ ↔ FØL 0.043 * exp(v / 5e4)
Modifications for WT-NaV1.1 Model Without FO state (omit rate 6) 
(5) O ↔ FØL 5.2 *exp(v / 31.25) 0.006013 *exp(v / 23.952) 
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 average surface area measured for WT-NaV1.1 expressing tsA201 cells (7.6x10-6 cm2, n 
= 15) (Rhodes et al., 2005). For single channel simulations we constructed an in silico 
single compartment model of an outside-out membrane patch with a length of 0.5 μm, 
diameter of 0.5 μm and membrane capacitance of 1 μf/cm2. The resulting computational 
surface area corresponds to a pipette tip diameter of 1 μm. 
 To minimize artifacts due to voltage protocol discrepancies, simulation protocols 
were identical to those used to experimentally characterize WT-NaV1.1 and R1648H 
(Lossin et al., 2002; Lossin et al., 2003; Rhodes et al., 2004; Rhodes et al., 2005; 
Vanoye et al., 2006). This includes test voltage sequence as well as relaxation time. 
After the entire protocol had been recorded the model was re-initialized to steady-state 
(–120 mV) prior to the next simulation. Therefore, non-specific protocol effects (e.g. 
accumulation of inactivation) should be identical between the model and the 
heterologously expressed channel. 
 The four previously reported NaV1.1 computational models were constructed 
using the published parameters (Barela et al., 2006; Clancy and Kass, 2004; 
Spampanato et al., 2004b; Spampanato et al., 2004a). For simulation purposes, the 
GNa_bar of each model was reset to 0.02 S/cm2, the value used with our WT-NaV1.1 
model. Due to the arbitrary nature of GNa_bar, all comparisons between the previously 
reported NaV1.1 computational models and the empirically recorded NaV1.1 biophysical 
data are performed using normalized data (with the exception of Figure 9A in the online 
supplement). The four previously reported NaV1.1 models include one Markov (Model A) 
(Clancy and Kass, 2004) and three Hodgkin-Huxley style models (Models B-D) (Barela 
et al., 2006; Spampanato et al., 2004b; Spampanato et al., 2004a). The discrepancies 
between the previously reported activity of Model A and our simulations most likely 
reflect differences in simulation environment differences. These considerations are not 
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applicable to Models B-D as these were previously constructed and reported using the 
NEURON simulation environment. 
 
Data Analysis 
 Data analysis was performed using Clampfit 9.2, OriginPro 7.0 and GraphPad 
Prism 4.0. Channel inactivation was evaluated by fitting the decay phase of the whole-
cell current with the two exponential function, I/Imax = A1 × exp(-t/τ1) + A2 × exp(-t/τ2) + Ir, 
where τ1 and τ2 denote the time constants (fast and slow components, respectively), A 
represents a fractional amplitude and Ir is the level of non-inactivating current. Whole-cell 
conductance was calculated by GNa = INa / (V-ENa) and normalized to the maximum 
conductance between –80 and +20 mV. Conductance-voltage and steady-state 
availability curves were fit with Boltzmann functions to determine the voltage for half-
maximal activation/inactivation (V1/2) and the slope factor (k). The time-dependent entry 
into and the recovery from inactivation was evaluated by fitting the peak current with the 
two exponential function I/Imax = A1 × [1 – exp(-t/τ1)] + A2 × [1 – exp(-t/τ2)]. Persistent 
current was measured during the final 10 ms of a 200 ms depolarization to –10 mV and 
expressed as a percentage of peak current.  
 Using the same model parameters, sequential whole-cell simulations generate 
the identical model response. In contrast, single channel simulations are stochastic and 
sequential runs generate unique data.  Thus, whole-cell results are reported as the value 
of the measured activity and single channel results are presented as mean ± SEM for 
independent simulation sequences. To allow direct comparison of the single channel 
simulations with previously reported empirical data (Vanoye et al., 2006), single channel 
events less than 0.1 ms were excluded from analysis. 
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Results 
 The majority of ion channel computational models rely on the quantitative 
descriptions of axonal ionic currents first introduced in 1952 by Hodgkin and Huxley 
(Hodgkin and Huxley, 1952b). Subsequent work has shown that HH-style equations can 
only approximate neuronal voltage-gated sodium channel behavior (Hille, 2001; Patlak, 
1991; Baranauskas and Martina, 2006; Naundorf et al., 2006). We developed enhanced 
Markov chain models for WT-NaV1.1 and the GEFS+ mutant R1648H that very 
accurately reproduce the observed biophysical characteristics of the corresponding 
heterologously expressed channels.  
 
NaV1.1 Markov model 
 Figure 4 illustrates our Markov model for NaV1.1. The model is composed of two 
interconnected layers of states: 1) a bottom layer containing the closed (C), open (O, 
conducting; Ø, open but non-conducting) and fast inactivated states (F), and 2) a parallel 
upper layer containing the slow inactivated states (S). Only the O state conducts ions as 
Ø states have undergone inactivation. Each state approximates a theoretical 
conformation NaV1.1 adopts during activation and inactivation. However, any direct 
correlation between a state within the diagram and a particular protein conformation is 
not possible. It is likely that many transient NaV1.1 protein conformations are grouped 
and represented as a single state within the model.  
 This scheme integrates many features of previous sodium channel models 
including multiple closed states, a single conducting state, closed state inactivation and 
silent recovery from inactivation (Horn and Vandenberg, 1984; Vandenberg and Horn, 
1984; Hille, 2001; Patlak, 1991). We positioned slow inactivation as a second upper 
layer due to the experimental observations that fast and slow inactivation are discrete, 
although not entirely autonomous, mechanisms (Featherstone et al., 1996; Vedantham 
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and Cannon, 1998). Featherstone and colleagues reported that removing fast 
inactivation increased the rate of entry into slow inactivation (Featherstone et al., 1996). 
As a result, the state of one inactivation gate (open versus closed) impacts the kinetics 
of the other and parallel transitions in the model for NaV1.1 are not modeled with 
identical kinetics (e.g. C1 to SC1 compared to FC1 to SFC1). In the model, fast and slow 
inactivation mechanisms are able to independently terminate current flow through the 
pore (transitions out of O). The transitions O to FØ and O to SØ represent closure of the 
fast and slow inactivation gates, respectively. Both gates can be closed simultaneously 
(states labeled SF), but this requires two independent and sequential steps (e.g. closure 
of the fast gate followed by closure of the slow gate). 
 Transitions are described by rate equations that are instantaneously voltage-
dependent and were adjusted using previously recorded NaV1.1 whole-cell recordings as 
a calibration standard (Rhodes et al., 2005). The model reproduces many key features 
of voltage-gated sodium channel behavior. At the holding potential of –120 mV (under 
steady-state conditions) 97% of channels are located in C4. Upon depolarization, 
channels move through the 4 closed states (C4-C1) before entering the ion conducting O 
state. Channels can enter fast inactivation (F states) from either open or closed states. 
For a depolarization to –10 mV, a transient equilibrium is established after 20 ms with 
69% of channels occupying FØL and 24% in FC1. Long lasting depolarizations drive 
channels from the F states into the upper layer of slow inactivated states (S states). After 
10 s at –10 mV, channels predominately occupy the upper states (44% FSØ, 32% FSC1, 
and 6% FSC2). After repolarization, channels return to the lower layer reestablishing the 
steady-state equilibrium (either transitioning though the F states or moving directly into C 
states). 
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Open State Inactivation 
 The whole-cell current carried by human NaV1.1 inactivates following a double 
exponential time course (Lossin et al., 2002; Rhodes et al., 2004; Rhodes et al., 2005; 
Vanoye et al., 2006; Lossin et al., 2003). Figure 5 illustrates theoretical investigations 
into possible mechanisms for generating this behavior. We first attempted to model open 
state inactivation with a single step (O to FØL, Figure 5A). The resulting simulated 
whole-cell current (“Model”) decayed too quickly and followed a single exponential time 
course. For comparison with the current generated by heterologously expressed NaV1.1, 
the average NaV1.1 whole-cell current recorded from multiple independent cells is 
depicted as “Actual” in Figure 5A (Rhodes et al., 2005). Integrating the Model and Actual 
current traces between the peak and 10 ms reveals that a single step inactivation 
pathway conducts only 65.4% of the actual sodium influx. We next adjusted the rate 
constants for the O to FØL transition in an effort to introduce a second component to the 
whole-cell current inactivation. Slowing the O to FØL transition significantly increased 
the peak current amplitude and slowed the overall current decay without introducing a 
second time component (data not shown). Slowing inactivation by allowing channel 
reopening (increasing the FØL to O transition in Figure 5A) increased the peak current 
and induced a significant persistent current without introducing a second inactivation 
component (data not shown).  
 We next attempted to model the biphasic whole-cell current decay with two, 
parallel fast inactivation transitions (two transitions leading from O to the F states). 
Preliminary experiments with these models were unable to generate a whole-cell current 
decay that was well fit by a two-exponential equation (data not shown). Moreover, the 
mechanism of fast inactivation for voltage-gated sodium channels has been described in 
great detail and consists of pore occlusion by the DIII-DIV intracellular loop (Catterall et 
al., 2005; Vassilev et al., 1989). Introduction of a second fast inactivation pathway from  
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Figure 5. Secondary stabilization is essential for open state inactivation. NaV1.1 
open state inactivation was explored by modeling different inactivation mechanisms. (A) 
An open state inactivation pathway consisting of a single step (O to FØL) was unable to 
reproduce the biphasic whole-cell current characteristic of NaV1.1. (B) A two step 
inactivation pathway reproduces the NaV1.1 biphasic whole-cell current decay. The 
modeled inactivation pathway includes an unstable intermediate state FØ between the 
open state O and the stabilized “latched” inactivated state FØL. 
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O would imply a second fast inactivation gate that is not supported by the experimental 
data. 
 An alternative approach to reproduce the biphasic whole-cell current decay is to 
add an intermediate state in the open state inactivation pathway. Figure 5B illustrates an 
inactivation mechanism for NaV1.1 that consists of 2 states in series (FØ and FØL). In 
this design, channels leaving O first enter the less stable fast inactivated state FØ. Most 
channels quickly transition into the absorbing fast inactivated locked state FØL. A small 
fraction of FØ channels transiently return to O thereby re-opening before inactivating 
again to FØ and finally arriving in FØL. The sodium current generated by this model 
overlay the current recorded for heterologously expressed NaV1.1 (Figure 5B). 
Integrating the Model current trace between the peak and 10 ms reveals that a two step 
open state inactivation pathway conducts 98.5% of the actual sodium influx. All 
subsequent simulations were performed with models including the FØ state.  
  
Model WT-NaV1.1 generates accurate whole-cell currents 
 To verify that the WT-NaV1.1 model reproduces the fundamental characteristics 
of NaV1.1 activity, we characterized the whole-cell sodium currents generated by the 
model and compared these results to those previously reported for NaV1.1 (Rhodes et 
al., 2005). Figure 6 illustrates a representative family of sodium current traces elicited by 
voltage steps to various potentials for (A) a tsA201 cell heterologously expressing WT-
NaV1.1 and (B) model WT-NaV1.1. In both cases, the measured currents were inward 
and transient due to the rapid activation and inactivation of sodium influx. Overlaying the 
–10 mV current trace from panels A and B verifies that the model WT-NaV1.1 activates 
and inactivates with kinetics similar to those actual measured for WT-NaV1.1 (Figure 
6C). Figure 6D illustrates normalized current traces generated by the previously reported  
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Figure 6. WT-NaV1.1 model generates accurate whole-cell currents. (A) 
Representative whole-cell currents recorded from a tsA201 cell co-expressing the 
human wild-type SCN1A and the human β1 and β2 accessory subunits. Currents were 
elicited by voltage steps to potentials between –80 and +60 mV from a holding potential 
of –120 mV shown as panel inset. (B) Model WT-NaV1.1 whole-cell currents recorded in 
response to the stimulation protocol in panel A. (C) Comparison of actual and model 
WT-NaV1.1 current traces for the –10 mV voltage step from panels A and B, 
respectively. (D) Comparison of actual WT-NaV1.1 and all previously reported NaV1.1 
computational models (Barela et al., 2006; Clancy and Kass, 2004; Spampanato et al., 
2004b; Spampanato et al., 2004a) in response to the -10 mV voltage step. 
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NaV1.1 models in response to a voltage step to –10 mV (Barela et al., 2006; Clancy and 
Kass, 2004; Spampanato et al., 2004b; Spampanato et al., 2004a). In our simulation 
environment, each model displayed altered current kinetics compared to those actually 
measured for WT-NaV1.1. Figure 7 illustrates the whole-cell current generated by the 
previously reported WT-NaV1.1 models in response to the voltage protocol in Figure 6A. 
 To further demonstrate the accuracy of the whole-cell currents generated by 
model WT-NaV1.1, we characterized their activation and inactivation kinetics.  Figure 8A 
illustrates the peak current-voltage relationship for the whole-cell currents shown in 
Figure 6. There is minimal difference between the peak current generated by the WT- 
NaV1.1 model (open symbols) and actual NaV1.1 (filled symbols). At 0 mV, the model 
generates a peak current of –307 pA/pF compared to –305 ± 38 pA/pF (n = 14) for 
actual WT-NaV1.1 (Rhodes et al., 2005). We measured time to peak current for each 
voltage as an estimation of the rate of channel activation. Plotting the time to peak 
current for simulated and actual WT-NaV1.1 demonstrates that our model activates with 
a similar time course (Figure 8B). At –10 mV, the time to peak current for model WT-
NaV1.1 was 0.35 ms compared to 0.38 ± 0.03 ms (n = 14) for actual WT-NaV1.1. Figure 
8C illustrates that the voltage-dependence of activation obtained from the normalized 
conductance values for simulated WT-NaV1.1 is similar to that directly measured for the 
heterologously expressed channel (fit parameters are listed in Table 6) (Rhodes et al., 
2005). To quantitatively evaluate NaV1.1 current inactivation, the decay of the whole-cell 
current trace was fit with a two exponential equation (Table 7). Figure 8D demonstrates 
that the fast and slow inactivation components (τ1 and τ2, respectively) for model WT- 
NaV1.1 are comparable to those previously reported. The differences in τs most likely 
reflect the contribution (5 ms after voltage step) of non-specific whole-cell currents in the 
heterologous recording system that are absent in silico (Figure 6A). These results  
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Figure 7. Whole-cell currents generated by previously reported NaV1.1 models. 
Simulated whole-cell currents generated by previously reported computational models 
for NaV1.1 (Barela et al., 2006; Clancy and Kass, 2004; Spampanato et al., 2004b; 
Spampanato et al., 2004a). The stimulation protocol was identical to that used in Figure 
6A and the red trace highlights the voltage step to –10 mV. 
  56  
 
 
Figure 8. Analysis of simulated WT-NaV1.1 whole-cell current. The WT-NaV1.1 
computational model (open symbols) reproduces the whole-cell biophysical 
characteristics of WT-NaV1.1 heterologously expressed in tsA201 cells (n = 14, filled 
symbols).  Whole-cell currents were elicited by the voltage protocol in panel A inset. (A-
B) Peak current amplitude and time to peak current were plotted for each potential, 
respectively. (C) The voltage dependence of channel activation was calculated from the 
normalized conductance values. Data were fit using a Boltzmann equation and fit 
parameters are provided in Table 6. (D) Inactivation time constants were estimated by 
fitting the decay phase of the whole-cell current with a two exponential function. Fit 
parameters are provided in Table 7 and the fast and slow inactivation time constants are 
plotted for each potential.  
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Table 6. Biophysical parameters for activation and fast inactivation for NaV1.1 models 
  Activation Voltage dependence of fast inactivation 
Recovery from fast 
inactivation§ 
  V1/2 (mV) k (mV) n  V1/2 (mV) k (mV) n  τ1 (ms)  τ2 (ms) n 
Actual WT-NaV1.1 -19.4 ± 1.4 7.9 ± 0.2 13  -62.7 ± 1.7 -6.9 ± 0.2 14  2.4 ± 0.3   (85 ± 1%) 
41.0 ± 6.0 
   (15 ± 1%) 14 
             
Model WT-NaV1.1 -19.9 8.5   -61.3 -7.7   2.2  (82 %) 
26.6 
 (18 %)  
Model R1648H -19.9 8.5   -61.3 -7.8   2.1 (81%) 
23.0 
 (19 %)  
§ values in parentheses represent amplitude. 
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Table 7. Whole-cell current inactivation time constants for NaV1.1 models 
 Fast Component§  Slow Component§ 
Actual Model Model  Actual Model Model  WT-NaV1.1 WT-NaV1.1 R1648H  WT-NaV1.1 WT-NaV1.1 R1648H 
-30 mV 2.73 ± 0.49    (69 ± 18%) 
2.20 
(81 %) 
2.22 
(86 %)  
6.4 ± 1.5 
   (31 ± 18%) 
5.9 
(19 %) 
7.0 
(14 %) 
-20 mV 1.34 ± 0.18  (86 ± 5%) 
1.04 
(81 %) 
1.03 
(83 %)  
5.5 ± 0.6 
(14 ± 5%) 
4.0 
(19 %) 
3.8 
(17 %) 
-10 mV 0.72 ± 0.06  (93 ± 1%) 
0.62 
(82 %) 
0.68 
(87 %)  
6.0 ± 0.7 
     (7 ± 0.8%) 
3.0 
(18 %) 
3.3 
(13 %) 
0 mV 0.47 ± 0.03  (94 ± 1%) 
0.46 
(87 %) 
0.46 
(89 %)  
4.4 ± 0.5 
      (6 ± 0.7%) 
2.8 
(13 %) 
2.6 
(11 %) 
10 mV 0.37 ± 0.02  (94 ± 1%) 
0.32 
(87 %) 
0.33 
(89 %)  
3.9 ± 0.6 
      (6 ± 0.6%) 
2.2 
(13 %) 
2.2 
(11 %) 
20 mV 0.31 ± 0.02  (92 ± 1%) 
0.26 
(89 %) 
0.23 
(85 %)  
3.0 ± 0.3 
      (8 ± 1.2%) 
1.9 
(11 %) 
1.6 
(15 %) 
30 mV 0.28 ± 0.02  (90 ± 1%) 
0.20 
(84 %) 
0.19 
(83 %)  
2.7 ± 0.2 
    (10 ± 1.3%) 
1.5 
(16 %) 
1.4 
(17 %) 
§ values in parentheses represent fractional amplitude. 
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demonstrate that our WT-NaV1.1 model reproduces the fundamental properties of the 
whole-cell current (activation and inactivation) recorded from heterologously expressed 
NaV1.1 (Rhodes et al., 2005). For comparisons with our model, Figures 9-11 illustrate 
properties of the whole-cell currents generated by other previously reported WT-NaV1.1 
models (Barela et al., 2006; Clancy and Kass, 2004; Spampanato et al., 2004b; 
Spampanato et al., 2004a). 
 
Model WT-NaV1.1 replicates fast and slow inactivation 
 Sodium channel fast inactivation is critical for limiting sodium influx during 
excitation and an accurate computational model should reproduce the fast inactivation 
properties of NaV1.1. We examined both entry into (Figure 12A) and recovery from 
(Figure 12B) fast inactivation for our WT-NaV1.1 model using standard two-pulse voltage 
protocols. The results were compared to the parameters measured for WT-NaV1.1 
(Table 6) (Rhodes et al., 2005). Figure 12A illustrates that our WT-NaV1.1 model (open 
symbols) simulates currents that entered fast inactivation with the same voltage 
dependence as actual WT-NaV1.1 (filled symbols). Similar to heterologously expressed 
WT-NaV1.1, the model also exhibited recovery from fast inactivation that is well fit with a 
two exponential equation. 
 Slow inactivation has been proposed to regulate channel availability and may 
play a significant role during periods of prolonged depolarization or repetitive stimulation. 
We used two-pulse voltage protocols to test the ability of our WT-NaV1.1 model to 
accurately emulate the time and voltage dependence of slow inactivation. The results 
were compared to the parameters actually measured for WT-NaV1.1 (Table 8) (Rhodes 
et al., 2005). Model WT-NaV1.1 (open symbols) exhibits the same time dependence of 
entry into slow inactivation as actual WT-NaV1.1 (filled symbols, Figure 13A). Figure 13B 
shows that simulated WT-NaV1.1 enters slow inactivation with an equivalent voltage 
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Figure 9. Analysis of whole-cell currents generated by other NaV1.1 models. 
Comparison of the whole-cell current measured from heterologously expressed WT-
NaV1.1 (black symbols) and those generated by the previously reported NaV1.1 
computational models (colored symbols). Whole-cell currents were elicited by voltage 
steps to potentials between –80 and +60 mV from a holding potential of –120 mV 
(stimulation protocol used in Figures 8A). (A-B) Peak current amplitude and time to peak 
current plotted for each potential, respectively. (C) The voltage dependence of channel 
activation was plotted using the normalized conductance values. (D) Inactivation time 
constants were estimated by fitting the decay phase of the whole-cell currents in Figure 
7 with a single exponential function. Fitting the current decay with a double exponential 
equation failed to reveal a second inactivation time component. For comparison with 
actual NaV1.1 inactivation, the fast inactivation time constants are plotted for each 
potential (data from Figure 8D).  
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Figure 10. Fast inactivation exhibited by other NaV1.1 models. Comparison of fast inactivation exhibited by heterologously 
expressed WT-NaV1.1 (black symbols) and the previously reported NaV1.1 computational models (colored symbols). (A) Voltage 
dependent entry into fast inactivation was examined using a two-pulse protocol consisting of a 100 ms conditioning pulse at various 
potentials followed by a test pulse at –10 mV. (B) Time dependent recovery from fast inactivation was examined using a two-pulse 
protocol consisting of a 100 ms inactivation pulse at –10 mV followed by a variable length return to –120 mV and a second test pulse 
to –10 mV.  
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Figure 11. Slow inactivation exhibited by other NaV1.1 models. Comparison of the 
slow inactivation exhibited by heterologously expressed WT-NaV1.1 (black symbols) and 
previously reported NaV1.1 computational models (colored symbols). (A) Time 
dependent entry into slow inactivation was examined using a two-pulse protocol 
consisting of a variable length inactivation pulse to –10 mV followed by a test pulse at –
10 mV. Effects of fast inactivation were minimized using a 50 ms inter-pulse to –120 mV 
to relieve fast inactivation.  (B) Voltage dependent entry into slow inactivation was 
examined using a two-pulse protocol consisting of a 30 sec conditioning pulse at various 
potentials followed by a test pulse at –10 mV. Effects of fast inactivation were minimized 
using a 50 ms inter-pulse to –120 mV to relieve fast inactivation.  (C) Time dependent 
recovery from slow inactivation was examined using a two-pulse protocol consisting of a 
30 sec inactivation pulse to –10 mV followed by a variable length inter-pulse to –120 mV 
and a test pulse to –10 mV. 
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Figure 12. Analysis of simulated WT-NaV1.1 fast inactivation. The WT-NaV1.1 model (open symbols) reproduces the fast 
inactivation characteristics of channels heterologously expressed in tsA201 cells (n = 14, filled symbols). (A) Voltage-dependent 
entry into fast inactivation was examined using a two pulse protocol consisting of a 100 ms conditioning pulse at various potentials 
followed by a test pulse at –10 mV. (B) Time-dependent recovery from fast inactivation was examined using a two pulse protocol 
consisting of a 100 ms inactivation pulse at –10 mV followed by a variable length return to –120 mV and a second test pulse to –10 
mV. Data were fit using either a Boltzmann (A) or two exponential (B) equation; fit parameters are provided in Table 6. 
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Figure 13. Analysis of simulated WT-NaV1.1 slow inactivation. The WT-NaV1.1 model (open symbols) reproduces the slow 
inactivation characteristics of heterologously expressed channels (n = 11, filled symbols). (A) Time-dependent entry into slow 
inactivation was examined using a two-pulse protocol consisting of a variable length inactivation pulse to –10 mV followed by a test 
pulse at –10 mV. Effects of fast inactivation were minimized using a 50 ms inter-pulse step to –120 mV to relieve fast inactivation.  
(B) Voltage-dependent entry into slow inactivation was examined using a two-pulse protocol consisting of a 30 sec conditioning pulse 
at various potentials followed by a test pulse at –10 mV. Effects of fast inactivation were minimized using a 50 ms inter-pulse step to 
–120 mV to relieve fast inactivation. (C) Time-dependent recovery from slow inactivation was examined using a two pulse protocol 
consisting of a 30 sec inactivation pulse to –10 mV followed by a variable length inter-pulse step to –120 mV and a test pulse to –10 
mV. Data were fit using either a two exponential (A and C) or Boltzmann (B) equation; fit parameters are provided in Table 8. 
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Table 8. Slow inactivation parameters for NaV1.1 models 
  Onset of slow inactivation§ Voltage dependence  of slow inactivation 
Recovery from slow 
inactivation§ 
  τ1 (ms) τ2 (ms) Ir n  V1/2 (mV) k (mV) Ir n  τ1 (ms)  τ2 (ms) n 
Actual WT-NaV1.1 30 ± 7 (3 ± 1%) 
3029 ± 283 
(83 ± 1%) 14 ± 1 14  -66.7 ± 2.0 7.8 ± 0.2 10 ± 1  11  
 238 ± 16  
    (65 ± 3%)
2487 ± 240 
   (35 ± 3%) 11 
               
Model WT-NaV1.1 30 (1 %) 
2793 
(84 %) 15   -68.5 6.2 17   
225 
 (63 %) 
2647 
 (37 %)  
Model R1648H 30 (1 %) 
3112 
(83 %) 16   -68.6 6.1 18   
221 
(63 %) 
2650 
 (37 %)  
§values in parentheses represent amplitude. 
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dependence compared to actual WT-NaV1.1. In addition, simulated WT-NaV1.1 
recovered from slow inactivation with the same biphasic time-dependence of actual WT-
NaV1.1 (Figure 13C).  
 
Modeling increased persistent current 
 Beginning with the model for WT-NaV1.1, we constructed a computational model 
for the GEFS+ mutant R1648H. The major biophysical defect exhibited by R1648H is an 
increased persistent current resulting from increased probability of late single channel 
openings (Lossin et al., 2002; Rhodes et al., 2004; Vanoye et al., 2006). We were able 
to generate this biophysical phenotype by destabilizing the fast inactivated state FØL 
within the WT-NaV1.1 Markov model (Figure 4).  Increasing the rate constant for the 
transition from FØL to FØ (β6, Table 5) allowed a small fraction of channels to transiently 
re-enter the open state O and generate the increased persistent current (Figure 14A, 
inset). No other changes, such as additional states, were needed to generate this 
aberrant channel activity. 
 Figure 14A illustrates whole-cell current traces for the models WT-NaV1.1 and 
R1648H in response to a voltage step to –10 mV from a holding potential of –120 mV. 
R1648H exhibits a significant persistent current beginning 10 ms after the voltage step. 
The persistent current predicted between 190-200 ms after the voltage step for our 
R1648H model was 1.8 % of peak current compared to 0.3 % for the WT-NaV1.1 model. 
Figure 14B illustrates that the persistent current generated by both models (open bars) 
corresponds well with the persistent current measured for heterologously expressed WT-
NaV1.1 (filled bar, 0.3 ± 0.1 % of peak, n = 9) and R1648H (filled bar, 1.8 ± 0.3 % of 
peak, n = 6) (Rhodes et al., 2004).  
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Figure 14. Computational model of GEFS+ mutant R1648H. (A) The model for R1648H was constructed by destabilizing the fast 
inactivated state FØL (6-fold increase in β6, inset). Whole-cell current simulations of R1648H reveal increased persistent sodium 
current compared to simulated WT-NaV1.1. (B) Levels of simulated persistent current for models WT-NaV1.1 (open bar, 0.3 % of 
peak current) and R1648H (open bar, 1.8 % of peak current) replicate the average persistent current empirically measured for 
heterologously expressed WT-NaV1.1 (filled bar, 0.3 ± 0.1 % of peak current, n = 9) and R1648H (filled bar, 1.8 ± 0.3 % of peak 
current, n = 6). Persistent current was measured during the final 10 ms of a 200 ms voltage step to –10 mV. 
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 Complete characterization of simulated R1648H activation, fast inactivation and 
slow inactivation was performed as described for the WT-NaV1.1 model. There was no 
difference between R1648H and WT-NaV1.1 (Tables 6-8) in agreement with the original 
study of this mutant (Lossin et al., 2002). Both computational models accurately 
reproduce the biophysical parameters that were measured for each channel. Using our 
simulation environment, previously reported NaV1.1 models predicted persistent current 
levels that varied widely between 0.6 and 2.3% of peak current (Figure 15). 
 
Simulated R1648H exhibits late channel openings 
 The computational models for WT-NaV1.1 and R1648H were generated using 
experimentally recorded NaV1.1 whole-cell data as a calibration standard to tune the 
voltage-dependent rate equations (Table 5). We next tested whether our models could 
reproduce the single channel properties observed for WT-NaV1.1 and R1648H (Vanoye 
et al., 2006). We used the stochastic single channel simulator in NEURON to test the 
single channel characteristics of model WT-NaV1.1 and model R1648H in response to 
voltage steps to 0 mV. Figures 16A and 16B illustrate 5 consecutive voltage step 
simulations for models WT-NaV1.1 and R1648H, respectively. The mean open time 
determined for simulated WT-NaV1.1 was 0.29 ± 0.02 ms (n = 3) compared to 0.30 ± 
0.02 ms (n = 3) for that generated by the R1648H model. These open times compare 
well with the open times measured for heterologously expressed WT-NaV1.1 (0.25 ± 
0.03 ms, n = 4) and R1648H (0.23 ± 0.02 ms, n = 5) (Vanoye et al., 2006). 
 Model R1648H exhibits an increase in late single channel openings (>10 ms after 
voltage step) compared to WT-NaV1.1. Averaging 200 consecutive simulations reveals 
that WT-NaV1.1 exhibits a low level of late single channel activity (Figure 16C). In 
contrast, model R1648H opens late in many simulations (Figure 16D).  Figures 16E and 
16F illustrate the open probability (Po) diary for the same 200 consecutive simulations of  
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Figure 15. Persistent current exhibited by other NaV1.1 models. (A) Whole-cell simulations of previously reported NaV1.1 models 
(colored lines) reveal wide variation in levels of persistent current compared to heterologously expressed WT-NaV1.1 (black line). 
Representative currents generated in response to a 200 ms voltage step to –10 mV and normalized to peak current amplitude. (B) 
The persistent current generated by previously reported NaV1.1 models varied between 0.06 and 2.28 % of peak. Persistent current 
measurements were made during the final 10 ms of a 200 ms voltage step. 
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Figure 16. Late channel openings underlie model R1648H persistent current. (A-B) 
Five consecutive single channel simulations for WT-NaV1.1 and R1648H, respectively. 
Downward deflections represent channel openings and arrows indicate onset of voltage 
step from –120 to –10 mV. (C-D) Representative ensemble average of 200 consecutive 
simulations using WT-NaV1.1 and R1648H models, respectively. (E-F) Open probability 
(Po) diary for each of the 200 simulations for WT-NaV1.1 and R1648H, respectively. Po 
calculated 0-80 ms following voltage step. 
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model WT-NaV1.1 and R1648H.  The average probability of late channel opening (Po 20-
100 ms) for model R1648H (0.0036 ± 0.0002, n = 3) was 6-fold greater than simulated 
WT-NaV1.1 (0.0006 ± 0.0002, n = 3, students t-test, P < 0.0001). These results are very 
similar to the 7.4-fold increase in late Po measured for heterologously expressed 
R1648H compared to WT-NaV1.1 (Vanoye et al., 2006). 
 These data demonstrate that the whole-cell persistent current generated by 
model R1648H (Figure 14) results from an increase in late single-channel openings as a 
direct result of destabilizing the fast inactivation locked state (FØL). Based on these 
findings, we propose that selective impairment of the “latching” step of fast inactivation is 
responsible for the increased persistent current observed for this GEFS+ mutant. It is not 
yet understood how the R1648H mutation impair the “latching” step of fast inactivation, 
but the mutation may disrupt the conformation such that the proximal C-terminus is 
unable stabilize the fast inactivated state. 
 
Discussion 
 Computational modeling is an effective experimental approach to explore 
alterations in ion channel behavior that result from disease-associated mutations. Here 
we describe the construction of ion channel models for WT-NaV1.1 and R1648H that are 
based on previously recorded NaV1.1 whole-cell experimental data. We fully 
characterized each model to ensure biophysical accuracy. Moreover, our models provide 
novel insight into WT-NaV1.1 open state inactivation and define a previously 
unrecognized molecular mechanism to explain increased persistent current exhibited by 
a GEFS+ mutant. 
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Comparison of NaV1.1 models 
 Previous attempts to generate computational models for WT-NaV1.1 have been 
based on either HH-style differential equations or Markov chains (Barela et al., 2006; 
Clancy and Kass, 2004; Spampanato et al., 2004b; Spampanato et al., 2004a). We 
initially sought to modify an existing WT-NaV1.1 model to fit our experimentally recorded 
NaV1.1 activity. Each previously reported WT-NaV1.1 model was reconstituted and the 
resulting whole-cell currents were compared to heterologously expressed human NaV1.1 
co-expressed with both human β1 and β2 accessory subunits in human tsA201 cells 
(Figures 6D, 7, 9-11, and 15). Although each previously reported WT-NaV1.1 model 
reproduced certain NaV1.1 activities, a rigorous characterization of the currently 
available models revealed that none were able to fully replicate the behavior of the 
channel (Figures 6D, 7, 9-11, and 15). This may reflect the source of data used during 
the construction and calibration of each model. The models sharing the HH-equation 
architecture were calibrated using currents recorded from Xenopus laevis oocytes co-
expressing rat Scn1a and only β1. In contrast, the previously reported NaV1.1 Markov 
model was constructed using human NaV1.1 data.  
 We chose to extend the efforts of Clancy and Kass (Clancy and Kass, 2004) to 
generate a Markov chain model for NaV1.1 that reproduces all the experimentally 
recorded whole-cell properties of the heterologously expressed channels. A Markov 
design provides the parameter flexibility necessary to calibrate the rate equations to fit 
our experimental data. The major alterations to the previous model include the addition 
of a two-step open state inactivation pathway and a second layer of slow inactivated 
states. All rate equations were modified to reproduce the previously recorded activity of 
heterologously expressed human NaV1.1. 
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 The computational models we developed for WT-NaV1.1 and R1648H generated 
whole-cell currents that are highly similar to the experimentally recorded data (Figures 5-
6) (Lossin et al., 2002; Rhodes et al., 2004; Rhodes et al., 2005; Vanoye et al., 2006). 
Channel current was voltage-dependent, inward and transient. Characterization of the 
whole-cell currents revealed the proper biophysical parameters for the peak current 
amplitude (Figure 8A), time course of activation (Figure 8B), voltage-dependence of 
activation (Figure 8C) and biphasic whole-cell current inactivation (Figure 8D). Moreover, 
the model WT-NaV1.1 and model R1648H reproduced the fast and slow inactivation 
processes for each channel, respectively. Specifically, the models exhibited virtually the 
same voltage-dependence of fast inactivation (Figure 12A), time-dependent recovery 
from fast inactivation (Figure 12B), time-dependent entry into slow inactivation (Figure 
13A), voltage-dependence of slow inactivation (Figure 13B) and time-dependent 
recovery from slow inactivation (Figure 13C) as experimentally determined channel 
properties. This comprehensive characterization confirms that the models WT-NaV1.1 
and R1648H exhibit the proper biophysical parameters necessary to accurately emulate 
the heterologously expressed channel.  
 
Open state inactivation is a two-step process 
 Our NaV1.1 model incorporates a two-step pathway for open state inactivation 
(Figures 4 and 5). This scheme was necessary to reproduce the biphasic decay of the 
NaV1.1 whole-cell current (Figure 5) (Lossin et al., 2002; Rhodes et al., 2004; Rhodes et 
al., 2005; Vanoye et al., 2006; Lossin et al., 2003). The cardiac voltage-gated sodium 
channel (SCN5A, NaV1.5) also exhibits a two-component whole-cell current decay 
(Makita et al., 2000; Wang et al., 1996; Wang et al., 2000). Recent experiments have 
revealed NaV1.5 inactivation to be a multiple step process resulting from pore occlusion 
by the DIII-DIV inactivation loop followed by inactivation gate stabilization by a second 
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structure encoded in the proximal C-terminal tail (Cormier et al., 2002; Cormier et al., 
2002; Glaaser et al., 2006; Motoike et al., 2004). The sodium channel C-terminal tail also 
influences the rate of fast inactivation. In experiments involving NaV1.5/NaV1.2 chimeras, 
the rate of whole-cell current inactivation was determined primarily by the C-terminal tail 
(Mantegazza et al., 2001).  
 Although the C-terminus of NaV1.1 has not been directly linked to inactivation, a 
high homology exists between the neuronal isoforms SCN1A and SCN2A (~87%) as 
well as the cardiac SCN5A (~60%) (Plummer and Meisler, 1999; Catterall et al., 2005). 
Our NaV1.1 models predict that similar to NaV1.5 and NaV1.2, a second molecular 
interaction is important for the stabilization of the inactivation gate. This stabilization 
could result from the NaV1.1 C-terminus as has been proposed for NaV1.5 (Cormier et 
al., 2002; Mantegazza et al., 2001; Glaaser et al., 2006; Motoike et al., 2004). However, 
models alone cannot implicate structural interactions. The stabilization of inactivation 
may rely on additional channel regions or other associated proteins, such as the 
accessory β subunits.  
 It is worth noting that the biphasic open state inactivation proposed here for 
NaV1.1 (Figure 5B) should not be confused with (or compared to) the two-phase 
recovery from fast and slow inactivation (Figures 12B and 13C). Extensive biophysical 
characterization of NaV1.1 as well as other voltage-gated sodium channels has 
demonstrated that inactivated channels do reopen during the recovery process (Kuo et 
al., 2006). Thus, recovery from inactivation is distinct from entry into inactivation. The 
mechanism(s) underlying the biphasic recovery from inactivation have not been 
completely explored. 
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Novel mechanism for increased persistent current 
 The persistent current model R1648H was constructed by altering a single rate 
constant in the WT-NaV1.1 model. The fast inactivated state FØL was destabilized by 
increasing the rate constant β6. This modification allows a small number of channels to 
re-enter the open state and generate the characteristic persistent current recorded for 
this GEFS+ mutant. Figure 14 illustrates that model R1648H exhibits whole-cell 
persistent current that is comparable to the increased persistent current actually 
measured for this mutant (Rhodes et al., 2004). In agreement with actual observations, 
this abnormal activity results from model R1648H exhibiting an increase in late channel 
openings (Figure 16) and not bursting behavior (Vanoye et al., 2006). 
 It is worth noting that the R1648H model did not generate Po values as large as 
those actually reported for R1648H (Vanoye et al., 2006). The large open probability for 
R1648H (0.1 - 0.3) observed for a subset of voltage sweeps partially reflects a second 
prolonged open time (Vanoye et al., 2006). Although the models for WT-NaV1.1 and 
R1648H accurately reproduce the NaV1.1 whole-cell biophysical activity, future versions 
of the models may need to include a second open state with a longer dwell time to 
improve the simulated single-channel behavior. Nevertheless, our models have accurate 
whole-cell sodium current properties to begin neuronal simulations investigating 
mechanisms of R1648H epileptogenesis. 
 The model for R1648H predicts a novel mechanism for the persistent current 
generated by this GEFS+ mutant. We were able to replicate the increased persistent 
current exhibited by R1648H by altering a single rate constant (β6) in the WT-NaV1.1 
model. This implies that introducing a histidine at position 1648 within the S4 segment of 
DIV (R1648H) inhibits the secondary stabilization of fast inactivation. Experimental 
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investigation will be necessary to confirm and characterize these theoretical predictions 
for open state inactivation. 
 Our models of WT-NaV1.1 and R1648H generate whole-cell currents that very 
accurately recapitulate the currents measured for heterologously expressed channels 
(Figure 6). This feature of our models will be highly valuable when constructing neuronal 
simulations. It is well accepted that proper in vivo excitability results from the integrated 
activity of a collection of ion conductances. Simulating accurate channel behavior is vital 
for engineering the next generation of neuronal excitability models. 
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CHAPTER III 
 
IMPAIRED NAV1.2 FUNCTION AND REDUCED CELL SURFACE 
EXPRESSION IN BENIGN FAMILIAL NEONATAL-INFANTILE SEIZURES 
 
 
Introduction 
 Voltage-gated sodium channels are responsible for the initiation and propagation 
of action potentials in excitable tissues. These heteromultimeric complexes are 
comprised of a large (~260 kDa) pore-forming α subunit and smaller (~30 kDa) β 
accessory subunits. The α subunit is comprised of four homologous domains (DI-DIV) 
and exhibits significant homology to voltage-gated potassium and calcium channels. 
Recent structural studies have shown functional voltage-sensing and central pore 
subdomains within the predicted four-fold pseudo-symmetrical DI-DIV arrangement 
(Figures 3 and 17A) (Catterall, 2000). Abnormal biophysical activity caused by mutations 
within channel subdomains is a common theme in inherited channelopathies, and 
epilepsy in particular. 
 Mutations in three neuronal voltage-gated sodium channel genes (SCN1A, 
SCN2A, and SCN1B) have been associated with a genetic predisposition to epilepsy 
(Meisler and Kearney, 2005; Harkin et al., 2007). Specifically, most mutations in SCN2A, 
encoding the pore-forming subunit of NaV1.2, have been identified in cases of benign 
familial neonatal-infantile seizures (BFNIS) (Heron et al., 2002; Berkovic et al., 2004; 
Herlenius et al., 2007) (Figure 17A). This epileptic syndrome is characterized by the 
onset of afebrile generalized seizures at an early age and spontaneous remission within 
the first year of life. The onset of symptoms in BFNIS, typically between 2 days and 3.5 
months, overlaps that of benign familial neonatal convulsions (BFNC) and benign familial 
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infantile seizures (BFIS) (Kaplan and Lacey, 1983). BFNC caused by mutations in 
KCNQ2 and KCNQ3 potassium channel genes has an earlier age of onset (Singh et al., 
1998; Charlier et al., 1998). BFIS shares some clinical features with BFNIS, but has a 
later onset (after three months) and can be associated with mutations in SCN2A, 
ATP1A2, as well as other unidentified genes (Striano et al., 2006a). Seizures associated 
with BFNIS respond well to anticonvulsants and spontaneously remit within the first year 
of life without long term neurological sequelae. BFNIS exhibits autosomal dominant 
inheritance with a high degree of penetrance (Berkovic et al., 2004).  
 Mutations in NaV1.2 have been infrequently associated with more severe forms of 
epilepsy. A missense SCN2A mutation was identified in a generalized epilepsy with 
febrile seizures plus (GEFS+) patient (Sugawara et al., 2001) and a truncation mutation 
was identified in a patient exhibiting features of severe myoclonic epilepsy of infancy 
(SMEI) (Kamiya et al., 2004). These two mutations appear to cause severe defects in 
channel activity (Sugawara et al., 2001; Kamiya et al., 2004). However, the relationships 
among specific mutations, channel dysfunction and corresponding clinical phenotype are 
not well defined for benign SCN2A-associated epilepsies, like BFNIS. 
 To date, eight SCN2A mutations have been associated with BFNIS (Figure 17A) 
(Heron et al., 2002; Berkovic et al., 2004; Herlenius et al., 2007). The BFNIS mutations 
affect different regions of the protein structure and affect highly conserved residues 
(Figures 17A and 32). Four of the BFNIS mutations have been studied previously by 
overexpressing the α subunit alone in either rat cortical neurons or HEK293T cells 
(Scalmani et al., 2006; Xu et al., 2007b). Here we present the functional characterization 
of three BFNIS mutations (R1319Q, L1330F and L1563V) using a recombinant human 
NaV1.2 expressed with the accessory subunits, hβ1 and hβ2, in an effort to better define 
functional defects that may be unique to BFNIS. We found that these mutations had 
mixed effects on channel activity predicting either loss (R1319Q, L1330F) or gain 
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(L1563V) of function. Unexpectedly, all three BFNIS mutations exhibited substantially 
lower levels of protein expression at the cell surface compared to the wild type channel 
suggesting that reduced sodium channel density may contribute to the pathophysiology 
of this inherited epilepsy. 
 
Materials and Methods 
 
Mutagenesis of human NaV1.2 cDNA 
 Full-length human NaV1.2 cDNA was obtained as a generous gift from M. Montal 
(Ahmed et al., 1992). The ORF was subcloned into the mammalian expression plasmid 
pCMV-Script, the 5’ UTR was removed to improve expression, and two cloning errors 
(G334D and R1744G) were corrected (see Chapter Three for details). PCR site-directed 
mutagenesis was used to engineer individual mutations into pCMV-NaV1.2 using a 
previously described method (primer sequences provided in Table 16) (Lossin et al., 
2002; Lossin et al., 2003; Rhodes et al., 2004; Ohmori et al., 2006). Three BFNIS-
associated mutations were constructed using codon usage typical of human tissues. 
Multiple attempts to construct other BFNIS-associated mutations were unsuccessful. 
Due to the tendency of neuronal voltage-gated sodium channel cDNAs to spontaneously 
mutate within bacterial culture, we propagated clones in Max Efficiency Stbl2 host cells 
(Invitrogen Corporation, Carlsbad, CA) at 30 °C, and the entire ORF of each construct 
was completely sequenced to exclude polymerase errors and inadvertent mutations.  
 
Heterologous expression of NaV1.2 
 Recombinant NaV1.2 was heterologously coexpressed in human tsA201 cells 
(HEK293 derivative stably transfected with SV40 large T antigen) with the human β1 and 
β2 voltage-gated sodium channel accessory subunits similar to our previous method of 
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NaV1.1 expression (Lossin et al., 2002; Lossin et al., 2003; Rhodes et al., 2004; Ohmori 
et al., 2006). Cells were grown in Dulbecco’s Modified Eagle’s Medium (Invitrogen Corp., 
Carlsbad, CA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Norcross, 
GA), L-glutamine (2 mM) and penicillin-streptomycin (50 units/ml and 50 µg/ml, 
respectively) in a humidified, 5% CO2 atmosphere at 37°C. Only low passage number (< 
15) cells were used. Expression of NaV1.2, β1 and β2 was achieved by transient 
cotransfection using Superfect (Qiagen Inc., Valencia, CA, U.S.A.) (5 µg of DNA was 
transfected at a plasmid mass ratio of 10:1:1 for α2:β1:β2). The human β1 and β2 cDNAs 
were expressed from plasmids that contained separate coding sequences of the 
fluorescent proteins eGFP (hβ1-IRES2-eGFP) or DsRed (hβ2-IRES2-DsRed2) preceded 
by an internal ribosome entry site (IRES). Cells were plated on glass coverslips and only 
cells successfully transfected with β1 and β2 were used for electrophysiological studies. 
Unless otherwise noted, all reagents were purchased from Sigma Aldrich (Sigma, St 
Louis, MO, U.S.A.). 
 
Electrophysiology and data analysis 
 Whole-cell voltage-clamp recordings were used to characterize the functional 
properties of wild-type (WT) and mutant sodium channels, as described previously 
(Lossin et al., 2002; Lossin et al., 2003; Rhodes et al., 2004; Ohmori et al., 2006). 
Sodium channel currents were recorded at room temperature, 48 to 72 hrs after 
transfection. Patch pipettes were fabricated from borosilicate glass (Warner Instrument 
Co., Hamden, CT, U.S.A) by a multistage P-97 Flaming-Brown micropipette puller 
(Sutter Instruments Co., San Rafael, CA, U.S.A.) and fire-polished by using a microforge 
(MF 830, Narashige, Japan). Pipette resistance was between 1.0 and 2.0 MΩ. The 
pipette solution consisted of (in mM) 110 CsF, 10 NaF, 20 CsCl, 2 EGTA, 10 HEPES, 
with a pH of 7.35 and osmolarity of 310 mOsmol/kg. The bath solution contained in 
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(mM): 145 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES, with a pH of 7.35 and osmolarity 
of 310 mOsmol/kg. The osmolarity was adjusted with sucrose. The bath solution was 
continuously exchanged by a gravity-driven perfusion system. The reference electrode 
consisted of a 2% agar bridge with composition similar to the bath solution. Cells were 
allowed to stabilize for 15 min after establishment of the whole-cell configuration before 
current was measured. Cells exhibiting peak current amplitudes < -0.6 nA were excluded 
from analysis of biophysical properties to avoid contamination of recordings by a low 
amplitude (< -0.1 nA) endogenous sodium current that is sometimes present in tsA201 
cells. Cells exhibiting peak current amplitudes > -6 nA were also generally excluded from 
analysis to ensure accurate voltage control. Whole-cell capacitance and access 
resistance were determined by integrating capacitive transients in response to voltage 
steps from −120 to −110 mV filtered at 10 kHz. Series resistance was compensated 90-
95% to assure that the command potential was reached in less than 100 µs with a 
voltage error ≤ 2 mV. Leak currents were subtracted by using an online P/4 procedure. 
All data were low-pass Bessel filtered at 5 kHz and digitized at 50 kHz. 
 Specific voltage-clamp protocols assessing channel activation, voltage 
dependence of fast inactivation, and recovery from a 100 ms inactivating prepulse 
(recovery from fast inactivation) were used as described previously (Lossin et al., 2002; 
Lossin et al., 2003; Rhodes et al., 2004; Ohmori et al., 2006) and described by figure 
insets. All voltage-clamp protocols utilized a holding potential of –120 mV and a 60 sec 
interpulse at the holding potential between sequential protocols. Voltage steps (20 ms) 
to between –80 to +60 mV in 10 mV increments were used to create a family of voltage-
gated inward sodium current traces. The peak current was normalized for cell 
capacitance and plotted against voltage to generate peak current density-voltage 
relationships. Conductance (GNa) was calculated as GNa = I/(V – Erev) where I is the 
measured peak current, V is the test voltage, and Erev is the calculated sodium reversal 
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potential. To provide a quantitative evaluation of the voltage dependence of activation, 
normalized G-V curves were fit with a Boltzmann function, G/Gmax = (1 + exp[(V – 
V1/2)/k])-1, where V1/2 is the curve midpoint indicating the voltage at which half of the 
channels are activated and k is a slope factor corresponding with voltage sensitivity of 
the channel. The time to peak current and 10 – 90% rise time were quantified for the –30 
to +30 mV range using the same voltage-clamp protocol described above. Together 
these parameters define the magnitude of depolarization needed for channel opening. 
Voltage dependence of fast inactivation was assessed by 100 ms prepulses to between 
–160 to –10 mV in 10 mV increments followed by a 20 ms test pulse to –10 mV. The 
normalized current is plotted against the voltage and the data were fit with Boltzmann 
functions to determine the voltage for half-maximal inactivation (V1/2) and a slope factor 
(k). Voltage dependence of fast inactivation provides information about the level of 
depolarization necessary for the channel to enter fast inactivation under steady-state 
conditions including the physiological range of potentials. Recovery from fast inactivation 
was determined using a two-pulse protocol. A 100 ms prepulse to –10 mV was followed 
by a variable amount of time for channel recovery and a 20 ms test pulse to –10 mV. 
The peak current from the test pulse was normalized to the peak current from the 
prepulse and plotted against the recovery period. Data were fit with the two exponential 
function, I/Imax = A1 × [1 – exp(–t/τ1)] + A2 × [1 – exp(–t/τ2)], where τ1 and τ2 denote time 
constants (fast and slow components, respectively), and A1 and A2 represent the fast 
and slow fractional amplitudes. Time dependent recovery from inactivation provides 
information about how rapidly the channels can be available for a subsequent 
depolarization stimulus. A second recovery from fast inactivation protocol utilized a 5 ms 
prepulse to -10 mV followed by a variable amount of time for channel recovery and a 20 
ms test pulse to -10 mV. The peak current from the test pulse was normalized to the 
peak current from the prepulse and plotted against the recovery period. Data were fit 
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with the two exponential function, I/Imax = A1 × [1 – exp(–t/τ1)] + A2 × [1 – exp(–t/τ2)],  
where τ1 and τ2 denote time constants (fast and slow components, respectively), and A1 
and A2 represent the fast and slow fractional amplitudes. This recovery from fast 
inactivation protocol was used to see whether a shorter prepulse alters channel 
availability to a subsequent depolarizing stimulus. 
 Inactivation of the whole-cell sodium current was evaluated by fitting the decay 
phase of the current with the two exponential function, I/Imax = A1 × exp(−t/τ1) + A2 × 
exp(−t/τ2), where τ1 and τ2 denote time constants (fast and slow components, 
respectively), A1 and A2 represent the fast and slow fractional amplitudes. For use-
dependence studies, cells were stimulated with depolarizing pulse trains (100 pulses, 5 
ms, 0 mV) at the indicated frequencies. A recovery interval (15 sec, −120 mV) followed 
each pulse train. Currents were normalized to the peak current recorded in response to 
the first pulse in each frequency train. Persistent current was evaluated during the final 
10 ms of a 200 ms depolarization to −10 mV and expressed as a percentage of peak 
current following digital subtraction of currents recorded in the presence and absence of 
10 µM tetrodotoxin (TTX). To prevent potential experimenter bias, persistent current 
experiments and analysis were performed blinded to genotype. 
 Slow inactivation was examined by paired-pulse protocols in which the response 
to a 4 ms test pulse to -10 mV was measured before (P1) and after (P2) variable 
conditioning protocols. Current measured during P2 was then normalized to the maximal 
current measured during P1. In detail, for onset of slow inactivation, the conditioning 
comprised voltage steps to -10 mV lasting from 1 ms to 100 sec, followed by a 50 ms 
recovery from fast inactivation at -120 mV. Conditioning for steady-state slow inactivation 
consisted of a 30 sec step to voltages between -140 and -10 mV and a 50 ms fast 
inactivation recovery at -120 mV. Conditioning for recovery from slow inactivation 
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experiments used a 30 sec pulse to -10 mV, followed by recovery periods ranging from 
100 ms to 100 sec. P1 pulses were repeated before each change of condition to 
minimize offset from run-down. In all cases, sufficient recovery time at -120 mV was 
allotted between different conditions to avoid accumulation of slow inactivation 
(determined in preliminary experiments; data not shown). Recordings with noticeable 
changes in P1 amplitude during the course of the experiment were discarded. Data from 
onset of slow inactivation experiments were plotted versus the length of the conditioning 
pulse and fitted to the two-exponential decay function, I/Imax = A1 × exp(−t/τ1) + A2 × 
exp(−t/τ2) + y0 where τ1 and τ2 denote time constants (fast and slow components, 
respectively), A1 and A2 represent the fast and slow fractional amplitudes and y0 
represents the fraction of the channels that remains active. Steady-state slow 
inactivation data were fitted with the Boltzmann function, I/Imax = ((1 - y0) / (1 +exp((x-V1/2) 
/ k)) + y0, where V1/2 is the voltage at which half-maximal slow inactivation occurs, k is 
the slope factor of the fit, and y0 is the fraction of the channels that remain active. 
Recovery from slow inactivation was fitted with the two-exponential function, I/Imax = A1 × 
(1- e^ −x/τ1) + A2 × (1-e^ −x/τ2) + y0, where A1 refers to the fraction of the channels 
recovering with τ1, A2 refers to the fraction of the channels recovering with τ2, and y0 is 
the fraction of the channels that remain active. 
            Results are presented as mean ± SEM. Statistical comparisons were made in 
reference to WT-NaV1.2 by using the unpaired Student’s t test. Chi-square analysis was 
used to determine significance level for expression efficiency of mutant alleles compared 
to WT-NaV1.2. One-way ANOVA analysis with a Newman-Keuls Multiple Comparison 
post-test was performed to determine significance for peak whole-cell inward sodium 
current. Data analysis was performed using Clampfit 9.2 (Axon Instruments, Union City, 
CA, U.S.A), Excel 2002 (Microsoft, Seattle, WA, U.S.A.), GraphPad Prism 4.0 
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(GraphPad Software Inc., San Diego, CA), and OriginPro 7.0 (OriginLab, Northampton, 
MA, U.S.A) software. 
 
Cell Surface Biotinylation 
 Cell surface biotinylation was performed as described previously (Kahlig et al., 
2004; Kahlig et al., 2006a; Carvelli et al., 2002; Daws et al., 2002), with minor 
modifications for NaV1.2 detection. Wild-type NaV1.2, R1319Q, L1330F, and L1563V 
were epitope tagged with a triple FLAG tag on the C-terminus to increase detection 
sensitivity. Cells transfected with WT-NaV1.2 or mutant NaV1.2, β1, and β2 as described 
above were washed twice with 4 oC PBS, then cell surface proteins were labeled with 
the cell membrane impermeant biotinylating reagent, Sulfo-NHS-Biotin (Pierce 
Biotechnology, Rockford, IL), for 1 hr. The reaction was quenched with 100 mM glycine. 
Cells were then lysed with RIPA buffer (150 mM NaCl, 50 mM Tris-base, 1% IGEPAL 
CA-630, 0.5% Na Deoxycholate, 0.1 % SDS, pH 7.5) supplemented with Complete Mini 
Protease Inhibitor Cocktail Tabs (Roche Applied Science, Indianapolis, IN). Scraped 
lysates were centrifuged at 16,000 x g for 30 min at 4 oC. Biotinylated proteins in the 
supernatant were recovered by incubation (2 hrs at 4 oC) with High Capacity Streptavidin 
Agarose beads (Pierce Biotechnology, Rockford, IL) followed by centrifugation. The 
beads were extensively washed with RIPA buffer and biotinylated proteins eluted with 
2X Laemmli Sample Buffer containing fresh 5% β-mercaptoethanol. Proteins were 
separated using SDS-polyacrylamide (7.5%) gel electrophoresis and transferred to 
polyvinylidene difluoride membranes. Membranes were incubated at room temperature 
for two hours in 5% milk. NaV1.2 was detected with primary antibodies directed against 
the FLAG epitope (mouse, anti-FLAG M2, 1:15000, Sigma). The quantity of loaded 
protein in each lane was determined using a primary antibody directed against the 
endogenous protein transferrin (mouse, anti-human transferrin receptor, 1:10000 for 
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total protein and 1:2500 for biotinylated protein, Zymed, Carlsbad, CA). Immunoreactive 
bands were visualized using horseradish peroxidase-conjugated secondary antibody 
(goat anti-mouse, 1:30000 for total protein and 1:10000 for biotinylated proteins, Santa 
Cruz Biotechnology, Santa Cruz, CA), directed against the primary antibody, ECL Plus 
(GE Healthcare, Buckinghamshire, UK) incubation and Hypersensitive ECL film 
detection. Protein band densitometry was performed using ImageJ software (NIH, 
Bethesda, MD). To control for protein loading, each NaV1.2 band was normalized to the 
amount of endogenously expressed transferrin detected for each experimental condition. 
One-way ANOVA analysis with a Newman-Keuls Multiple Comparison post-test was 
performed to determine significance for cell surface biotinylation experiments. 
 
Results 
 We functionally characterized three BFNIS mutations (R1319Q, L1330F, and 
L1563V) using a recombinant human NaV1.2 co-expressed with the human β1 and β2 
subunits in cultured cells (tsA201) of human origin. The three missense mutations have 
been reported previously; L1330F and L1563V by Heron et al. (Heron et al., 2002) and 
R1319Q by Berkovic et al. (Berkovic et al., 2004). Figure 17A illustrates the approximate 
position of each mutation within the predicted NaV1.2 two-dimensional topology.  
 
BFNIS mutations cause reduced inward sodium current 
 All three mutations (R1319Q, L1330F, and L1563V) generated functional sodium 
channels when transiently expressed in tsA201 cells. Figure 17B illustrates 
representative whole-cell currents evoked by a series of depolarizing test potentials in 
cells transiently expressing wild-type NaV1.2 (WT-NaV1.2), R1319Q, L1330F, or L1563V, 
while Figure 18A presents the corresponding peak current density-voltage relationships. 
The percentage of tested cells exhibiting quantifiable sodium currents (defined as peak 
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Figure 17. Representative WT-NaV1.2 and mutant NaV1.2 whole-cell sodium 
currents. (A) Predicted transmembrane topology of NaV1.2 showing the location of 
BFNIS mutations as circles (open circles represent mutations characterized in this 
study). (B) Sodium currents recorded from tsA201 cells co-expressing the indicated 
NaV1.2 allele with the β1 and β2 accessory subunits. Currents were activated by voltage 
steps to between –80 and +60 mV from a holding potential of −120 mV (see pulse 
protocol inset). 
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current ≥ -0.6 nA) was significantly lower for R1319Q and L1563V as compared to WT-
NaV1.2 channels (WT-NaV1.2, 66%, n = 174; R1319Q, 41%, n = 161, p < 0.001; L1563V, 
45%, n = 115, p < 0.01). In this analysis, L1330F expression was not significantly 
different than WT-NaV1.2 (61%, n = 149). However, when we examined the inward 
current from all tested cells, thus removing the selection bias for high NaV1.2 expression, 
the data revealed that all three BFNIS mutants displayed significantly lower peak current 
amplitudes compared to WT-NaV1.2. Wild-type channels exhibited a mean peak current 
of −1.96 nA (n = 174), compared to −0.81 nA for R1319Q (n = 161; p < 0.001), −1.52 nA 
for L1330F (n = 149; p < 0.05), and −1.12 nA for L1563V (n = 115; p < 0.001). 
Subsequent experiments assessing the kinetics and voltage dependences of activation 
and inactivation as well as the time course of recovery from inactivation utilized cells with 
peak inward sodium current ≥ -0.6 nA. In the following subsections, specific biophysical 
properties of the three mutant channels are presented individually.  
 
L1563V exhibits impaired inactivation 
 The BFNIS mutant L1563V affects a highly conserved residue within the S2 
transmembrane helix of the 4th domain (DIV/S2, Figure 17A and 32). Activation 
properties (voltage dependence of activation, time to peak current, 10 – 90% rise time of 
activation) of L1563V were not significantly different than WT-NaV1.2 channels (Figures 
18B, 19B, and Tables 9 and 10). However, L1563V appeared to exhibit slower whole-
cell current decay (Figure 17B). To quantify the time course of inactivation to enable 
statistical comparisons between WT- NaV1.2 and L1563V, the whole-cell current decay 
was fitted with a two-exponential equation and the time constant with the dominant 
amplitude (τ1) was plotted against the test potential for L1563V and WT-NaV1.2 (Figure 
19A, fit parameters for all mutants provided in Table 11). For cells expressing L1563V 
  89 
we observed significantly larger time constants for inactivation during voltage steps 
between −10 and 10 mV suggesting impaired fast inactivation. In addition, the voltage 
dependence of fast inactivation following an inactivating prepulse was significantly 
shifted in the depolarizing direction for L1563V suggesting that this mutant resists entry 
into the fast inactivated state (Figure 20A and Table 9). Furthermore, L1563V exhibited 
an accelerated recovery from fast inactivation indicated by a significantly smaller fast 
time constant (τ1) (Figure 20B and Table 9). These data illustrate that L1563V has 
impaired fast inactivation. 
 
R1319Q has mixed activation and inactivation defects 
 The R1319Q mutation neutralizes a highly conserved arginine residue in the S4 
voltage-sensing segment of domain 3 (Figures 17A and 32). This mutant exhibited a 
small but significant increase in the slower time constant for inactivation (τ2) only at −30 
mV (Table 11), but otherwise had inactivation kinetics that were not significantly different 
than WT-NaV1.2 channels. Voltage dependence of fast inactivation for R1319Q was also 
not significantly different from WT-NaV1.2 (Figure 20A and Table 9), but R1319Q did 
exhibit a significant difference in recovery from fast inactivation (τ1) compared to WT-
NaV1.2 (Figure 20B and Table 9). We observed a significantly greater time to peak 
current over the –10 to +20 mV range (Table 10) for R1319Q channels as well as a 
significantly increased 10-90 % rise time of activation compared to WT-NaV1.2 (Figure 
19B).  These findings demonstrated slower activation of this mutant. Further evidence 
for a defect in activation was reflected by a conductance-voltage relationship that was 
significantly shifted in the depolarizing direction for R1319Q as compared to WT-NaV1.2 
(Figure 18B, Table 9).  The slope factor (k) also exhibited a significant difference 
suggesting less steep voltage dependence for R1319Q compared to WT-NaV1.2. These
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Figure 18. Activation properties of wild-type and mutant NaV1.2. Biophysical properties of human WT-NaV1.2, R1319Q, L1330F, 
and L1563V expressed in human tsA201 cells. (A) Peak current density elicited by test pulses to various potentials and normalized to 
cell capacitance. (B) Voltage dependence of channel activation measured during voltage steps to between –80 and +20 mV. 
R1319Q displayed a significant depolarizing shift in activation compared to WT-NaV1.2. Pulse protocols are shown as panel insets 
and fit parameters are provided in Table 9. 
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Figure 19. Inactivation and activation kinetics for wild-type and mutant NaV1.2. (A) Fast inactivation time constants for WT-
NaV1.2 and BFNIS-associated mutants plotted against test potential. Fast time constants were significantly larger for L1563V 
(between –10 to + 10 mV, p < 0.05) compared to WT-NaV1.2 channels. Fit parameters for all mutants are provided in Table 11.  (B) 
Activation kinetics assessed by 10 – 90% rise time plotted against test potential for WT-NaV1.2 and BFNIS-associated mutants. The 
rise time was significantly longer for R1319Q over the –10 to +20 mV range (p < 0.05) and significantly shorter for L1330F at –10 mV 
(p < 0.05) compared to WT-NaV1.2. 
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Figure 20. Fast inactivation of wild-type and mutant NaV1.2. (A) Voltage dependence of fast inactivation assessed in response to 
inactivating prepulses to between –160 and –10 mV. L1563V displayed a significant depolarizing shift in the voltage dependence of 
fast inactivation compared to WT-NaV1.2. (B) Time dependent recovery from fast inactivation assessed following an inactivating 
prepulse (100 ms at –10 mV). Significant defects in the recovery were observed for both R1319Q (delayed recovery) and L1563V 
(accelerated recovery). Pulse protocols are shown as panel insets and fit parameters are provided in Table 9. 
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Recovery from 100 ms 
inactivating prepulse 
 τ1 (ms)§         τ2 (ms)§       n 
Voltage dependence  
of fast inactivation 
V1/2 (mV)       k (mV)       n 
Voltage dependence 
of activation 
 V1/2 (mV)       k (mV)        n 
WT-NaV1.2    -25.3 ± 1.4    7.5 ± 0.4      14     -67.4 ± 1.7     9.1 ± 0.8    14       1.4 ± 0.1      53.6 ± 6.9      16 
                                (75 ± 2%)      (24 ± 2%)
L1330F         -25.5 ± 0.7     7.5 ± 0.2      15     -69.7 ± 1.0     8.2 ± 0.4    18       1.5 ± 0.1     65.5 ± 7.4      16 
            (79 ± 2%)     (21 ± 2%) 
R1319Q        -21.4 ± 0.9*   8.6 ± 0.2*     15     -67.1 ± 1.0   10.4 ± 0.9    16       1.7 ± 0.1*    69.8 ± 13.0    15 
            (74 ± 2%)     (25 ± 2%)
L1563V         -27.4 ± 1.8     6.5 ± 0.3      16     -62.9 ± 1.1*   8.1 ± 0.3    16       1.0 ± 0.1*** 63.6 ± 8.3      16 
                   (80 ± 1%)*    (19 ± 1%)*
Table 9. Biophysical parameters of NaV1.2 BFNIS mutations 
Values significantly different from WT are indicated as follows *p < 0.05, ***p < 0.001.   
§ values in parentheses are amplitude. 
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 0.29 ± 0.02 
n = 16 
0.25 ± 0.01 
n = 15 
0.28 ± 0.01 
n = 15 
0.26 ± 0.01 
n = 14 
30 mV 
 0.31 ± 0.02 
n = 16 
0.27 ± 0.01 
n = 15 
0.32 ± 0.01** 
n = 15 
0.28 ± 0.01 
n = 14 
20 mV 
 0.34 ± 0.02 
n = 16 
0.29 ± 0.01** 
n = 15 
0.36 ± 0.01* 
n = 15 
0.33 ± 0.01 
n = 14 
10 mV 
 0.40 ± 0.02 
n = 16 
0.34 ± 0.02 
n = 15 
0.43 ± 0.01* 
n = 15 
0.37 ± 0.02 
n = 14 
0 mV 
 0.48 ± 0.03 
n = 16 
0.40 ± 0.02 
n = 15 
0.52 ± 0.02** 
n = 15 
0.44 ± 0.02 
n = 14 
-10 mV 
 0.61 ± 0.05 
n = 16 
0.51 ± 0.03 
n = 15 
0.65 ± 0.04 
n = 15 
0.56 ± 0.04 
n = 14 
-20 mV 
 0.85 ± 0.08 
n = 16 
0.72 ± 0.05 
n = 15 
0.90 ± 0.04 
n = 15 
0.79 ± 0.06 
n = 14  
-30 mV 
L1563V L1330F R1319Q WT-NaV1.2 
  Table 10. Time to peak current for BFNIS mutations 
For statistical differences from WT-NaV1.2 *p < 0.05, **p < 0.01. 
  
95
 
 
 
 
3.0 ± 0.5 
(7 ± 1%) 
3.9 ± 0.4 
(6 ± 3%) 
2.6 ± 0.1 
(10 ± 2%) 
2.4 ± 0.2 
(7 ± 1%) 
 0.29 ± 0.01 
(93 ± 1%) 
0.23 ± 0.01 
(94 ± 3%) 
0.29 ± 0.02 
(89 ± 2%) 
0.26 ± 0.02 
(93 ± 1%) 
30 mV 
3.9 ± 0.5 
(5 ± 1%) 
3.7 ± 0.4 
(6 ± 3%) 
2.7 ± 0.1 
(7 ± 0.4%) 
3.0 ± 0.4 
(7 ± 2%) 
 0.32 ± 0.01 
(95 ± 1%) 
0.24 ± 0.01 
(94 ± 3%) 
0.32 ± 0.02 
(92 ± 0.4%) 
0.27 ± 0.02 
(93 ± 2%) 
20 mV 
3.6 ± 0.6 
(5 ± 1%) 
3.9 ± 0.4* 
(5 ± 2%) 
3.2 ± 0.7 
(7 ± 1%) 
3.0 ± 0.4 
(6 ± 1%) 
 0.39 ± 0.01* 
(95 ± 1%) 
0.27 ± 0.01 
(95 ± 2%) 
0.35 ± 0.02 
(93 ± 1%) 
0.31 ± 0.03 
(94 ± 1%) 
10 mV 
3.6 ± 0.5 
(6 ± 2%) 
4.1 ± 0.6 
(4 ± 1%) 
4.0 ± 0.5 
(6 ± 1%) 
3.3 ± 0.5 
(6 ± 1%) 
 0.47 ± 0.02* 
(94 ± 2%) 
0.33 ± 0.02 
(96 ± 1%) 
0.41 ± 0.02 
(94 ± 1%) 
0.39 ± 0.03 
(94 ± 1%) 
0 mV 
4.1 ± 0.4 
(5 ± 1%) 
5.0 ± 0.5* 
(4 ± 1%) 
4.0 ± 0.5 
(7 ± 1%) 
3.3 ± 0.3 
(7 ± 1%) 
 0.63 ± 0.04* 
(95 ± 1%) 
0.43 ± 0.02 
(96 ± 1%) 
0.50 ± 0.04 
(93 ± 1%) 
0.47 ± 0.04 
(93 ± 1%) 
-10 mV 
4.3 ± 0.5 
(10 ± 1%) 
5.1 ± 0.7 
(5 ± 0.4%) 
3.7 ± 0.6 
(10 ± 3%) 
3.6 ± 0.3 
(9 ± 3%) 
 0.84 ± 0.08 
(90 ± 1%) 
0.62 ± 0.03 
(95 ± 1%) 
0.75 ± 0.06 
(90 ± 3%) 
0.65 ±0.06 
(91 ± 2%) 
-20 mV 
4.8 ± 0.9 
(19 ± 5%) 
6.4 ± 0.9* 
(11 ± 3%) 
5.4 ± 0.2* 
(20 ± 1%) 
4.3 ± 0.2 
(19 ± 9%) 
 1.22 ± 0.17 
(81 ± 6%) 
1.00 ± 0.08 
(90 ± 3%) 
1.03 ± 0.12 
(81 ± 6%) 
1.06 ± 0.16 
(81 ± 9%)  
-30 mV 
L1563V L1330F R1319Q WT-NaV1.2  L1563V L1330F R1319Q WT-NaV1.2 
  
Table 11. Whole-cell current inactivation time constants for BFNIS mutations 
Values significantly different from WT-NaV1.2 are indicated as follows *p < 0.05.  § values in parentheses are amplitude. 
Fast Component§ Slow Component§ 
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differences are consistent with neutralization of an S4 positive charge important for 
voltage sensing (Stühmer et al., 1989). Our data suggest that the R1319Q mutation 
alters both inactivation and activation in a manner that predicts a net decrease in 
channel activity. 
 
L1330F exhibits enhanced use-dependent behavior 
 The L1330F mutation affects the short intracellular S4-S5 linker connecting the 
voltage-sensing and central-pore regions of DIII (Figures 17A and 32) (Long et al., 2005; 
Heron et al., 2002). Comparison of inactivation kinetics between WT-NaV1.2 and L1330F 
revealed significant differences in the time constant representing the minor (slow) 
component of inactivation but only at a few test voltages (Table 11). There were no 
statistical differences between L1330F and WT-NaV1.2 channels in the voltage 
dependence of activation, voltage dependence of fast inactivation, and recovery from 
fast inactivation (Figures 18, 20, and Table 9). L1330F displayed minor differences in the 
10-90% rise time and time to peak current compared to WT-NaV1.2 (Figure 19B and 
Table 10). 
 In the absence of major gating abnormalities for L1330F, we utilized a voltage 
clamp protocol consisting of a train of depolarizing steps at varying frequencies to test 
for differences in use-dependent channel behavior. L1330F exhibited a significantly 
enhanced use-dependent loss of channel availability compared to WT-NaV1.2 over a 
large range of frequencies (22 to 133 Hz; Figure 21A). By contrast, the other two 
mutations we studied exhibited no significant differences in channel availability during 
the same pulse protocol (Figure 21A). The enhanced use-dependent loss of channel 
availability for L1330F was evident within the first several pulses as illustrated in Figure 
21B for pulsing frequencies of 22, 85, and 133 Hz. These data predict that L1330F will 
have a net reduction in channel function during rapid stimulation.  
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 The enhanced use-dependent channel availability exhibited by L1330F was not 
predicted by the individual activation and fast inactivation parameters described above. 
Recovery from fast inactivation is thought to influence use-dependent channel 
availability by affecting how quickly the channels are ready for subsequent 
depolarization as in the pulse train experiments. We performed an alternative recovery 
from fast inactivation protocol that used a 5 ms prepulse instead of 100 ms because this 
would more closely simulate the protocol for testing use-dependent channel behavior. 
L1330Fand WT-NaV1.2 were not statistically different in the recovery from a 5 ms 
prepulse (Figure 22). We next looked at slow inactivation properties to see if this could 
explain the difference in use-dependent channel availability since slow inactivation is 
known to regulate availability of channels at steady-state. We looked at the onset, 
voltage dependence, and recovery from slow inactivation of WT-NaV1.2 and L1330F. 
There were no statistical differences between L1330F and NaV1.2 in any of these slow 
inactivation properties (Figure 23 and Table 12). 
 
Absence of increased persistent current in BFNIS mutations 
 We previously observed that several NaV1.1 mutations associated with various 
genetic epilepsy syndromes cause significantly increased persistent current (Lossin et 
al., 2002; Rhodes et al., 2004; Rhodes et al., 2005; Ohmori et al., 2006). However, none 
of the BFNIS mutants we studied exhibited this biophysical phenotype as compared to 
WT-NaV1.2 channels (magnitude of persistent current as percentage of peak current 
amplitude: WT-NaV1.2: 1.64 ± 0.35%, n = 10; R1319Q: 1.74 ± 0.24%, n = 9; L1330F: 
1.51 ± 0.14%, n = 7; L1563V: 1.23 ± 0.39%, n = 7). This finding suggests that increased 
persistent current is not a common biophysical hallmark of NaV1.2 mutations associated 
with BFNIS. 
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Figure 21.  Use-dependent behavior of wild-type and mutant NaV1.2. The response of NaV1.2 alleles to repetitive depolarization 
(use-dependence of channel behavior) was measured by stimulating cells with voltage step pulse trains (100 pulses, 5 ms, 0 mV) 
from a holding potential of –120 mV at the indicated frequencies (see inset in panel A). (A) Residual peak current amplitude of the 
25th pulse for WT-NaV1.2, R1319Q, L1330F and L1563V plotted against pulse frequency. Fewer L1330F channels were available for 
activation in response to the 25th pulse compared to WT-NaV1.2 for the stimulation frequencies of between 22 and 133 Hz (*, p < 
0.05; **, p < 0.01). (B) Normalized peak current measured in response to a voltage step train at frequencies of 22, 85, and 133 Hz. 
L1330F displays significantly decreased residual current for pulses 2 and 5 to 100 for 22 Hz, pulses 8 to 100 for 85 Hz, and pulses 2 
to 100 for 133 Hz (p ≤ 0.05). 
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Figure 22. Recovery from a 5 ms inactivating prepulse. Time dependent recovery 
from fast inactivation assessed following an inactivating prepulse (5 ms at –10 mV) with 
pulse protocol shown as inset. L1330F displays no differences compared to WT-NaV1.2 
in recovery from a short prepulse. The WT-NaV1.2 recovered with a τ1 of 1.4 ± 0.2 for 81 
± 4% and a τ2 of 18.8 ± 5.3 for 19 ± 4% of channels (n = 7). The L1330F mutant 
recovered with a τ1 of 1.8 ± 0.2 for 84 ± 4% and a τ2 of 21.5 ± 6.7 for 16 ± 4% of 
channels (n = 8). 
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Figure 23. Slow inactivation properties of WT-NaV1.2 are not different than L1330F. (A) Time-dependent entry into slow 
inactivation was examined using a two-pulse protocol consisting of a variable length inactivation pulse to –10 mV followed by a test 
pulse at –10 mV. Effects of fast inactivation were minimized using a 50 ms inter-pulse to –120 mV to relieve fast inactivation.  (B) 
Voltage-dependent entry into slow inactivation was examined using a two-pulse protocol consisting of a 30 sec conditioning pulse at 
various potentials followed by a test pulse at –10 mV. Effects of fast inactivation were minimized using a 50 ms inter-pulse to –120 
mV to relieve fast inactivation.  (C) Time-dependent recovery from slow inactivation was examined using a two-pulse protocol 
consisting of a 30 sec inactivation pulse to –10 mV followed by a variable length inter-pulse to –120 mV and a test pulse to –10 mV. 
All fit parameters in Table 12 and voltage protocols are shown as figure insets. 
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Recovery from 
slow inactivation 
  τ1(ms)§          τ2 (ms)§          n 
Voltage dependence of 
slow inactivation 
V1/2 (mV)       k (mV)         IR        n 
Onset of slow inactivation 
 τ1(ms)§        τ2 (ms)§        n 
  WT-NaV1.2  2064 ± 277    21105 ± 7838   6       -65.3 ± 2.5       8.7 ± 0.4    13 ± 1%   6           194 ± 20         6307 ± 814        5 
              (73 ± 3%)         (18 ± 2%)                                                  (66 ± 3%)         (34 ± 3%) 
L1330F      2160 ± 374   36671 ± 11495  6       -68.3 ± 3.4       8.1 ± 0.9    19 ± 3%   6           166 ± 32         6517 ± 825        5 
         (66 ± 2)           (23 ± 2)                                   (59 ± 2%)         (41 ± 2%) 
Table 12. Slow inactivation parameters of WT-NaV1.2 and L1330F
§ values in parentheses are amplitude. 
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BFNIS mutants exhibit reduced cell surface expression 
 All three BFNIS mutations exhibited significantly smaller mean whole-cell peak 
current levels as compared to WT-NaV1.2. We tested the hypothesis that these 
mutations affected the level of protein at the plasma membrane by using cell surface 
biotinylation. Figure 24A illustrates that each BFNIS mutant exhibits lower cell surface 
expression compared to WT-NaV1.2. Quantification of total cellular proteins levels 
showed no significant differences for any of the mutants compared with WT-NaV1.2 
(Figure 24B). By contrast, quantification of cell surface NaV1.2 protein expression from 
four independent experiments (Figure 24C) demonstrated that, compared to WT-NaV1.2, 
each mutant exhibits a substantial reduction in cell surface expression: 79% for R1319Q 
(p < 0.001), 47% for L1330F (p < 0.01), and 61% for L1563V (p < 0.01; n = 4). Reduced 
NaV1.2 cell surface expression is a novel finding and this predicts a lower number of 
channels available for generating inward current, a potentially important factor in BFNIS 
pathogenesis. 
 
Discussion 
 Elucidation of the molecular basis for brain sodium channelopathies and 
establishment of genotype-phenotype correlations may shed light on epileptogenesis 
and help conceptualize new treatment strategies. In this chapter, we examined the 
properties of three BFNIS mutations (R1319Q, L1330F, and L1563V) using the human 
NaV1.2 α-subunit coexpressed with human β1 and β2 subunits. Although the clinical 
characteristics of patients with each of these mutations were similar (Heron et al., 2002; 
Berkovic et al., 2004), our findings indicate that NaV1.2 mutations may exhibit a range of 
functional abnormalities as well as reduced cell surface expression signifying the 
complex molecular mechanisms underlying this inherited epilepsy. 
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Figure 24.  Reduced cell surface protein expression of BFNIS mutants. Cell surface expression of WT and the three BFNIS 
mutations was measured using cell surface biotinylation. Endogenous transferrin levels were measured as a gel loading control. (A) 
Representative experiment illustrating total (top) and cell surface (bottom) NaV1.2 protein detected with anti-FLAG antibody. NaV1.2 
immunoreactive bands were normalized to the amount of an endogenous protein (transferrin) detected in each experimental lane 
(below NaV1.2 detection). The first lane was isolated from cells transfected with untagged WT-NaV1.2. Lanes 2 – 5 are the FLAG 
tagged NaV1.2 constructs (WTFLAG, R1319QFLAG, L1330FFLAG, L1563VFLAG, respectively). Lane 6 was isolated from untransfected 
tsA201 cells (mock). All three BFNIS mutations exhibited decreased cell surface NaV1.2 protein expression. (B) Quantification of four 
independent experiments demonstrated that each BFNIS mutant exhibits total protein expression similar to WT-NaV1.2 (C) 
Quantification of four independent experiments demonstrated that each BFNIS mutant exhibits a significantly lower level of cell 
surface channel expression: R1319Q is 21% of WT-NaV1.2 (***, p < 0.001), L1330F is 53% of WT-NaV1.2 (**, p < 0.01) and L1563V 
is 39% of WT-NaV1.2 (**, p < 0.01) (n = 4 for WT-NaV1.2, R1319Q, L1330F, and L1563V).  The biotinylated and total NaV1.2 bands 
were normalized to the corresponding transferrin band and the ratio of the normalized biotinylated to total are shown for WT-NaV1.2, 
R1319Q, L1330F and L1563V. 
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 In this study we examined the biophysical properties of wild-type and BFNIS 
mutant NaV1.2. The R1319Q mutation caused a more positive and less steep voltage 
dependence of activation, slower activation, and delayed recovery from fast inactivation 
(Figures 18B, 19B, 20B and Tables 9, 10). These biophysical features predict a loss of 
channel function. L1330F decreased channel availability in response to repetitive 
stimulation over a large range of frequencies that may also indicate a loss of channel 
function (Figure 21). The L1563V mutation impaired fast inactivation, caused a positive 
shift in the voltage dependence of fast inactivation and displayed accelerated recovery 
from fast inactivation (Figures 19A, 20 and Tables 9, 11). The functional characteristics 
of L1563V predict a net gain of channel function. Previous studies have examined 
expression of voltage-gated sodium channel subunits in brain regions, but few studies 
convincingly show what neurons highly express NaV1.2. Recent studies using mouse 
models of SMEI caused by haploinsufficiency of the highly homologous α isoform, 
NaV1.1 preferentially affected inhibitory interneurons (Yu et al., 2006; Ogiwara et al., 
2007). We predict that mutations correlated with a predicted loss of function, R1319Q 
and L1330F, might preferentially affect inhibitory interneurons while the L1563V mutation 
might exert its overall gain of function in excitatory neurons. This may help to explain 
how seemingly divergent biophysical effects may give rise to the same epilepsy 
syndrome although the exact mechanism for preferentially affecting one functional class 
of neurons is unknown. In general, these various and subtle biophysical effects probably 
contribute to the pathogenesis of BFNIS but may not represent the entire story. 
 In addition to the functional defects conferred by BFNIS mutations, we observed 
that cells expressing mutant channels exhibited lower peak current levels compared to 
WT-NaV1.2. Further, all three BFNIS mutants exhibited between 47 and 79% lower cell 
surface expression of channel protein compared to WT-NaV1.2 in tsA201 cells (Figure 
24), and the relative magnitude of the reduction was concordant with mean whole-cell 
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peak current levels. For example, R1319Q exhibited the largest decrease in mean 
whole-cell peak current as well as the lowest number of cells passing minimum current 
threshold, and this mutation exhibited the greatest decrement in cell surface expression. 
By contrast, L1330F had only a moderate reduction in both current amplitudes and cell 
surface expression. This finding suggests that reduced sodium channel density may be 
an important factor in the pathogenesis of BFNIS. Many potential mechanisms for 
decreased protein expression exist including reduced mRNA stability (Wada et al., 2004; 
Yanagita et al., 2003) and increased protein turnover rate (Gallagher et al., 2007). 
Previous studies of sodium channel mutations have suggested a role of altered temporal 
or spatial channel expression in promoting abnormal excitability  (Wada, 2006; Waxman, 
2007; Yu et al., 2006). 
 SCN2A encodes NaV1.2, a voltage-gated sodium channel pore forming α-subunit 
expressed abundantly in the adult central nervous system. Knockout mice deficient in 
NaV1.2 die perinatally from neuronal apoptosis and hypoxia, suggesting that expression 
is crucial for early postnatal, but not embryonic development (Planells-Cases et al., 
2000). Early in development, NaV1.2 is highly expressed in regions destined to become 
nodes of Ranvier, and is developmentally replaced by NaV1.6 in adult rat brains (Kaplan 
et al., 2001). NaV1.2 is also enriched at axon initial segments in developing neurons 
(Boiko et al., 2003; Garrido et al., 2003b; Garrido et al., 2003a). In the adult brain, 
unmyelinated axons throughout the rostral central nervous system, including the cortex 
and hippocampus, have high NaV1.2 expression (Westenbroek et al., 1989; 
Westenbroek et al., 1992). Clusters of NaV1.2 at nodes and the axon initial segments 
contribute to determining axonal firing frequency and action potential propagation 
(Carras et al., 1992; Boiko et al., 2003). Abnormal NaV1.2 function may disrupt the 
physiological role of this channel in controlling excitability and underlie pathogenesis of 
genetic epilepsy syndromes. We speculate that the observed temporal transition of 
  107
NaV1.2 to NaV1.6 (Salzer, 2002) may also be affected by abnormal NaV1.2 expression or 
activity. 
 The three BFNIS mutations presented in our study have been previously 
analyzed using cultured rat cortical neurons transfected with rat NaV1.2 (Scalmani et al., 
2006). Differences in functional properties of the mutant channels between our study 
and that performed in rat neurons may be explained by species differences of the 
cDNAs, or experimental limitations (e.g., uncertain voltage control) of the on-cell 
macropatch recording configuration applied to cultured neurons in that study. In addition, 
without a selective blocker of NaV1.2, it is technically difficult to assign kinetic properties 
to NaV1.2 expressed within the background of other voltage-gated sodium channels 
(Cummins et al., 2001; Herzog et al., 2001; Rush et al., 2005) especially if the mutant 
channels are expressed at very low levels as we have demonstrated. In our study, we 
used human NaV1.2 coexpressed with the human β1 and β2 accessory subunits in 
cultured non-neuronal human cells. We further recorded NaV1.2 activity using the whole-
cell configuration of the patch-clamp allowing that enables more precise voltage and 
ionic control. This well established expression and recording approach uniquely permits 
the isolation and primary characterization of mutant human NaV1.2 channels associated 
with BFNIS.  
 Another previous study proposed that the L1563V mutation preferentially affects 
a putative neonatal isoform of NaV1.2 (Xu et al., 2007b). Although, a preferential 
functional impact of a mutation on a developmentally regulated splice variant provides 
an intriguing explanation for the abatement of seizures during late infancy in BFNIS, this 
should be considered speculative because the temporal regulation of this splicing event 
is not fully defined (Sarao et al., 1991; Kasai et al., 2001; Raymond et al., 2004; Tate et 
al., 2005). Further, this previous study characterized NaV1.2 in the absence of β subunits 
that are known modulators of neuronal sodium channel gating properties (Isom et al., 
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1994; Catterall, 2000; Catterall et al., 2005), and this limits an accurate correlation with 
native channels. The absence of β subunits may help to explain why the previous study 
did not observe significant effects of the L1563V mutation on the same NaV1.2 splice 
variant that we used (Xu et al., 2007b).  
Aberrant trafficking of the mutant proteins to the plasma membrane, possibly 
because of mis-folding or altered interactions with chaperone proteins including β-
subunits, is the most plausible explanation for the findings described in this chapter 
(Hirose, 2006). However, the mechanism of decreased cell surface expression for each 
of the BFNIS missense mutations was not determined. Because tsA201 cells are not 
neuronal in origin, future studies in neurons may help confirm our findings and aid in 
elucidating the cellular mechanism of altered excitability in BFNIS. Further, it will be 
interesting to determine NaV1.2 expression levels when WT-NaV1.2 and BFNIS mutants 
are cotransfected because this would represent the heterozygous state and may 
account for the autosomal dominant inheritance of the disease. We speculate that 
reduction of cell surface expression is the predominant effect of these mutations and that 
loss of NaV1.2 expression on inhibitory interneurons may underlie BFNIS. We also 
speculate that NaV1.2 expression on interneurons is dynamically regulated with high 
expression early in life and decreased expression later in life explaining the spontaneous 
seizure remission within the first year of life.  
In summary, we have demonstrated that three SCN2A mutations associated with 
BFNIS cause subtle and divergent biophysical defects in NaV1.2, but also impair cell 
surface expression. A greater understanding of the exact composition of sodium channel 
complexes in vivo and their targeting to different subcellular localizations will be required 
to fully understand how these defects cause BFNIS. Future studies will also need to 
account for the developmentally regulated role of NaV1.2 in neuronal excitability and how 
this relates to the early seizure remittance seen in BFNIS. Animal models with 
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genetically engineered NaV1.2 mutations may help elucidate the physiological 
contribution of this isoform and further explain the pathogenesis of BFNIS. 
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CHAPTER IV 
 
INCREASED NAV1.1 FUNCTION IN MESIAL TEMPORAL LOBE EPILEPSY 
 
Introduction 
 Temporal lobe epilepsy (TLE) is one of the most common and severe forms of 
partial epilepsy. TLE and antecedent febrile seizures (FS) have a controversial 
relationship. Antecedent FS has been found in 25% of TLE patients (Hamati-Haddad 
and Abou-Khalil, 1998) and 50-80% of refractory TLE patients (French et al., 1993; 
Baulac et al., 2004). The hypothesis was put forth that prolonged or complex FS (FS+) in 
childhood could damage the hippocampus causing hippocampal sclerosis (HS) and 
eventually lead to refractory temporal lobe seizures, most commonly affecting the mesial 
temporal lobe (Maher and McLachlan, 1995; Baulac et al., 2004). HS and mesial 
temporal sclerosis can be determined from MRI studies by visualizing hippocampal 
atrophy or hyperintensities. Alternatively HS can be seen pathologically as neuronal loss 
in the CA1, CA3, and hilar regions of the hippocampus with pronounced astrogliosis 
(Maurer-Morelli et al., 2006). To date there has been no conclusive prospective study to 
show a causal relationship between complex FS, TLE, and HS. 
 Initially TLE was primarily considered an acquired disorder and little was known 
about its inheritance (Baulac et al., 2001b). Sporadic TLE may affect either the mesial or 
lateral regions of the temporal lobe and has been associated with polymorphisms in 
several genes including interleukin-1β, prodynorphin, a prion protein gene, and the 
GABAB receptor 1 gene (Baulac et al., 2004). Familial forms of lateral TLE that are not 
linked to FS have been associated with leucine-rich, glioma inactivated 1 (LGI1) (Baulac 
et al., 2004; Wang and Lu, 2008).  
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 Several studies have examined the genetics of TLE in families with FS resulting 
in several different candidate loci or genes. One study of a French family with FS and 
subsequent TLE without hippocampal abnormalities on MRI showed digenic inheritance 
of particular haplotypes on 18qter and 1q25-q31 (Baulac et al., 2001b). Another family 
with FS and childhood absence epilepsy (CAE) had one member with febrile seizures 
plus (FS+) who developed pharmacoresistant TLE. FS+ are FS that persist beyond six 
years of age or FS in combination with afebrile seizures. In this study, a region of 3p and 
a possible modifier locus on 18p were implicated in the epilepsy phenotype because all 
FS patients who developed epilepsy shared both haplotypes (Nabbout et al., 2007).  
 A mutation in a well conserved SCN1A residue, M145T, was isolated in a family 
with FS (Mantegazza et al., 2005). Three of the family members also developed TLE 
and two of these patients also had HS via MRI studies (Colosimo et al., 2007). Genetic 
analyses were also performed on families with generalized epilepsy with febrile seizures 
plus (GEFS+). One large GEFS+ family had several members who had subsequent 
epilepsy including individuals who had TLE. A combination of pedigree analysis and 
gene sequencing showed autosomal dominant inheritance of the SCN1A mutation, 
K1270T, in all affected family members and one asymptomatic individual (Abou-Khalil et 
al., 2001). Another study of several GEFS+ families found several patients who 
developed TLE with the SCN1B mutation C121W (Scheffer et al., 2007). These findings 
suggest that mutations in voltage-gated sodium channel subunits, either α or β, can lead 
to TLE. 
 Our collaborators screened brain tissue resected from mesial TLE (MTLE) 
patients for mutations in the voltage-gated sodium channel genes SCN1A, SCN2A, and 
SCN3A. A novel mutation in SCN1A, N211S, was identified by Jennifer A. Kearney, 
Sarah K. Bergren, James O. McNamara, and Miriam H. Meisler (unpublished 
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observations). We functionally characterized the mutant and found that it caused an 
increase in function. 
 
Materials and Methods 
 
Subjects and mutation detection 
 46 patients with MTLE were diagnosed according to the criteria of the 
Commission on Classification and Terminology of the ILAE (1989). DNA was extracted 
from resected brain tissue by proteinase-K digestion, followed by phenol:chloroform 
extraction and ethanol precipitation. The 26 coding exons of SCN1A, SCN2A and 
SCN3A were amplified individually from genomic DNA and analyzed by conformation 
sensitive gel electrophoresis. PCR products containing variants were gel purified and 
sequenced on an ABI Model 3730 automated sequencer in the University of Michigan 
DNA Sequencing Core. NINDS Neurologically Normal Caucasian Control Panels (Coriell 
NDPT006 and NDPT009; n = 184) and a panel of 111 subjects who were > 60 years of 
age without personal or family history of neurological disease (Rainier et al., 2006) were 
screened for N211S by PCR-RFLP analysis, based on an alternative BsrDI restriction 
site. 
 
Mutagenesis of human NaV1.1 cDNA 
 The full-length human NaV1.1 cDNA was previously cloned into the mammalian 
expression plasmid pCMV-Script. PCR site-directed mutagenesis was used to engineer 
individual mutations into pCMV-NaV1.1 using a previously described method (Lossin et 
al., 2002; Lossin et al., 2003; Rhodes et al., 2004; Ohmori et al., 2006). The mesial 
temporal lobe epilepsy-associated mutation, N211S, was constructed using codon 
usage typical of human tissues. Due to the tendency of neuronal voltage-gated sodium 
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channel cDNAs to spontaneously mutate within bacterial culture, we propagated clones 
in Max Efficiency Stbl2 host cells (Invitrogen Corporation, Carlsbad, CA) at 30 °C, and 
the entire ORF of each construct was completely sequenced to exclude polymerase 
errors and inadvertent mutations. Two recombinant clones of the mutation were 
evaluated functionally. 
 
Heterologous expression of NaV1.1 
 Recombinant NaV1.1 was heterologously coexpressed in human tsA201 cells 
(HEK293 derivative stably transfected with SV40 large T antigen) with the human β1 and 
β2 voltage-gated sodium channel accessory subunits similar to our previous method of 
NaV1.1 expression (Lossin et al., 2002; Lossin et al., 2003; Rhodes et al., 2004; Ohmori 
et al., 2006). Cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Invitrogen Corp., Carlsbad, CA) supplemented with 10% fetal bovine serum (Atlanta 
Biologicals, Norcross, GA), L-glutamine (2 mM) and penicillin-streptomycin (50 units/ml 
and 50 µg/ml, respectively) in a humidified, 5% CO2 atmosphere at 37°C. Only low 
passage number (< 15) cells were used. Expression of NaV1.1, β1 and β2 was achieved 
by transient transfection using Fugene 6 (Roche Applied Science, Indianapolis, IN) (5 µg 
of DNA was transfected at a plasmid mass ratio of 10:1:1 for α2:β1:β2). The human β1 
and β2 cDNAs were expressed from plasmids that contained separate coding sequences 
of the marker genes CD8 (pCD8-IRES-hβ1) or the fluorescent protein GFP (pGFP-IRES-
hβ2) preceded by an internal ribosome entry site (IRES). Transfected cells were 
dissociated by brief exposure to Trypsin/EDTA, resuspended in supplemented DMEM 
medium and allowed to recover for 30 min at 37 °C at 5% CO2. CD8 antibody-covered 
microbeads (Dynabeads M-450 CD8, Dynal, Norway) suspended in 150 μl DMEM were 
added to the cell suspension and gently shaken. Only cells positive for CD8 antigen and 
GFP fluorescence indicative of hβ1 and hβ2 expression were used for 
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electrophysiological analysis. Unless otherwise noted, all reagents were purchased from 
Sigma Aldrich (Sigma, St Louis, MO). 
 
Electrophysiology and data analysis 
 Whole-cell voltage-clamp recordings were used to characterize the functional 
properties of WT and mutant sodium channels, as described previously (Lossin et al., 
2002; Lossin et al., 2003; Rhodes et al., 2004; Ohmori et al., 2006). Sodium channel 
currents were recorded at room temperature, 24 to 48 hr after transfection. Patch 
pipettes were fabricated from borosilicate glass (Warner Instrument Co., Hamden, CT) 
by a multistage P-97 Flaming-Brown micropipette puller (Sutter Instruments Co., San 
Rafael, CA) and fire-polished by using a microforge (MF 830, Narashige, Japan). Pipette 
resistance was between 1.0 and 2.0 MΩ.  The pipette solution consisted of (in mM) 110 
CsF, 10 NaF, 20 CsCl, 2 EGTA, 10 HEPES, with a pH of 7.35 and osmolarity of 310 
mOsmol/kg. The bath solution contained in (mM): 145 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 
10 HEPES, with a pH of 7.35 and osmolarity of 310 mOsmol/kg. The osmolarity was 
adjusted with sucrose. The bath solution was continuously exchanged by a gravity-
driven perfusion system. The reference electrode consisted of a 2% agar bridge with 
composition similar to the bath solution. Cells were allowed to stabilize for 15 min after 
establishment of the whole-cell configuration before current was measured. Cells 
exhibiting peak current amplitudes < -0.6 nA were excluded from analysis of biophysical 
properties to avoid contamination of recordings by low amplitude (< -0.1 nA) 
endogenous sodium current that is sometimes present in tsA201 cells. Cells exhibiting 
peak current amplitudes > -6 nA were also generally excluded from analysis to ensure 
accurate voltage control. Whole-cell capacitance and access resistance were 
determined by integrating capacitive transients in response to voltage steps from −120 to 
−110 mV filtered at 10 kHz. Series resistance was compensated 90-95% to assure that 
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the command potential was reached in less than 100 µs with a voltage error < 2 mV. 
Leak currents were subtracted by using an online P/4 procedure. All data were low-pass 
Bessel filtered at 5 kHz and digitized at 50 kHz. 
 Specific voltage-clamp protocols assessing channel activation, voltage 
dependence of fast inactivation, and recovery from a 100 ms inactivating prepulse 
(recovery from fast inactivation) were used as described previously (Lossin et al., 2002; 
Lossin et al., 2003; Rhodes et al., 2004; Ohmori et al., 2006) and described by figure 
insets. All voltage-clamp protocols utilized a holding potential of –120 mV and a 60 sec 
interpulse at the holding potential between sequential protocols. Voltage steps (20 ms) 
to between –80 to +60 mV in 10 mV increments were used to create a family of voltage-
gated inward sodium current traces. The peak current was normalized for cell 
capacitance and plotted against voltage to generate peak current density-voltage 
relationships. Conductance (GNa) was calculated as GNa = I/(V – Erev) where I is the 
measured peak current, V is the test voltage, and Erev is the calculated sodium reversal 
potential. To provide a quantitative evaluation of the voltage dependence of activation, 
normalized G-V curves were fit with a Boltzmann function, G/Gmax = (1 + exp[(V – 
V1/2)/k])-1, where V1/2 is the curve midpoint indicating the voltage at which half of the 
channels are activated and k is a slope factor corresponding with voltage sensitivity of 
the channel. The time to peak current and 10 – 90% rise time were quantified for the –30 
to +30 mV range using the same voltage-clamp protocol described above. Together 
these parameters define the magnitude of depolarization needed for channel opening. 
Voltage dependence of fast inactivation was assessed by 100 ms prepulses to between 
–140 to –10 mV in 10 mV increments followed by a 20 ms test pulse to –10 mV. The 
normalized current is plotted against the voltage and the data were fit with Boltzmann 
functions to determine the voltage for half-maximal inactivation (V1/2) and a slope factor 
(k). Voltage dependence of fast inactivation provides information about the level of 
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depolarization necessary for the channel to enter fast inactivation under steady-state 
conditions including the physiological range of potentials. Recovery from fast inactivation 
was determined using a two-pulse protocol. A 100 ms prepulse to –10 mV was followed 
by a variable amount of time for channel recovery and a 20 ms test pulse to –10 mV. 
The peak current from the test pulse was normalized to the peak current from the 
prepulse and plotted against the recovery period. Data were fit with the two exponential 
function, I/Imax = A1 × [1 – exp(–t/τ1)] + A2 × [1 – exp(–t/τ2)],  where τ1 and τ2 denote time 
constants (fast and slow components, respectively), and A1 and A2 represent the fast 
and slow fractional amplitudes. Time dependent recovery from inactivation provides 
information about how rapidly the channels can be available for a subsequent 
depolarization stimulus.  
 Inactivation of the whole-cell sodium current was evaluated by fitting the decay 
phase of the current with the two exponential function, I/Imax = A1 × exp(−t/τ1) + A2 × 
exp(−t/τ2), where τ1 and τ2 denote time constants (fast and slow components, 
respectively), A1 and A2 represent the fast and slow fractional amplitudes. For studies of 
use-dependent channel availability, cells were stimulated with depolarizing pulse trains 
of 200 pulses to 0 mV for 5 ms each at the indicated frequencies. A recovery interval of 
15 sec at −120 mV followed the pulse train at each frequency. Currents were normalized 
to the peak current recorded in response to the first pulse in each frequency train. 
Persistent current was evaluated during the final 10 ms of a 200 ms depolarization to 
−10 mV and expressed as a percentage of peak current following digital subtraction of 
currents recorded in the presence and absence of 10 µM tetrodotoxin (TTX). To prevent 
potential experimenter bias, persistent current experiments and analysis were performed 
blinded to genotype. 
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Cell Surface Biotinylation 
 Cell surface biotinylation was performed as described previously (Kahlig et al., 
2004; Kahlig et al., 2006a; Carvelli et al., 2002; Daws et al., 2002), with minor 
modifications for NaV1.1 detection. Wild-type NaV1.1 and N211S were epitope tagged 
with a triple FLAG tag on the C-terminus to increase detection sensitivity. Cells 
transfected with WT-NaV1.1 or N211S, β1, and β2 as described above were washed 
twice with 4 oC PBS, then cell surface proteins were labeled with the cell membrane 
impermeant biotinylating reagent, Sulfo-NHS-Biotin (Pierce Biotechnology, Rockford, IL), 
for 1 hr. The reaction was quenched with 100 mM glycine. Cells were then lysed with 
RIPA buffer (150 mM NaCl, 50 mM Tris-base, 1% IGEPAL CA-630, 0.5% Na 
Deoxycholate, 0.1 % SDS, pH 7.5) supplemented with Complete Mini Protease Inhibitor 
Cocktail Tabs (Roche Applied Science, Indianapolis, IN). Scraped lysates were 
centrifuged at 16,000 x g for 30 min at 4 oC. Biotinylated proteins in the supernatant 
were recovered by incubation (2 hrs at 4 oC) with High Capacity Streptavidin Agarose 
beads (Pierce Biotechnology, Rockford, IL) followed by centrifugation. The beads were 
extensively washed with RIPA buffer and biotinylated proteins eluted with 2X Laemmli 
Sample Buffer containing fresh 5% β-mercaptoethanol. Proteins were separated using 
SDS-polyacrylamide (7.5%) gel electrophoresis and transferred to polyvinylidene 
difluoride membranes. Membranes were incubated at room temperature for two hrs in 
5% milk. NaV1.1 was detected with primary antibodies directed against the FLAG 
epitope (mouse, anti-FLAG M2, 1:15000, Sigma). The quantity of loaded protein in each 
lane was determined using a primary antibody directed against the endogenous protein 
transferrin (mouse, anti-human transferrin receptor, 1:10000 for total protein and 1:2500 
for biotinylated protein, Zymed, Carlsbad, CA). Immunoreactive bands were visualized 
using horseradish peroxidase-conjugated secondary antibody (goat anti-mouse, 1:30000 
for total protein and 1:10000 for biotinylated proteins, Santa Cruz Biotechnology, Santa 
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Cruz, CA), directed against the primary antibody, ECL Plus (GE Healthcare, 
Buckinghamshire, UK) incubation and Hypersensitive ECL film detection. Protein band 
densitometry was performed using ImageJ software (NIH, Bethesda, MD). To control for 
protein loading, each NaV1.1 band was normalized to the amount of endogenously 
expressed transferrin detected for each experimental condition. One-way ANOVA 
analysis with a Newman-Keuls Multiple Comparison post-test was performed to 
determine significance for cell surface biotinylation experiments. 
 
Results 
 
Sequence analysis 
 46 patients underwent surgical resection of mesial temporal lobe following a 
diagnosis of intractable MTLE. Our collaborators, Kearney et al. isolated genomic DNA 
from the brain tissue and the coding exons of three sodium channel genes, SCN1A, 
SCN2A, and SCN3A, were sequenced. One sample had an A632G nucleotide 
substitution in the coding region of exon 5 in SCN1A. This substitution alters a highly 
conserved  asparagine  for a  serine  residue  at  position  211  (N211S)  (Figure 25).  
The N211S mutation was confirmed to affect a residue in exon 5A and not the 
alternatively spliced exon 5N. The heterozygote frequency was 0.02 (n = 46) with a 
minor allele frequency of 0.01 (n = 92) in the MTLE samples. In control samples the 
heterozygote frequency was 0 (n = 295) and the minor allele frequency was 0 (n = 590). 
 
N211S causes increased inward sodium current 
 We functionally characterized the mesial temporal lobe epilepsy-associated 
mutation (N211S) using a recombinant human NaV1.1 co-expressed with the human β1 
and β2 subunits in cultured cells (tsA201) of human origin. N211S is a novel missense  
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Figure 25. Evolutionary conservation of N211S. Alignment of amino acid sequences 
of SCN1A region containing DI S3-S4 linker with N211S. The residue is highlighted in 
yellow and shows a high level of conservation across other human voltage-gated sodium 
channels and across species. 
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mutation identified by our collaborators. N211S disrupts a residue in the extracellular 
linker between S3-S4 of Domain I. Figure 26A illustrates the approximate position of 
N211S within the predicted NaV1.1 two-dimensional topology.   
 N211S generated functional voltage-gated sodium channels when transiently 
expressed in tsA201 cells with the auxiliary hβ1 and hβ2 subunits. Figure 26B illustrates 
representative whole-cell currents evoked by a series of depolarizing test potentials in 
cells transiently expressing wild-type NaV1.1 (WT-NaV1.1) or N211S (shown as protocol 
inset Figure 26B). Cells transfected with N211S displayed a significant increase in the 
peak inward sodium current over a large range of test voltage potentials. The 
corresponding peak current density-voltage relationships are presented in Figure 27A. 
After normalizing for cell capacitance, N211S caused a significant increase in current 
density (p ≤ 0.05) over the -20 to +50 mV voltage range compared to WT-NaV1.1 (Figure 
27A). 
 
N211S exhibits normal gating behaviors 
 Activation properties were determined from the family of voltage steps to 
between -80 to +60 mV from a holding potential of -120 mV (Figure 26B). Activation 
kinetics were examined by measuring the time to peak current and 10 – 90% rise time 
for activation for the -30 to +30 mV range. N211S did not display differences in activation 
kinetics compared to WT-NaV1.1 (Table 13). Additionally the voltage dependence of 
activation was not significantly different between N211S and WT-NaV1.1 channels 
(Figures 27B and Table 14).  
N211S does not exhibit altered whole-cell current decay compared to WT-NaV1.1 
when the data was fitted with a two-exponential equation (fit parameters provided in 
Table 15). The voltage dependence of fast inactivation following an inactivating prepulse 
was similar for WT-NaV1.1 and N211S (Fig. 28A and Table 14). Furthermore, N211S 
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Figure 26. Representative WT-NaV1.1 and N211S whole-cell sodium currents. (A) 
Predicted transmembrane topology of NaV1.1 showing the location of novel MTLE 
mutation N211S as a filled circle. (B) Sodium currents recorded from tsA201 cells 
coexpressing the indicated NaV1.1 allele with the hβ1 and hβ2 accessory subunits. 
Currents were activated by voltage steps to between –80 and +60 mV from a holding 
potential of −120 mV (see pulse protocol shown as panel inset).  
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Figure 27. Voltage dependence of activation for WT-NaV1.1 and N211S. (A) Peak current density elicited by test pulses to various 
potentials and normalized to cell capacitance. N211S exhibits increased peak current density compared to WT-NaV1.1 for the -20 to 
+50 mV range (*p < 0.05, **p < 0.01). (B) Voltage dependence of channel activation measured during voltage steps to between –80 
and +20 mV. N211S does not exhibit altered voltage dependence of activation compared to WT-NaV1.1. Pulse protocol is shown as a 
panel inset and fit parameters are provided in Table 14. 
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Figure 28. Fast inactivation properties of WT-NaV1.1 and N211S. (A) Voltage dependence of fast inactivation assessed in 
response to inactivating prepulses to between –140 and –10 mV. N211S displayed similar voltage dependence of fast inactivation 
compared to WT. (B) Time dependent recovery from fast inactivation assessed following an inactivating prepulse (100 ms at –10 
mV). No significant defects in the recovery in fast inactivation were found for N211S. Pulse protocols are shown as panel insets and 
fit parameters are provided in Table 14. 
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0.24 ± 0.01 
 (n = 13) 
0.25 ± 0.01 
   (n = 11) 
 0.08 ± 0.01 
(n = 13) 
0.07 ± 0.01 
(n =11) 
30 mV 
0.27 ± 0.01 
  (n = 13) 
0.27 ± 0.01 
   (n = 11) 
 0.10 ± 0.01 
(n = 13) 
0.09 ± 0.01 
(n = 11) 
20 mV 
0.31 ± 0.01 
(n = 13) 
0.31 ± 0.01 
   (n = 11) 
 0.12 ± 0.01 
(n = 13) 
0.12 ± 0.01 
(n = 11) 
10 mV 
0.37 ± 0.01 
(n = 13) 
0.36 ± 0.01 
   (n = 11) 
 0.15 ± 0.01 
(n = 13) 
0.15 ± 0.01 
(n = 11) 
0 mV 
0.47 ± 0.02 
(n = 13) 
0.46 ± 0.02 
   (n = 11) 
 0.20 ± 0.01 
(n = 13) 
0.21 ± 0.01 
(n = 11) 
-10 mV 
0.67 ± 0.04 
(n = 13) 
0.65 ± 0.04 
   (n = 11) 
 0.32 ± 0.02 
(n = 13) 
0.30 ± 0.02 
(n = 11) 
-20 mV 
0.98 ± 0.07 
(n = 13) 
1.05 ± 0.10 
 (n = 11) 
 0.56 ± 0.05 
(n = 13) 
0.60 ± 0.09 
(n = 11)  
-30 mV 
N211S WT-NaV1.1  N211S WT-NaV1.1 
  
Table 13. Activation kinetics of WT-NaV1.1 and N211S 
10 – 90% Rise Time Time to Peak Current 
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Recovery from 100 ms 
inactivating prepulse 
 τ1 (ms)§         τ2 (ms)§        
n
Voltage dependence  
of fast inactivation 
V1/2 (mV)       k (mV)       n 
Voltage dependence 
of activation 
 V1/2 (mV)       k (mV)        n 
WT-NaV1.1   -23.8 ± 1.7    7.2 ± 0.2      11     -64.1 ± 1.2     6.2 ± 0.1     9       2.6 ± 0.2      48.5 ± 7.7      10 
                             (84 ± 1%)      (16 ± 1%)
 N211S          -21.5 ± 1.1   7.36 ± 0.2     13     -61.2 ± 1.6     6.0 ± 0.1    13      2.3 ± 0.3     50.1 ± 15.0     13 
                     (80 ± 3%)     (19 ± 3%)
Table 14. Biophysical parameters of WT-NaV1.1 and N211S 
§ values in parentheses are amplitude. 
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1.94 ± 0.20 
   (6 ± 1%) 
4.13 ± 0.66 
   (6 ± 2%) 
 0.21 ± 0.01 
  (94 ± 1%) 
0.25 ± 0.02 
 (95 ± 2%) 
30 mV 
2.13 ± 0.27 
   (6 ± 1%) 
3.78 ± 0.71 
   (6 ± 1%) 
 0.23 ± 0.01 
  (93 ± 1%) 
0.25 ± 0.01 
 (94 ± 1%) 
20 mV 
2.92 ± 0.30 
   (4 ± 1%) 
3.27 ± 0.39 
   (4 ± 1%) 
 0.28 ± 0.01 
  (95 ± 1%) 
0.30 ± 0.01 
 (95 ± 1%) 
10 mV 
3.57 ± 0.46 
   (4 ± 1%) 
4.82 ± 1.24 
   (4 ± 1%) 
 0.35 ± 0.01 
  (95 ± 1%) 
0.35 ± 0.02 
 (95 ± 2%) 
0 mV 
4.26 ± 0.37 
   (4 ± 1%) 
7.71 ± 1.44 
   (4 ± 1%) 
 0.52 ± 0.03 
 (95 ± 1%) 
0.49 ± 0.02 
 (96 ± 1%) 
-10 mV 
7.87 ± 3.01 
   (4 ± 2%) 
3.76 ± 3.22 
   (4 ± 1%) 
 0.96 ± 0.11 
 (95 ± 2%) 
0.88 ± 0.07 
  (96 ± 1%) 
-20 mV 
12.39 ± 3.25 
     (23 ± 10%) 
17.69 ± 7.55 
     (39 ± 11%) 
 1.82 ± 0.29 
  (77 ± 9%) 
1.50 ± 0.22 
   (65 ± 11%)  
-30 mV 
N211S WT-NaV1.1  N211S WT-NaV1.1 
 
Table 15. Whole-cell current inactivation time constants for WT-NaV1.1 and N211S 
§ values in parentheses are amplitude.  For WT-NaV1.1, n = 11 and for N211S, n = 13. 
Fast Component§ Slow Component§ 
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recovered from fast inactivation similarly to WT-NaV1.1 (Figures 28B and Table 14). 
These data illustrate that N211S has kinetic and voltage dependent behaviors similar to 
WT-NaV1.1. 
 In the absence of major gating abnormalities for N211S, we utilized a voltage 
protocol consisting of a train of depolarizing steps at varying frequencies to test for 
differences in use-dependent channel behavior. N211S exhibited use-dependent loss of 
channel availability similar to WT-NaV1.1 over a large range of frequencies (1 to 140 Hz; 
Figure 29A). No significant differences in channel availability during the pulse protocol 
were visible over 200 pulses (Figure 29B). These data predict that N211S and NaV1.1 
will behave similarly during rapid stimulation.  
 
Absence of increased persistent current in the N211S mutation 
 We previously observed that several NaV1.1 mutations associated with various 
genetic epilepsy syndromes cause significantly increased persistent current (Lossin et 
al., 2002; Rhodes et al., 2004; Rhodes et al., 2005; Ohmori et al., 2006). However, the 
N211S mutant did not exhibit an increased persistent current as compared to WT 
channels (magnitude of persistent current as percentage of peak current amplitude: WT: 
1.64 ± 0.35%, n = 10; N211S: 1.74 ± 0.24%, n = 9). This finding suggests that increased 
persistent current is not a common biophysical hallmark of NaV1.1 mutations associated 
with MTLE. 
 
N211S exhibits normal cell surface expression 
 N211S exhibited significantly larger mean whole-cell peak current levels 
compared to WT-NaV1.1. No other biophysical parameters we assayed were significantly 
different between N211S and WT-NaV1.1. We tested the hypothesis that N211S 
increases the level of protein in the plasma membrane by performing cell surface 
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Figure 29. Use-dependent channel behavior of a MTLE mutant.  The response of WT-NaV1.1 and N211S to repetitive 
depolarization (use-dependent channel behavior) was measured by stimulating cells with voltage step pulse trains (200 pulses, 5 ms, 
0 mV) from a holding potential of –120 mV at the indicated frequencies (see pulse protocol inset in panel B). (A) Residual peak 
current amplitude of the 200th pulse for WT-NaV1.1 (n = 9) and N211S (n = 11) plotted against pulse frequency. (B) Normalized peak 
current measured in response to a voltage step train at a frequency of 120 Hz. N211S has similar use-dependent channel behavior 
to WT-NaV1.1. 
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biotinylation. Figure 30A illustrates that WT-NaV1.1 and N211S exhibited similar total 
and cell surface expression. Quantification of cell surface NaV1.1 protein expression 
from four independent experiments (Fig. 30B, C) demonstrated that N211S does not 
significantly increase total protein (70% for N211S; n = 4) or cell surface expression 
compared to WT-NaV1.1 (120% for N211S; n = 4). Surprisingly the two-fold increase in 
mean peak current density is not due to an alteration of the cell surface expression of 
N211S compared to WT-NaV1.1. This suggests that N211S would differ from WT-NaV1.1 
in single channel properties of single channel conductance or open channel probability. 
 
Discussion 
 Elucidation of the molecular basis for brain sodium channelopathies and 
establishment of genotype-phenotype correlations may shed light on epileptogenesis 
and help conceptualize new treatment strategies. Our collaborators identified a novel 
mutation in NaV1.1 from brain tissue resected from a case of intractable MTLE.  We then 
examined the functional properties of the MTLE mutation (N211S) using the human 
NaV1.1 α-subunit coexpressed with human β1 and β2 subunits.  
Unfortunately we do not have access to the medical history and family history for 
the patient with the novel N211S mutation. We can hypothesize that the patient had 
antecedent FS like the previously reported 50 – 80% of intractable MTLE patients 
(French et al., 1993; Baulac et al., 2004). We can also hypothesize that the SCN1A 
mutation may be carried by other family members who have diverse epilepsy 
phenotypes (Abou-Khalil et al., 2001; Mantegazza et al., 2005; Colosimo et al., 2007). 
Another consideration is that N211S may be a benign variant that was present but not 
the primary cause of MTLE in the patient. N211S was not present in control samples, but 
it may be present in the general population at a low frequency. Screening more MTLE 
patients and control samples can help determine if N211S is a disease-causing mutation 
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Figure 30. Cell surface protein expression of WT-NaV1.1 and N211S. Cell surface 
expression of WT-NaV1.1 and N211S was measured using cell surface biotinylation. 
Endogenous transferrin levels were measured as a gel loading control. (A) 
Representative experiment illustrating total (top) and cell surface (bottom) NaV1.1 protein 
detected with anti-FLAG antibody. NaV1.1 immunoreactive bands were normalized to the 
amount of an endogenous protein (transferrin) detected in each experimental lane 
(below NaV1.1 detection). The first lane was isolated from cells transfected with 
untagged WT-NaV1.1. Lane 2 is WT-NaV1.1FLAG, lane 3 is N211SFLAG and lane 4 was 
isolated from untransfected tsA201 cells (mock). (B) Quantification of four independent 
experiments demonstrated that total protein levels are similar for WT-NaV1.1 and 
N211S. (C) Quantification of four independent experiments demonstrated that cell 
surface expression levels are similar for WT-NaV1.1 and N211S. The biotinylated and 
total NaV1.1 bands were normalized to the corresponding transferrin band and the ratio 
of the normalized biotinylated to total are shown for WT-NaV1.1 and N211S. 
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or rare benign variant. Also functional data that supports a mechanism for N211S 
causing MTLE would help demarcate N211S as a mutation. 
In this chapter, we examined the biophysical properties of WT-NaV1.1 and MTLE 
mutant N211S. In comparison to WT-NaV1.1, N211S did not alter voltage dependence or 
kinetics of activation, whole-cell current, fast inactivation, use-dependent channel 
behavior, or persistent sodium current (Figures 27B – 29, and Tables 13 – 15). The 
N211S mutation caused an increase of approximately two-fold in the current density-
voltage relationship (Figures 26B, 27A). The large increase in current density exhibited 
by N211S is in opposition with a previous report about a SCN1A mutation found in a 
family with febrile seizures and TLE (Mantegazza et al., 2005; Colosimo et al., 2007). 
Thus, our finding was novel and unexpected and exemplifies the complexity of 
determining how biophysical function relates to the epilepsy phenotype. 
We next sought to understand why the N211S mutation increased current 
density. We hypothesized that the increased current density might be due to an increase 
in the number of channels at the cell surface. To address this, we performed cell surface 
biotinylation. N211S had similar total and cell surface NaV1.1 protein expression (Figure 
30). Future experiments will need to utilize single channel analysis to look at open 
channel probability and single channel conductance to determine what property confers 
increased current density. To date only one study has examined the function of epilepsy 
associated mutations in NaV1.1. This study found that one mutation did not alter single 
channel properties and the other mutation, R1648H, caused an increase in late channel 
openings (Vanoye et al., 2006). Any single channel defects caused by N211S would be 
novel and increase understanding of the role NaV1.1 plays in TLE pathogenesis. 
 The N211S mutation also disrupts a predicted N-linked glycosylation sequence. 
Glycosylation of voltage-gated sodium channels confers isoform specific and 
developmental alterations of voltage dependent and kinetic properties (Bennett, 2002; 
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Stocker and Bennett, 2006). Determining whether N211S is disrupting glycosylation in 
vivo is a difficult experiment, but it would be informative to know whether the functional 
impact of the mutation is partly due to disruption of the N-linked glycosylation sequence. 
Originally thought to be an acquired disorder, TLE is now recognized to have 
genetic risk factors. Several families with other epilepsy syndromes such as FS, GEFS+ 
or CAE have family members who develop TLE (Colosimo et al., 2007; Nabbout et al., 
2007). One SCN1B mutation that is linked to GEFS+ was also found in several TLE 
patients (Scheffer et al., 2007). Two earlier studies found SCN1A mutations in TLE 
patients (Abou-Khalil et al., 2001; Colosimo et al., 2007) making identification of N211S 
an independent confirmation that NaV1.1 dysfunction can predispose or cause TLE. 
In summary, we characterized a novel SCN1A mutation identified in brain tissue 
samples isolated from a patient with intractable MTLE. N211S disrupts a highly 
conserved residue located in the extracellular linker between S3-S4 of Domain I (Figure 
25, 26A). The mutation causes an increase in current density (Figure 26B and 27A) 
without an alteration of voltage dependent and kinetic properties (Figures 27B – 29, and 
Tables 13 – 15) or number of channels at the cell surface (Figure 30). Future studies in 
neurons or the use of animal models may aid in elucidating the link between sodium 
channel mutation and MTLE. 
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CHAPTER V 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Summary 
 Epilepsy is a common neurological disorder affecting an estimated 2.7 million 
people in the United States (Centers for Disease Control). Inherited forms of epilepsy 
comprise a relatively small percentage of cases. In recent years, defects in several 
different genes have been associated with Mendelian forms of epilepsy. Genes involved 
in epilepsy are most commonly components of ion channels including voltage-gated 
sodium and potassium channels, GABAA receptors, and acetylcholine receptors. Other 
commonly mutated proteins are related to neuronal maturation and migration like LGI1. 
The category of ion channels most commonly mutated among genetic epilepsy 
syndromes is voltage-gated sodium channels. 
 This thesis research characterized voltage-gated sodium channel mutations 
associated with different forms of genetic epilepsy. In an attempt to better understand 
mechanisms underlying epilepsy, we utilized several model systems. In Chapter Two, 
we used computational modeling to investigate WT-NaV1.1 and a GEFS+ mutation. 
Chapters Three and Four and Appendix A used heterologous expression of mutant 
neuronal voltage-gated sodium channels in tsA201 cells for biophysical and biochemical 
studies. Finally in Appendix B, we described our experiments using a transgenic mouse 
model of epilepsy for electrophysiological and biochemical experiments. 
 Chapter Two described using computational modeling to investigate function of 
WT-NaV1.1. We used actual data acquired from heterologous expression in tsA201 cells 
to develop a Markov model of WT-NaV1.1. A novel aspect to our WT-NaV1.1 model was 
introduction of a biphasic open state inactivation process. The open channel transitions 
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to an unstable inactivated state before entering a “latched” or more stable inactivated 
state. Our model was able to replicate activation, fast inactivation, slow inactivation, 
persistent current and single channel properties of WT-NaV1.1. We then created a model 
for the GEFS+ mutation, R1648H. To create R1648H, we increased the rate constant 
from the stabilized fast inactivated state back to the unstable inactivated state. Altering 
just one rate constant was able to maintain the whole-cell properties including the 
increased persistent current and at the increased late channel openings at the single 
channel level that are seen when R1648H was patch clamped in heterologous 
expression systems.  
Chapters Three and Appendix A investigated the role BFNIS-NaV1.2 mutations. 
In Appendix A, we described setting up the conditions for the heterologous expression 
system used in subsequent chapters. We first constructed a human WT-NaV1.2 for 
functional expression and then used site-directed mutagenesis to create three BFNIS 
mutations (R1319Q, L1330F, and L1563V). We established the optimal conditions for 
transfection and whole-cell patch clamp experiments for the subsequent experiments 
described in Chapter Three. 
 Chapter Three described the functional characterization of three BFNIS alleles. 
We found that R1319Q caused a depolarizing shift in the voltage dependence of 
activation, slower activation kinetics, and a slightly delayed recovery from fast 
inactivation. The L1330F allele caused enhanced use-dependent channel behavior 
compared to WT-NaV1.2. The L1563V mutation slowed whole-cell current decay, 
depolarized voltage dependence of fast inactivation, and accelerated recovery from fast 
inactivation. All three mutations caused a decrease in mean inward peak current 
compared to WT-NaV1.2. We used cell surface biotinylation to examine the hypothesis 
that decreased mean inward peak current resulted from fewer channels at the cell 
surface. We found that all three mutations decreased cell surface expression by 
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between 47 and 79%. The decreased cell surface expression was a novel finding in 
BFNIS and probably represents a more pathophysiologically relevant deficit than the 
subtle biophysical defects exhibited by each mutation. 
 Chapter Four characterized a novel SCN1A mutation from brain tissue resected 
from a MTLE patient identified by our collaborators. The mutation, N211S, disrupts a 
highly conserved amino acid in the S3-S4 extracellular linker in DI that is part of a 
predicted N-linked glycosylation site. We used a heterologous expression system to 
functionally characterize N211S under conditions similar to those established in 
Appendix A. We found that N211S exhibited a large increase in current density 
compared to WT-NaV1.1. No other voltage dependent or gating properties we measured 
were altered. Additionally N211S did not lead to altered use-dependent channel behavior 
or increased persistent current. We performed cell surface biotinylation to explore the 
hypothesis that the increased current density was the result of increased number of 
channels at the cell surface. We did not find significant alterations in the expression of 
N211S at the cell surface.  
 In Appendix B, we discussed our initial experiments using transgenic mice 
carrying a Scn2a mutation (GAL879-881QQQ) that caused impairments in inactivation 
and increased persistent current. Transgenic mice from the congenic C57BL/6J 
background (B6.Q54) have low seizure susceptibility, whereas mice that are F1 from 
C67BL/6J crossed to SJL/J (F1.Q54) have a much more severe seizure phenotype. We 
hypothesized that genetic modifiers may directly influence voltage-gated sodium channel 
function and account for the differing seizure susceptibilities between the B6.Q54 and 
F1.Q54. We performed whole-cell patch clamp recordings from acutely dissociated 
hippocampal neurons from WT littermate mice. We established several conditions for 
recording voltage-gated sodium channel current. Once we had optimized aspects of the 
dissection and electrophysiological recordings, we performed whole-cell patch clamp 
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studies on acutely dissociated hippocampal neurons from both B6.Q54 and F1.Q54. We 
obtained several recordings, but have not made a final determination whether the two 
background strains have significant differences in voltage dependent or kinetic 
properties of voltage-gated sodium channels. Preliminarily, the two strains may have 
some voltage dependent differences that may contribute to altered excitability. We found 
that B6.Q54 neurons displayed persistent sodium current despite the low seizure 
threshold. We also sought to determine whether background strain influenced protein 
expression levels of the transgene by performing western blot analysis of membrane 
preparations from whole brain. Although we could specifically detect the transgene 
protein in mice from both background strains, determining differences in the transgene 
expression level were beyond the level of our detection. 
 
Implications for pathophysiology of epilepsy 
 The GEFS+ mutation SCN1A-R1648H disrupts a highly conserved arginine 
residue in the S4 of DIV. Generally, mutations in S4 segments are predicted to cause 
defective channel activation but mutations specifically in DIV of sodium channels have 
been demonstrated to disrupt inactivation as the primary consequence (Chahine et al., 
1994; Ji et al., 1996; Cha et al., 1999). The processes of activation and fast inactivation 
are coupled and define the biexponential whole-cell inactivation curve. The Markov chain 
models of WT-NaV1.1 and R1648H predicted that NaV1.1 undergoes fast inactivation in a 
two step manner. Destabilizing the reverse transition from the stable fast inactivated 
state to the unstable fast inactivated state was able to increase late channel openings on 
the single channel level and increase persistent current at the whole-cell level as is seen 
for R1648H when recorded at the patch clamp setup. This suggests that R1648H has a 
defect in stabilization of the fast inactivation gate. Although fast inactivation is known to 
be critical for limiting the amount of sodium ions that enter the cell following 
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depolarization, the way that defective fast inactivation results in epilepsy is not 
understood. Experiments need to be done to see how the R1648H mutation alters the 
conformation of the sodium channel to impair fast inactivation. This would then have 
broader implications for understanding the mechanism of increased persistent current 
exhibited by some other sodium channel mutations.  
We speculate that persistent sodium current from epilepsy mutations including 
R1648H cause an aberrant membrane depolarization that may lead to neuronal firing in 
the absence of strong depolarizing stimuli. Aberrant neuronal firing would offset the 
regulation of normal brain excitability and could lead to epilepsy. Enhanced 
understanding of the role persistent current plays in regulating neuronal firing may aid in 
better therapeutic options for specific epilepsy patients as discussed below. 
 Each of the BFNIS mutations exhibited subtle biophysical defects. R1319Q 
altered activation and L1330F exhibited enhanced use-dependent channel behavior 
predicting a loss of channel function for both of these mutations. The L1563V mutation 
exhibited impaired inactivation predicting a gain of channel function. One explanation for 
these divergent biophysical effects resulting in similar epilepsy phenotypes could be that 
R1319Q and L1330F preferentially affect excitatory neurons while L1563V preferentially 
affects inhibitory neurons. The mechanism for each mutation having a predominant 
effect on a different functional class of neurons is not understood.  
A recent mouse model of SMEI showed that haploinsufficiency of NaV1.1 
selectively reduced current density in inhibitory interneurons (Yu et al., 2006). 
Decreased sodium current density may underlie BFNIS if loss of NaV1.2 primarily affects 
inhibitory interneurons reducing the negative feedback on excitatory neurons as in the 
SMEI mouse model. Perhaps NaV1.2 expression is high in inhibitory neurons early in life 
and expressed at lower levels within the first year of life which may explain the early 
onset of seizures followed by spontaneous seizure remittance.  
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Decreased current density resulting from reduced mutant sodium channel cell 
surface expression appears important to the pathogenesis of BFNIS. Missense BFNIS 
mutations may result in misfolded proteins that cause disturbances in sodium channel 
membrane expression. Many potential mechanisms for decreased cell surface protein 
expression exist including decreased stability of mRNA, decreased delivery to the 
membrane, increased internalization, and altered interactions with chaperone proteins 
like β-subunits (Yanagita et al., 2003; Wada et al., 2004; Gallagher et al., 2007; Hirose, 
2006). Future studies will need to examine how the BFNIS missense mutations cause 
impaired protein trafficking and cell surface expression as discussed below.  
 The MTLE NaV1.1 mutation, N211S, displayed increased current density without 
an increase in cell surface expression. Increased sodium current density is a novel 
biophysical finding in an epilepsy-associated mutation. We can speculate that the 
increased current density of N211S is due to either increased single channel 
conductance or increased open channel probability. Gain of NaV1.1 function would be 
predicted to increase sodium current. To result in epilepsy, we speculate that N211S 
increases neuronal sodium current of excitatory neurons. This is in contrast to the finding 
that loss of NaV1.1 results in decreased sodium currents in hippocampal interneurons 
but does not affect sodium current from hippocampal excitatory neurons (Yu et al., 
2006). One thing that may account for our predicted defect is that increased NaV1.1 
function may result in decreased expression and sodium current through other sodium 
channel α isoforms.  
Many cases of TLE also present with damage to the temporal lobe including 
hippocampal sclerosis or mesial temporal lobe sclerosis. It is unclear whether physical 
damage to the temporal lobe precedes epilepsy. Perhaps increased sodium current as 
exhibited by N211S predisposes to neuronal injury in the temporal lobe which ultimately 
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results in epilepsy. Studying the N211S mutation may contribute to our understanding of 
what causes temporal lobe epilepsy and identify novel therapeutic options. 
 
Implications for treatment of epilepsy 
 Although one main goal of this research is to better understand mechanisms 
underlying epilepsy, another major goal is to aid in identification of novel treatment 
options for epilepsy. In the future, patients will be diagnosed with a particular epilepsy 
syndrome and treated with a pharmaceutical agent to target their specific problem. We 
hope that increased understanding of the biophysical defects or trafficking defects may 
enable development of better therapeutic agents. 
 R1648H is a GEFS+ mutation that exhibits increased persistent current. 
Therapeutic agents that specifically target the persistent sodium current are under 
development and may be the proper treatment option for patients with the R1648H 
mutation. Ranolazine specifically blocks persistent sodium current in the cardiac sodium 
channel, NaV1.5. Ranolazine has been used successfully to alleviate the frequency and 
severity of anginal attacks (Hale et al., 2008). Although no selective persistent sodium 
channel blocker has been used in patients with epilepsy, we predict that agents like 
ranolazine may have a large therapeutic benefit in patients where the primary defect is 
increased persistent sodium current. 
 Many epilepsy mutations exhibit decreased sodium current. The BFNIS 
mutations we characterized had decreased sodium current and reduced channel cell 
surface expression. Attempts have been made to rescue sodium current density by 
interactions with the proteins like the β subunits, low temperature incubation, and 
incubation with sodium channel blockers. For example, the GEFS+ mutation M1841T 
exhibits decreased sodium current density that can be partially restored by a 24 hr 
preincubation with phenytoin (Rusconi et al., 2007). Although this mutant channel 
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exhibits sodium channel attributes similar to that of WT-NaV1.1, when expression at the 
surface is increased the mutant channel may not behave similarly to WT. For example, a 
long QT syndrome mutation in NaV1.5, L1825P, can be partially rescued by incubation 
with cisapride. The mutant channels rescued to the cell surface exhibit increased 
persistent current (Liu et al., 2005). Therapeutic agents that restore cell surface channel 
expression should be pursued with caution to ensure that the rescued mutant channels 
have no underlying biophysical defects. Unexpected channel dysfunction after restoring 
membrane expression would decrease the benefit of these drugs or cause a worsening 
of the disease phenotype. 
 
Future directions 
 
Determine effects of epilepsy mutations using sodium channel Markov models 
 Now that we have established a Markov model of WT-NaV1.1 and R1648H that 
accurately generate sodium channel behavior. The NaV1.1 channel models can be taken 
from the single compartment environment we used in Chapter Two and insert the 
models into neuronal simulation environments. We would want to further examine the 
two step open state inactivation in a neuronal environment. Experiments investigating 
how excitability parameters including action potential threshold, width, and duration differ 
between the WT-NaV1.1 and R1648H models could yield informative data about how 
R1648H causes GEFS+. We would like to use the R1648H model to do in silico 
pharmacology experiments to find ideal therapeutics targeting persistent sodium current. 
The WT-NaV1.1 model can also be a starting point for other well characterized NaV1.1 
mutations with biophysical phenotypes that differ from that of R1648H. A few potentially 
interesting mutations to investigate would include the SMEI mutation R1648C, the 
GEFS+ mutation D1866Y, and the ICEGTC mutant V983A. The WT-NaV1.1 model could 
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help to generate other sodium channel models including NaV1.2 and NaV1.3 implicated 
in other genetic epilepsy syndromes. 
 
Determine source of reduced BFNIS mutant channel cell surface expression 
 We found subtle biophysical defects in each of the three BFNIS mutations we 
characterized in Chapter Three. In a heterologous expression system, it would be 
interesting to examine the sodium current in response to an action potential voltage 
waveform for each mutant in comparison to WT-NaV1.2. Similar to the use-dependent 
channel behavior experiments, this would be another way to see the cumulative 
functional impact of the biophysical defects. BFNIS is a developmentally regulated 
epilepsy syndrome, and it would be informative to examine how seizure remittance 
occurs within the first year of life. Experiments following coexpression of WT-NaV1.2 and 
the BFNIS mutants may elucidate the mechanism of autosomal dominant inheritance for 
this disorder. Another interesting direction for this project would be examining function of 
the BFNIS mutations in cells of neuronal origin. In neurons the expression and trafficking 
of mutant channels may be different than in tsA201 cells. Additionally in neurons, the 
biophysical properties may be affected by endogenous proteins thereby displaying 
defects that were not observed in tsA201 cells. 
We would like to determine why there are fewer mutant channels on the cell 
surface. Experiments examining channel turnover rates and subcellular distribution of 
channels may be informative. First we would want to determine where in the cells the 
channels reside because the total expression levels for the BFNIS mutants were not 
different than WT-NaV1.2. We could use subcellular fractionation by centrifugation with a 
density gradient and then examine NaV1.2 in each of the fractions using western blot 
analysis. Alternatively we could perform immunohistochemistry using fluorescent 
immunostaining to see colocalization of NaV1.2 and subcellular structures with confocal 
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microscopy. To study turnover of the sodium channels, we could first inhibit 
internalization with high sucrose and see if this restores cell surface expression of 
BFNIS mutant channels. We could also block internalization of the sodium channel with 
dominant-negative dynamin or a cholesterol-depleting drug to block clathrin or caveoli-
mediated internalization. Both experiments should be performed because the 
mechanism responsible for NaV1.2 internalization is unknown. This would help 
determine if the BFNIS mutant channels are removed from the plasma membrane more 
than WT-NaV1.2. We would also want to examine whether the BFNIS mutants have 
altered interactions with the β subunits, proteins known to regulate expression and 
localization of α subunits. NaV1.1 mutations associated with GEFS+ including M1841T 
and D1866Y have been shown to have decreased interaction with the β1 subunit. All of 
the above experiments collectively would help determine why BFNIS mutant NaV1.2 has 
reduced cell surface expression. Experiments described above would aid in 
understanding the pathophysiology of BFNIS and elucidate potential mechanisms for 
treatment. 
 
Define single channel properties of MTLE mutation N211S 
 The N211S mutation significantly increased current density without alteration of 
cell surface expression as described in Chapter Four. The next step to examining the 
increased current density would be single channel analysis. N211S likely has altered 
open channel probability or single channel conductance compared to WT-NaV1.1. 
Defects in either of these properties would be novel mechanisms of sodium channel 
mutations causing epilepsy. Similar to above, it would be interesting to examine N211S 
in neurons and determine if increased current density is the only alteration in function. 
The role of increased sodium current on temporal lobe damage as in hippocampal 
sclerosis should also be examined. 
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Determine sodium channel properties of Scn2a Q54 neurons 
 We optimized dissection and electrophysiological conditions for examining 
neurons from B6.Q54 and F1.Q54 neurons. Preliminary experiments described in 
Appendix B revealed that B6.Q54 neurons have a significant level of persistent current. 
We need to determine if F1.Q54 neurons also display similar levels of persistent current. 
The whole-cell patch clamp recordings need to be repeated to observe differences 
between the two background strains and potential effects of genetic modifiers. If we find 
that the background strains have similar voltage-gated sodium current, then we would 
predict that the genetic modifiers do not directly affect the voltage-gated sodium 
channels. We would then want to perform whole-cell voltage clamp experiments 
examining potassium current. We would want to conduct current clamp experiments to 
determine resting membrane potential, input-output relationships, and action potential 
characteristics. Another avenue for conducting these experiments would be to isolate 
embryonic cultures and maintain the cultures for approximately three weeks before 
conducting current clamp experiments. These experiments would decrease the 
difficulties of space clamp and high voltage error seen in voltage clamp of neurons 
isolated from P21 animals, but would require verification of transgene expression. The 
biochemical analysis of membrane preparations from B6.Q54 and F1.Q54 neurons could 
be optimized more to detect differences in transgene expression. Another interesting 
experiment would be to determine the amount of overexpression of the transgene 
compared to the endogenous NaV1.2 protein to see if this contributes to the differing 
seizure susceptibilities between the two background strains. 
 
Computational modeling of epilepsy mutations 
 Computational modeling can be an informative way to increase understanding of 
previous observations or to predict the impact of perturbations to an established system. 
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The earliest models of voltage-gated sodium channel function utilized a Hodgkin-Huxley 
(HH) type channel. The HH type of gating approximates voltage-gated sodium channel 
function but differs in many substantial ways. To more accurately replicate channel 
behavior, more complex models including Markov chains have been used. To date, 
computational models of several different ion channels have been created. 
Now that increasingly complicated ion channel models have been created, they 
can be used in combination with complex cellular environments including various 
functional classes of neurons from several brain regions (e.g. pyramidal neuron from 
area CA3 of the hippocampus). The expression level of the channels and test responses 
to various stimuli can be controlled. Additionally ion channels can be inserted into 
singular neurons or into neuronal networks ranging from two to hundreds of neurons. 
One large caveat to using computational modeling is that the user has control over many 
parameters that may not have biological data to suggest appropriate values. Caution 
should be exercised when interpreting what the model predicts especially if all 
assumptions used to set parameters are not known. Even with these drawbacks, 
computational modeling has enormous potential to supply mechanisms of abnormal 
excitability and will be increasingly utilized in the future to determine avenues for new 
research and explain complicated biological data. 
 
Novel epilepsy-associated sodium channel mutations 
 To date, mutations in many genes have been linked to epilepsy. Over 300 
mutations in sodium channels have been associated with several forms of inherited 
epilepsy. Initially mutations in a sodium channel β subunit, SCN1B, were found in 
GEFS+ patients. Subsequently, several mutations in SCN1A and one mutation in 
SCN2A were also identified in GEFS+ patients. Now mutations in SCN1A also have 
been found in patients with SMEI, ICEGTC, MTLE, IS, FS, and cryptogenic epilepsy 
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syndromes. Mutations in SCN2A have been associated with BFNIS most commonly, but 
have also been linked to BFIS and SMEI. Recently mutations in SCN3A were identified 
in cryptogenic pediatric partial epilepsy.  
 As screening candidate genes in patients with epilepsy becomes more common, 
mutations are identified with increasing rapidity. Although heterologous expression of 
epilepsy-associated mutations has been the most rapid source of functional data, it has 
been difficult to acquire the data rapidly enough to keep up with the identification of 
mutations. Interpretation of functional characterizations from heterologous systems has 
also not been straightforward. Mutations identified in patients with the same epilepsy 
syndrome often have different biophysical phenotypes and how these various deficits 
sum to a similar pathophysiology is not well understood. Some studies that only 
assessed standard whole-cell properties including voltage dependence and kinetics of 
gating would benefit from examining slow inactivation, use-dependent channel behavior, 
persistent current, responses to action potential waveforms, and other experiments that 
may mimic physiological inputs. Additionally performing single channel analysis to find 
single channel conductance and channel open probability may also provide useful 
information for mechanisms underlying epilepsy pathogenesis. Future experiments will 
need to determine new methods for interpreting data from heterologous expression 
studies and explain the seizure remittance seen in some inherited epilepsy syndromes. 
One major goal of this type of research is to understand the biophysical defect well 
enough to develop a therapeutic strategy for patients with that particular disease-causing 
mutation. One example of this might be the use of a persistent sodium current blocker 
for the treatement of GEFS+ in a patient with the R1648H mutation as discussed above. 
 Another consideration for studies using a heterologous expression model is 
trafficking of the proteins. Initially this model system was used to characterize 
biophysical functions and any alterations in current density were not further explored. 
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Other disease-causing mutations in non-neuronal voltage-gated sodium channels and 
epilepsy-associated mutations in non-sodium channels have been shown to have 
defective protein trafficking. Recently studies have been expanded to examine cell 
surface expression and protein trafficking especially in the presence of alterations in 
current density. It would be interesting to examine the protein expression and trafficking 
of biophysically nonfunctional mutations in SCN1A that are frequently associated with 
SMEI. It is likely that future experiments will further refine the use of heterologous 
expression systems for examination of protein trafficking and would also look at the 
modulation and regulation by auxiliary subunits or other interacting proteins. 
 A few heterologous expression studies have not been performed in immortalized 
cell lines such as tsA201 or CHO-K1 cells; instead the studies utilize acutely dissociated 
cells such as neurons for studying epilepsy-associated mutations. The acutely 
dissociated neurons are then transfected with WT and mutant cDNAs. Although this 
approach may be an improvement over cells of non-neuronal origin, there are still many 
considerations for interpreting this data. The first obstacle is that acutely dissociated 
neurons are difficult to transfect and result in low transfection efficiency making this 
difficult for biochemical experiments. The second consideration is that overexpression of 
a particular cDNA would overwhelm the endogenous interacting proteins. This potentially 
means that the overexpressed protein may not be trafficked correctly or undergo normal 
regulatory mechanisms which can confound interpretations of functional data. Another 
difficulty is distinguishing the overexpressed protein from the endogenous ones. In some 
cases, knockout or knockdown of the endogenous protein can aid in characterization of 
the transfected allele. If knockout or knockdown is not possible, an epitope tag or a point 
mutation that confers different pharmacological properties can be used to distinguish 
between the different alleles. One other issue will be determining what brain region or 
neuron type is of interest and importance to study. It is also possible that instead of 
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using acutely dissociated neurons, that heterologous expression of sodium channel 
proteins in primary neuronal culture preparations may be a less heterogenous system to 
utilize. Heterologous expression of mutant proteins in acutely dissociated cells or in 
primary neuronal culture preparations will continue to be refined and provide some novel 
directions for the study of disease causing mutations. 
 
Animal models of epilepsy 
Although there are several species that have been used for animal models of 
epilepsy, the most commonly used animal is the mouse. Transgenic mouse lines have 
provided sources for in vivo data but are now being replaced by knockout and targeted 
insertion models. The downside for transgenic mice is that the transgene is randomly 
integrated into the genome with differing copy numbers in each line. The knockout or 
targeted insertion models are ideal since they maintain the original chromosomal 
location and in the case of targeted insertion models maintain a total of two copies in the 
genome. A few lines are conditional targeted insertions where exposure to a chemical is 
required for activation of the inserted gene. Much progress has been made in the 
technology of creating better mouse models of disease. 
The initial mouse models of epilepsy included non-disease associated mutations 
and random mutations found in inbred strains. These models are able to replicate some 
epilepsy phenotypes and may provide information about some unexpected proteins 
important in the pathogenesis of epilepsy. Newer models have centered on known 
disease-causing mutations with the goal of understanding the more severe genetic 
epilepsy syndromes. Animal models will provide the best behavioral and physiological 
data to understand mechanisms of disease. The animal models can also be used to test 
novel therapeutic regimens in the hope of developing better clinical treatment strategies, 
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A few drawbacks of animal models include the time and money involved in developing 
and maintaining large mouse colonies. Now that so many epilepsy mutations have been 
discovered, there needs to be a lot of thought put into determining which animal models 
can provide answers unattainable by earlier models or other experimental designs. 
Another difficulty is determining how to conduct physiological experiments because there 
are almost endless possibilities. Despite these few disadvantages, eventually animal 
models will provide answers to the questions that the model systems discussed above 
will not be able to satisfy. 
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APPENDIX A 
 
HETEROLOGOUS EXPRESSION AND ELECTROPHYSIOLOGY OF      
HUMAN NaV1.2 
 
Introduction 
 Voltage-gated sodium channel mutations have been linked to many heritable 
diseases. Mutations in the cardiac isoform, SCN5A, which encodes the protein NaV1.5 
have been associated with congential long QT syndrome, Brugada Syndrome, sick sinus 
syndrome, and sudden infant death syndrome (Wang et al., 1995; Bezzina et al., 1999; 
Benson et al., 2003; Wedekind et al., 2001). Mutations in the skeletal muscle isoform, 
SCN4A, which encodes the protein NaV1.4 have been associated with paramyotonia 
congenita, and forms of periodic paralysis (Ebers et al., 1991; Bulman et al., 1999). The 
sodium channel NaV1.7 is encoded by the gene SCN9A and is highly expressed in the 
peripheral nervous system. Mutations in SCN9A are found in cases of primary 
erythermalgia and congenital insensitivity to pain (Yang et al., 2004; Cox et al., 2006). 
Brain sodium channel mutations result in a wide variety of inherited epilepsy syndromes 
and were more recently discovered to cause familial hemiplegic migraine (FHM) 
(Wallace et al., 1998; Escayg et al., 2000b; Claes et al., 2001; Sugawara et al., 2001; 
Heron et al., 2002; Fujiwara et al., 2003; Kamiya et al., 2004; Dichgans et al., 2005; 
Vanmolkot et al., 2007). My dissertation research has focused on mutations in SCN1A 
and SCN2A, the NaV1.1 and NaV1.2 proteins respectively, associated with generalized 
epilepsy with febrile seizures plus (GEFS+), mesial temporal lobe epilepsy (MTLE), and 
benign familial neonatal-infantile seizures (BFNIS). 
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Experimental strategy 
 Most of the information gathered on the functional impact of these 
channelopathy-associated voltage-gated sodium channel mutants has come from 
heterologous expression systems. The mutations are created in either human or rat 
cDNA and then overexpressed in tsA201 or CHO-K1 cells. Since neuronal voltage-gated 
sodium channels frequently spontaneously recombine, our laboratory has developed 
strategies to perform the molecular biology in human cDNAs. These strategies are 
described below for constructing the wild-type (WT) NaV1.2 and for making the BFNIS-
associated SCN2A mutations. The methods below were previously employed in our 
laboratory to acquire data for WT-NaV1.1 and R1648H to create the Markov models 
discussed previously in Chapter Two as part of Specific Aim I. The methods described 
here were also important for Specific Aim II experiments Chapters Three and Four. 
 
Materials and Methods 
 
Construction of pCMV-SCN2A 
 We received a clone of human SCN2A in the pSVK3 (Pharmacia Biotech, 
Sweden) vector as a gift from Mauricio Montal (Ahmed et al., 1992). We moved SCN2A 
to the pCMV-Script (Stratagene, La Jolla, CA) vector to improve expression. I did the 
molecular biology with the help of Kim Greene for one step. We used a forward primer 
introducing a NotI restriction site upstream of the start codon and a reverse primer that 
matched the SCN2A sequence downstream of an ApaLI (primer sequences in Table 16). 
The PCR fragment was purified and restriction digested with NotI and ApaLI (all 
enzymes from New England Biolabs, Ipswich, MA). We deleted most of the 3’ UTR by 
cutting with XhoI positioned 220 base pairs (bp) after the stop codon. The main SCN2A 
fragment, vector fragment, and the digested PCR product were gel purified. The three 
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 Forward Primer Reverse Primer 
   
SCN2A    
5’ end 
GACTGCTACACTACGTACGCGGCC
GCCATGGCACAGTCAGTGCTGGTA TCCCGTAAAAATGTGAAATCT 
G334D 
Outer 
Primers 
CGTCAGATCCGCTAGCTATT TAAAGGTTTTCCCAGAAGTC 
G334D 
Mutagenic 
Primers 
ATTTTTTAGAGGGGCAAAATGATG
CTCTGCTTTGTGGCAACAG 
CTGTTGCCACAAAGCAGAGCA
TCATTTTGCCCCTCTAAAAAAT 
R1744G 
Outer 
Primers 
CTTTGGCAACAGCATGATCT TCATACGAGGGTGGAGACGT 
R1744G 
Mutagenic 
Primers 
CCTGGAAGCTCAGTTAAAGGAGAC
TGTGGGAACCCAT 
ATGGGTTCCCACAGTCTCCTTT
AACTGAGCTTCCAGG 
   
R1319Q 
Outer 
Primer 
AGATAGTGGAGCACAATTGG TCCAGGGTGATCTTTGTCAG 
R1319Q 
Mutagenic 
Primers 
CACTGAGAGCTTTGTCCCAGTTCG
AAGGAATGAGGGCTGTTGTAAATG
CT 
AGCATTTACAACAGCCCTCATT
CCTTCGAACTGGGACAAAGCT
CTCAGTG 
L1330F 
Outer 
Primers 
AAAGCCTTTGTTAGGAAGCA  GAGAGATCAGTTTCAGCACAC 
L1330F 
Mutagenic 
Primers 
TGAGGGCTGTTGTAAATGCATTTTT
AGGAGCCATTCCATCTAT 
ATAGATGGAATGGCTCCTAAA
AATGCATTTACAACAGCCCTCA
L1563V 
Outer 
Primers 
GTTGATTCACGAAATGTAGA TCCCAAACCTCATAGAACAT 
L1563V 
Mutagenic 
Primers 
GTCAAGAAATGACAAACATTGTGT
ACTGGATCAATCTGGTGTTTATTGT
TCTG 
ACACCAGATTGATCCAGTACA
CAATGTTTGTCATTTCTTGAC 
 
 
Table 16. Primer sequences for construction of pCMV-SCN2A and BFNIS 
mutations 
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pieces were ligated together using T4 DNA Ligase. The ligation was incubated overnight 
at room temperature before transforming MAX Efficiency Stbl2 competent cells 
(Invitrogen Corp., Carlsbad, CA). Derived from JM109 cells, Stbl2 cells are specialized 
for cloning unstable inserts like the brain sodium channels. When neuronal sodium 
channels are transformed into other competent cells, frequent recombination events 
occur throughout the open reading frame (ORF). The cultures were grown at 30 °C for 
four or five days, the optimal conditions for Stbl2 cells. The purified cDNA was 
sequenced to check for errors in the 5’ and 3’ cloning sites and the ORF of SCN2A. 
 Once we transferred SCN2A to the pCMV-Script vector, we corrected two cloning 
errors in the original pSVK3-SCN2A vector. The two errors were G334D and R1744G 
that are G1001A and A5230G at the nucleotide level. We used a two-round or double 
overlap PCR strategy (Figure 31). The first round of PCR used a pair of outer primers 
and mutagenic primers to create two initial fragments. The forward outer primer was 
paired with the reverse mutagenic primer and vice versa. The second round of PCR 
annealed the two purified first round products during the first few cycles before the outer 
primers were added to amplify the whole target sequence which is then purified. The 
sequences of primers are shown in Table 16. The G334D substitution was subcloned 
into SCN2A with the NotI restriction site nine nucleotides upstream of the start codon 
and the BssSI restriction site at nucleotide position 416. The R1744G mutation was 
subcloned into SCN2A with the NheI site at nucleotide position 4481 and the EcoRI site 
at nucleotide position 5192. 
 Each PCR and vector fragment was restriction digested and gel purified. The 
fragments were ligated together using T4 DNA Ligase. The ligation was transformed into 
MAX Efficiency Stbl2 competent cells and grown at 30°C for about four days. The 
purified DNA was digested with multiple restriction enzymes and sequenced fully to  
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Figure 31. Schematic of double overlap PCR. The top section shows the double 
stranded DNA separated to show the location of primer binding sites and the target 
mutation. The first round PCR pairs the forward outer primer with the reverse mutagenic 
primer and the forward mutagenic primer with the reverse outer primer. The first round of 
PCR thus results in two products that have corrected the mutation. The second round of 
PCR requires a few cycles to anneal the purified two first round products before addition 
of both outer primers. Once the final corrected product is made, the DNA can be cut with 
restriction enzymes for cloning into a vector. 
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exclude inadvertent mutations. Correct fully sequenced clones were then used in 
experiments as wild-type NaV1.2, WT-NaV1.2, or for subsequent mutagenesis. 
 
Construction of BFNIS mutants 
 We next attempted to construct the mutations reported in the literature 
associated with BFNIS (Figure 17A) (Heron et al., 2002; Berkovic et al., 2004). After 
construction of three BFNIS mutations (R1319Q, L1330F, and L1563V) were completed, 
several unsuccessful attempts using multiple strategies were made to construct three 
others (R223Q, V892I, and L1003I). Subsequently another report came out with two 
other BFNIS mutations (Herlenius et al., 2007) that we never attempted to construct. 
 The R1319Q mutation results from a G3956A nucleotide substitution. R1319Q 
disrupts a highly conserved internal arginine in the S4 transmembrane segment of 
Domain III (DIII) (Figures 17A and 32A). The primers used to construct R1319Q and the 
other BFNIS mutations are listed in Table 16. All mutants were constructed using the 
double overlap PCR strategy schematized in Figure 31. R1319Q was cloned into pCMV-
SCN2A using the BlpI site at position 3656 and the NheI restriction site at position 5156. 
The L1330F mutation results from a C3988T nucleotide substitution. L1330F is a highly 
conserved residue in the S4-S5 intracellular linker of DIII (Figures 17A and 32B). L1330F 
was subcloned into pCMV-SCN2A with the BglII site at position 3128 and the PshAI 
restriction site at position 4659. Finally, the L1563V mutation results from a C4687G 
transversion. This mutation disrupts a highly conserved residue in the S2 
transmembrane segment of Domain IV (DIV) (Figures 17A and 32C). L1563V was 
subcloned into pCMV-SCN2A with the BsrGI restriction site at position 4339 and the 
BsgI site at 5356. PCR fragments were restriction digested and gel purified. Similar to 
above, the PCR and vector fragments were ligated with T4 DNA Ligase and transformed 
into MAX Efficiency Stbl2 cells and grown at 30 °C for four days. Each of BFNIS 
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Figure 32. Sequence alignment for BFNIS mutants. (A) The evolutionary conservation of R1319Q and surrounding amino acids is 
shown for human voltage-gated sodium channels and channels in other species. The yellow box highlights the residue of interest. 
The R1319Q mutation is shown to affect a residue near the intracellular face of S4. (B) The evolutionary conservation of L1330F and 
surrounding amino acids is shown for human voltage-gated sodium channels and orthologs. The yellow box highlights the residue of 
interest. The L1330F mutation affects a residue in the intracellular S4-S5 linker. (C) The evolutionary conservation of L1563V and 
surrounding amino acids is shown for human voltage-gated sodium channels and channels in other species. The yellow box 
highlights the residue of interest. The L1563V mutation disrupts a highly conserved residue close to the extracellular face of S2. 
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constructs required screening of between 48 and 210 clones to find two independent 
clones without mutations to be utilized for electrophysiological and biochemical 
experiments.  
 
Results 
 
Optimization of heterologous expression system 
 To begin our heterologous expression studies of NaV1.2, we used the conditions 
previously established in our laboratory for the related NaV1.1 studies (Lossin et al., 
2002; Lossin et al., 2003; Rhodes et al., 2004; Ohmori et al., 2006). Briefly, we selected 
the tsA201 cell line, a derivative of human embryonic kidney, HEK293, stably expressing 
the SV40 large T antigen. The tsA201 cell line has low endogenous voltage-gated 
sodium current (< -100 pA in non-transfected tsA201 cells) and high vector expression 
(data not shown). We used a minimum threshold of -600 pA to ensure that any low 
endogenous sodium current would not significantly alter voltage dependent or kinetic 
properties of our NaV1.2 constructs. We discarded cells with sodium current greater than 
-6 nA to ensure adequate voltage control. A range of -600 pA to -6 nA is within the range 
reported in the literature for whole-cell voltage-gated sodium current from acutely 
isolated hippocampal neurons. 
 
Amount of DNA transfected 
 Previously, about 4 μg of the pore-forming α subunit was transfected in 
combination with β subunits. We performed preliminary experiments to determine what 
amount of NaV1.2 cDNA should be transfected and whether it should be cotransfected 
with hβ1 and hβ2. We transiently transfected 1, 2, or 4 μg of WT-NaV1.2 into tsA201 cells. 
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We cotransfected vectors containing either eGFP or both hβ1-IRES2-eGFP and hβ2-
IRES2-DsRed2 to keep a mass ratio of 10 α:1 eGFP or 10 α: 1 β1: 1 β2. 
 For cells transfected with 1 μg of WT-NaV1.2 and eGFP, only 36% had current 
greater than the minimum threshold of -600 pA (n = 14). Similarly, cells transfected with 
2 μg of WT-NaV1.2 and eGFP had 19% of cells with current greater than the minimum 
threshold (n = 16). Conversely, cells transfected with 4 μg of WT-NaV1.2 and eGFP had 
50% of cells pass the minimum threshold (n = 10). When we examined the three 
conditions in the presence of the hβ1 and hβ2 subunits, 25% of cells transfected with 1 
μg, 22% of cells transfected with 2 μg, and 83% of cells transfected with 4 μg of WT-
NaV1.2 had current that passed the minimum threshold (n ≥ 10 for each group). The 
current density-voltage relationships for the three different transfection amounts with 
cotransfection of either eGFP or the β subunits are shown in Figure 19. 
 
Amount of transfection reagent 
 Previous studies in our laboratory had used 36 μl of Superfect (Qiagen, Valencia, 
CA) with 4-5 μg of cDNA. We performed the above experiments with a standard 36 μl of 
Superfect. We also performed experiments on cells transfected with 4.5 μg of cDNA and 
72 μl of Superfect or 2.25 μg of cDNA and 18 μl of Superfect. Increasing the 
Superfect:DNA ratio by doubling the amount of cDNA and Superfect to 72 μl resulted in 
17% of cells passing the minimum threshold of -600 pA (n = 6). Keeping the 
Superfect:DNA ratio the same by halving the amount of each resulted in 25% of cells 
passing minimum threshold (n = 16). The experiments using between 1 and 4 μg of 
NaV1.2 cDNA transfected, cotransfected with either eGFP or the β subunits (Figure 33), 
and three transfection reagent ratios set up 4 μg NaV1.2, 0.5 μg hβ1, and 0.5 μg hβ2 with 
36 μl of Superfect as our standard transfection conditions for all future experiments 
(Figure 34).  
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Figure 33. Effect of amount of DNA transfected. (A) Current density-voltage relationship for cells cotransfected with three different 
amounts of NaV1.2 cDNA and eGFP. (B) Current density-voltage relationship from cells with three different amounts of NaV1.2 cDNA 
cotransfected with hβ1 and hβ2. We chose to use 4 μg of NaV1.2 cotransfected with both β subunits for subsequent experiments. (n  ≥  
4 for each condition). 
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Figure 34. Heterologous expression system. Here is a schematic diagram showing pertinent features of the heterologous 
expression system we employed for the electrophysiological experiments. This chapter describes several experiments to find optimal 
conditions for the heterologous expression system. We cotransfected 4.0 μg pCMV-SCN2A with 0.5 μg phβ1-IRES2-eGFP and 0.5 
μg phβ2-IRES2-DsRed2. We used 36 μl of Superfect in combination with our cDNAs to transfect tsA201 cells. We performed our 
whole-cell patch clamp experiments 48 to 72 hrs post transfection. Our inverted microscope for patch clamp experiments has a set of 
epifluoresence filters that allow us to detect cells that are expressing the eGFP and DsRed2 fluorophores. Cells that are expressing 
both fluorophores appear yellow and are presumed to have been successfully transfected with all three plasmids. 
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Cell line comparison 
Our laboratory had previously used tsA201 cells to characterize NaV1.1 (Lossin 
et al., 2002; Lossin et al., 2003; Rhodes et al., 2004; Rhodes et al., 2005; Ohmori et al., 
2006; Kamiya et al., 2004). Previous studies of NaV1.2 used CHO-K1 and HEK293 cells 
(Ahmed et al., 1992). We performed some preliminary experiments with NaV1.2, hβ1, and 
hβ2 cotransfected into tsA201 and CHO-K1 cells (Figure 35). We also found that 
currents from tsA201 cells were larger than CHO-K1 cells (Figure 35). We decided to 
perform all subsequent experiments in tsA201 cells using the amount of cDNA and 
transfection reagent described above (Figure 34). 
 
Optimization of whole-cell patch clamp conditions 
Time after transfection 
 We next sought to determine how long after transfecting cells we should perform 
electrophysiological experiments. Previous studies from our laboratory with the highly 
homologous NaV1.1 protein were conducted 24 to 48 hrs after transfection (Lossin et al., 
2002; Lossin et al., 2003; Rhodes et al., 2004; Rhodes et al., 2005; Ohmori et al., 2006). 
We decided to see whether the optimum time to do experiments would be 24, 48, 72, or 
96 hrs after transfection. At each of these time points we performed whole-cell patch 
clamp experiments to see what percentage of cells had current greater than the 
minimum threshold of -600 pA. At 24 hrs, there were many fewer cells that appeared 
yellow (denoting presence of both hβ1 and hβ2) or red (denoting presence of hβ2). This 
was likely caused by the slower time course of DsRed2 maturation compared to other 
fluorophores and that it appears green early in maturation before turning red (Verkhusha 
et al., 2004). When we patched yellow cells 24 hrs post transfection, only 15% of cells 
passed our current threshold. The 48 and 72 hr time points had 44% and 63% of cells 
pass threshold respectively. Only 8% of cells at 96 hrs after transfection had current 
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Figure 35. Comparison of WT-NaV1.2 in two cell lines. (A) Current density-voltage relationship for cells that transiently expressed 
WT-NaV1.2 with β1 and β2 in tsA201 and CHO-K1 cells. The current density is significantly larger over the -80 to -10 mV voltage 
range for tsA201 cells compared to CHO-K1 cells (p ≤ 0.05). (B) The voltage dependence of activation curves are similar for WT-
NaV1.2 in tsA201 and CHO-K1 cells. The V1/2 for activation was    -40.6 ± 0.7 mV for tsA201 cells and -35.0 ± 0.5 for CHO-K1 cells. 
The k for activation was 11.4 ± 0.6 for tsA201 cells (n = and 18) 10.6 ± 0.5 for CHO-K1 cells (n = 15).  
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greater than our threshold (n = 12 - 16 for each time point). We chose to continue 
experiments only within 48 to 72 hrs post transfection (Figure 34). 
 
Time after establishing whole-cell configuration 
 We next wanted to determine how long after establishing the whole-cell 
configuration the electrophysiological recordings should be performed. Previous studies 
of NaV1.1 began experiments ten minutes after establishing the whole-cell configuration. 
Because initial experiments with NaV1.2 showed high variability, we decided to perform a 
time course by running a family of 20 ms voltage steps to between -80 and 60 mV from a 
holding potential of -120 mV. We then converted the peak currents at each test potential 
to normalized conductances and fitted the data with a Boltzmann equation to look at the 
voltage dependence of activation. We did recordings in two minute increments beginning 
just after establishing the whole-cell configuration and ending at 30 minutes. In Figure 
36, we show two representative time points, 10 and 20 minutes, to illustrate that we 
observed a time-dependent hyperpolarizing shift in the voltage dependence of activation, 
similar to that previously observed for NaV1.1 (Vanoye et al., 2006). We decided to do all 
subsequent experiments 15 min after establishing the whole-cell configuration to allow 
for equilibration of the internal pipette solution, stabilization of variability, and to decrease 
the length of all experiments. 
 
Holding potential 
 In preliminary experiments, we found a high amount of variability in recordings 
and saw that the voltage dependence of fast inactivation data was inconsistently 
affected by the most negative potentials (-120 to -140 mV) we examined (data not 
shown). We had been using a holding potential of -120 mV and decided to see if a 
holding potential of -150 mV might improve either of these parameters. We performed 
  
165
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. Effect of holding potential and time course. (A) The current density-voltage relationships for WT-NaV1.2 from a holding 
potential of -120 or -150 mV at 10 and 20 minutes after establishing the whole-cell configuration. (B) Voltage dependence of 
activation for WT-NaV1.2 from a holding potential of -120 and -150 mV at 10 and 20 minutes after establishing the whole-cell 
configuration. The V1/2 for 10 minutes from -120 mV is -32.3 ± 4.1, 10 minutes from -150 mV is -30.7 ± 4.2, 20 minutes from -120 mV 
is -38.6 ± 3.3, and 20 minutes from -150 mV is -36.4 ± 3.5. The k for voltage dependence of activation for 10 minutes from -120 mV is 
8.0 ± 0.5, 10 minutes from -150 mV is 8.2 ± 0.5, 20 minutes from -120 mV is 8.2 ± 0.4, and 20 minutes from -150 mV is 8.8 ± 0.4. (n 
= 7-9 for each condition).  
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these experiments concurrently with the above experiments on amount of time after 
establishing the whole-cell configuration. In Figure 36, current density-voltage 
relationships and voltage dependence of activation are shown for 10 and 20 min after 
establishing whole-cell configuration from holding potentials of both -120 and -150 mV. 
We found that the holding potential of -150 mV did not decrease variability but did 
increase the difficulty of the experiments since cells were not as stable when held at 
such a hyperpolarized potential (Figure 36). We subsequently used -120 mV for a 
holding potential and began our recordings 15 min after establishing the whole-cell 
configuration between 48 and 72 hrs post transfection. 
 
Discussion 
 Heterologous expression systems have been a fundamental tool for 
understanding the functional impact of disease-causing mutations. Electrophysiological 
experiments in a heterologous expression system can provide rapid functional data 
about disease-causing mutations. In particular for the neuronal voltage-gated sodium 
channels, NaV1.1 and NaV1.2, epilepsy-associated mutations have been investigated 
using whole-cell patch clamp of tsA201 or CHO-K1 cells.  
 In this appendix, we described the construction of a human SCN2A cDNA and 
specific methods employed for construction of BFNIS associated NaV1.2 mutations for 
electrophysiological study. We then conducted a series of preliminary experiments to 
optimize our heterologous expression system to achieve a high level of NaV1.2 
expression conducive for functional testing. We also conducted a series of preliminary 
experiments to optimize our electrophysiological recordings. From these experiments, 
we were able to establish baseline conditions to perform functional characterizations of 
WT-NaV1.2 and three BFNIS mutants (R1319Q, L1330F, and L1563V). These studies 
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will increase our understanding of mechanisms underlying neuronal excitability disorders 
including benign monogenic epilepsies. 
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APPENDIX B 
 
CHARACTERIZATION OF NEURONAL SODIUM CHANNELS FROM MUTANT 
Scn2a TRANSGENIC MICE WITH DIFFERING SEIZURE SUSCEPTIBILITY 
 
Introduction 
 Animal models allow for investigation of mechanisms underlying epilepsy in a 
more physiological setting than heterologous expression studies. The early animal 
models of epilepsy involved seizure induction in animals by administration of chemicals 
like pilocarpine or pentylenetetrazole (PTZ) or by electrical stimulation as in kindling 
protocols. Alternatively, spontaneous mutations in inbred mouse and rat strains, like 
slow-wave epilepsy (swe) or stargazer (stg), have resulted in a variety of epilepsy 
phenotypes. More recent animal models of epilepsy are the result of genetically altering 
animals through knockout or transgenic expression of specific genes (Frankel, 1999; 
Bertram, 2007). 
Early investigations of voltage-gated sodium channels created substitutions in 
different regions of the predicted channel topology to determine functional domains. The 
substitutions were then characterized in a heterologous expression system. One 
mutation that increased persistent current and impaired whole-cell current inactivation in 
Xenopus oocytes was the GAL879-881QQQ mutation located in the S4-S5 intracellular 
linker of DII of rat Scn2a (Smith and Goldin, 1997). This is a region of the sodium 
channel now implicated in fast inactivation by interacting with the fast inactivation gate. 
 Prior to the identification of epilepsy-associated mutations in neuronal voltage-
gated sodium channels, the GAL879-881QQQ mutation in rat Scn2a was introduced as 
a transgene into mice. The transgene was driven by the neuronal specific enolase (NSE) 
promoter and contains a FLAG epitope in close proximity to the ATG of Scn2a (Figure 
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46A). The original characterization was of transgenic mice (Q54) with a mixed 
background comprised mostly of C57BL/6J and (12-25%) SJL/J (Table 4). The Q54 
mice had spontaneous seizures originating in the hippocampus around two months, one 
month after increased persistent current could be observed in acutely isolated 
hippocampal neurons (Kearney et al., 2001).  
The Q54 mice were then bred onto a congenic C57BL/6J background (B6.Q54) 
where a significant decrease in the number of seizures, the number of mice with 
seizures, and seizure severity were observed compared to the mice from a mixed 
background (Bergren et al., 2005). A forward cross with the SJL/J line was performed 
resulting in F1.Q54 mice that are 50% C57BL/6J and 50% SJL/J. The F1.Q54 mice had 
a significantly higher incidence of seizures, increased seizure severity, and a shorter 
lifespan compared to the B6.Q54 mice. A genome wide scan identified two loci 
(modifiers of epilepsy, MOE1 and MOE2) that could account for the majority of the 
difference in seizure susceptibility between the two backgrounds (Bergren et al., 2005). 
Although genetic modifiers modulate the seizure susceptibility in these mice, it is 
unknown whether the modifiers modulate the voltage-gated sodium channels directly or 
modulate a different protein such as another ion channel or cytoskeletal protein. We 
hypothesized that the difference in seizure susceptibility was due to the genetic modifier 
directly affecting the function of the sodium channel transgene. We sought to determine 
the effect of the modifier on the sodium channel using two different methods: 
electrophysiology and biochemistry. The electrophysiological experiments were 
performed on acutely isolated hippocampal neurons and the biochemical experiments 
were performed on membrane preparations isolated from whole mouse brain. Below we 
describe steps to optimize these experiments and results from our preliminary 
characterization of brain sodium channels from the two Q54 mouse lines (B6.Q54 and 
F1.Q54) with differing seizure susceptibility. 
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Materials and methods 
 
Preparation of neuronal cultures 
 Mice aged between postnatal (P) day P21 and P23 were deeply anesthetized 
with isoflurane (MINRAD Inc., Orchard Park, NY). The animals were decapitated with 
surgical scissors (unless otherwise noted, all surgical tools were from Fine Science 
Tools Inc., Foster City, CA) and the heads were soaked in a beaker of 70% ethanol. The 
dissection was performed in less than 30 minutes from the point of decapitation to 
getting the tissue in trypsin to increase cell viability as determined by counting cells with 
trypan blue (Invitrogen Corp., Carlsbad, CA) staining. The skin and skull were cut along 
midline using small angled scissors. Curved forceps were used to remove the overlying 
skull. The brain was removed and put into 4 ml of ice cold sterile filtered dissection 
solution with 0.2% penicillin/streptomycin (in mM): 145 NaCl, 3 KCl, 10 HEPES, 5.6 
glucose, pH of 7.3 or Hanks’ balanced salt solution (HBSS) (product number H9394, 
Sigma. St. Louis, MO). This was repeated for each mouse. Then one brain at a time was 
put on a fresh piece of grade number 1 Whatman filter paper (VWR International, West 
Chester, PA) and the cerebellum was removed. Then the brain was hemisected, and 
one hemisphere was put into a 35 mm petri dish with 4 ml of fresh ice cold sterile filtered 
dissection solution until ready for hippocampal dissection.  
The other hemisphere was oriented with the cortex towards the filter paper and 
the midbrain facing up. The midbrain was removed using one hippocampus tool while 
the underlying hippocampus and cortex was protected with another hippocampus tool. 
The brain was reoriented so the anterior part was facing up. The hippocampus was 
removed with the rounded edge of the hippocampus tool and placed into a new 35 mm 
dish with 4 ml of fresh ice cold sterile filtered dissection solution. This was repeated until 
each hippocampus was removed. One hippocampus at a time was cut into two or three 
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pieces while in the dissection solution using a #20 scalpel blade (Roboz Surgical 
Instrument Co., Gaithersburg, MD). The piece of hippocampus was put on a fresh piece 
of Whatman filter paper with the cut face down and was kept moist with dissecting 
solution. The convex surface, presumed to be mostly CA1 region, under a dissecting 
microscope (Carl Zeiss Microimaging, Inc., Thornwood, NY) was removed and put into a 
new 35 mm dish with 4 ml of fresh ice cold sterile filtered dissection solution. This was 
repeated until all pieces of CA1 were in one dish. 
Next the CA1 tissue was trypsinized by combining 5 ml of ice cold dissection 
solution with 3 mg of Trypsin (Research Products International Corp., Mt. Prospect, IL) 
and sterile filtering directly into a new 35 mm dish. The pieces of CA1 were transferred 
using a sterile transfer pipette into the trypsin. The tissue was digested at room 
temperature using room air for 30 min. The dish was swirled every 10 min to ensure 
even distribution of trypsin to the CA1 tissue. After the trypsin digest was complete, the 
tissue was transferred to a dish with 5 mL dissection solution and swirled for 30 sec. 
This was repeated in three more times for a total of four washes each time using a new 
sterile transfer pipette. 
After thoroughly washing the trypsinized tissue, a sterile transfer pipette was 
used to move just the CA1 pieces to a 15 ml conical tube containing plating media (84% 
Neurobasal-A, 8% F-12, 8% FBS, 0.2% penicillin/streptomycin, 0.08 mM L-glutamine). 
The volume of plating media depended upon the number of animals and size of tissue 
digested. The least volume ever used was 1 ml (for one mouse only) and the maximum 
was 3 ml (when three or four mice were used).  Typically the dissection was performed 
on two mice of the same genotype and the tissue was triturated in 2 ml. The trituration 
was performed with a long Pasteur pipette that was lightly fire polished at the tip just 
prior to use. The tissue was triturated about 40 times or until the plating media was quite 
cloudy and small tissue pieces. When the tissue was triturated 20 times, the cell count 
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was too low and if the tissue was triturated > 80 times, the cell count increased but the 
cell viability decreased. The contents of the 15 ml conical tube (both media and 
remaining chunks of tissue) were passed through a 40 μm cell strainer (BD Biosciences, 
San Jose, CA) into a sterile 50 mL conical tube. From this tube, 25 μl were put into a 
sterile 1.5 ml tube with 25 μl of Trypan blue stain to count live and dead cells. The 
remaining cell suspension was plated in 250-275 μl volumes in the center glass coverslip 
of poly-d-lysine coated 35 mm dishes (MatTek Corp., Ashland, MA). The dishes were 
put in a 37 °C incubator humidified with 5% CO2 for two hours. The dish was then 
washed with 1 ml of media (either plating media as described above or maintenance 
media containing 98% Neurobasal-A, 2% B-27 supplement, and 0.2% 
penicillin/streptomycin). The media was aspirated and then 2 ml of fresh plating or 
maintenance media were added to each dish. The dishes were then returned to the 
incubator until they were used for whole-cell patch clamp studies. If the dishes were 
maintained in the incubator longer than 48 hrs, then 1 ml of the media was aspirated and 
replaced with 1 ml fresh media. 
 
Electrophysiological recording 
 Whole-cell voltage-clamp recordings were used to characterize the functional 
properties of voltage-gated sodium channels, as described previously with some small 
modifications (Lossin et al., 2002; Lossin et al., 2003; Rhodes et al., 2004; Ohmori et al., 
2006). Sodium channel currents were recorded at room temperature, 1 to 75 hrs after 
neuron plating. We identified isolated neurons with phase bright membranes and no 
blebbing that appeared somewhat pyramidal in morphology (branching level depended 
upon time after dissection as seen in Figure 38). Neurons were photographed using a 
Moticam 3000 camera and Motic Images Advanced 3.2 software (Motic, Richmond, 
British Columbia, Canada) to document cell morphology. After obtaining the whole-cell 
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configuration, another picture was taken and one last picture at the end of the recording 
to document changes in morphology over the course of the experiment. 
Patch pipettes were fabricated from custom 8520 patch glass (Warner Instrument 
Co., Hamden, CT) using a multistage P-97 Flaming-Brown micropipette puller (Sutter 
Instruments Co., San Rafael, CA) and fire-polished by using a microforge (MF 830, 
Narashige, Japan). Pipette resistance was between 1.4 and 4.0 MΩ (but ideally between 
2.0 and 2.5 MΩ).  The pipette solution consisted of (in mM) 140 CsF, 10 NaCl, 1 EGTA, 
10 HEPES, with a pH of 7.3. The bath solution was comprised of in (mM): 140 NaCl, 3 
KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, with a pH of 7.3. The dish of neurons was rinsed 
three times with freshly filtered extracellular bath solution and then filled with 2 ml of 
freshly filtered extracellular bath solution. Each dish was allowed to equilibrate for 10 min 
prior to the first recording and was discarded within 90 min of adding the extracellular 
solution. The reference electrode consisted of a 2% agar bridge with composition similar 
to the bath solution. Cells were allowed to stabilize for 10 min after establishment of the 
whole-cell configuration before current was measured. Cells exhibiting peak current 
amplitudes < -0.5 nA were excluded from analysis of biophysical properties to avoid 
contamination of noise in recordings and high levels of current at holding potential (leak 
current). Whole-cell capacitance and access resistance were determined by integrating 
capacitive transients in response to voltage steps from −100 to −110 mV filtered at 10 
kHz. Series resistance was compensated 90-95%. Leak currents were subtracted by 
using an online P/4 procedure. All data were low-pass Bessel filtered at 5 kHz and 
digitized at 50 kHz. 
 Specific voltage-clamp protocols assessing channel activation and voltage 
dependence of fast inactivation were used as described previously with small 
modifications (Lossin et al., 2002; Lossin et al., 2003; Rhodes et al., 2004; Ohmori et al., 
2006) and illustrated as panel insets in the figures. All voltage-clamp protocols utilized a 
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holding potential of –100 mV and a 60 sec interpulse at the holding potential between 
sequential protocols. The holding potential was -100 mV to prevent channels from 
opening or inactivating between test pulses but was not more hyperpolarized because 
that destabilized the neurons. Voltage steps (20 ms) to between –80 to +60 mV in 5 mV 
increments were used to create a family of voltage-gated inward sodium current traces. 
The peak current was normalized for cell capacitance and plotted against voltage to 
generate peak current density-voltage relationships. Conductance (GNa) was calculated 
as GNa = I/(V – Erev) where I is the measured peak current, V is the test voltage, and Erev 
is the calculated sodium reversal potential. To provide a quantitative evaluation of the 
voltage dependence of activation, normalized G-V curves were fit with a Boltzmann 
function, G/Gmax = (1 + exp[(V – V1/2)/k])-1, where V1/2 is the curve midpoint indicating the 
voltage at which half of the channels are activated and k is a slope factor corresponding 
with voltage sensitivity of the channel. These parameters define the magnitude of 
depolarization needed for channel opening. Voltage dependence of fast inactivation was 
assessed by 100 ms prepulses to between –140 to –10 mV in 10 mV increments 
followed by a 20 ms test pulse to –10 mV. The normalized current is plotted against the 
voltage and the data were fit with Boltzmann functions to determine the voltage for half-
maximal inactivation (V1/2) and a slope factor (k). Voltage dependence of fast inactivation 
provides information about the level of depolarization necessary for the channel to enter 
fast inactivation under steady-state conditions including the physiological range of 
potentials. When a neuron was stable, persistent current was evaluated during the final 
10 ms of a 200 ms depolarization to −10 mV and expressed as a percentage of peak 
current following digital subtraction of currents recorded in the presence and absence of 
10 µM tetrodotoxin (TTX).  
            Results are presented as mean ± SEM unless otherwise noted. Data analysis 
was performed using Clampfit 9.2 (Axon Instruments, Union City, CA), Excel 2002 
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(Microsoft, Seattle, WA), GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA), 
and OriginPro 7.0 (OriginLab, Northampton, MA) software. 
 
Membrane preparations 
For biochemical experiments from transgenic mice, we performed membrane 
isolations from whole brain as previously described with a few modifications (Hartshorne 
and Catterall, 1984). As described above, young mice (P21-P23) were deeply 
anesthetized with isoflurane and rapidly decapitated. The brain was dissected, weighed, 
and put in an ice cold Dounce homogenizer. Solution 1 comprised of 0.32 M sucrose 
and 5 mM Tris/HCl with a pH of 7.4 was sterile filtered and supplemented with complete 
protease inhibitor cocktail tabs, EDTA free (Roche Applied Science, Indianapolis, IN). 
Ice cold solution 1 (10 ml per gram of brain tissue) was added to the Dounce 
homogenizers and the brains were homogenized with 10 strokes. The homogenate was 
transferred to round bottom 14 ml falcon tubes and centrifuged at 700 x g for 10 min. 
The supernatant was saved and the pellet was resuspended in ice cold solution 1 
supplemented with protease inhibitors at 6.6 ml per gram of original tissue. The new 
homogenate was centrifuged in 14 ml falcon tubes at 700 x g for 10 min. The 
supernatant was combined with the previous supernatant in an Oak Ridge tube and the 
pellets were discarded. The supernatants were spun at 27,000 x g for 40 min. The 
supernatant was discarded. The pellet was resuspended in solution 2 in a volume of 
16.6 ml per gram of original tissue to cause osmotic lysis of cells in the homogenate. 
Solution 2 is comprised of 5 mM Tris/HCl with a pH of 8.2 and 1 mM EDTA 
supplemented with the protease inhibitors described above. The suspension was 
incubated on ice for 15 min and then homogenized for 4 strokes with the Dounce 
homogenizer. The homogenate was then spun at 27,000 x g for 40 min. The supernatant 
was discarded. The pellet was resuspended in solution 3 supplemented with protease 
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inhibitors at a volume of 2 ml per gram of tissue. Solution 3 contained 200 mM KCl, 10 
mM HEPES, adjusted with 1 M Tris-base to pH 7.5. The concentration of each 
membrane preparation was determined using the BCA protein assay kit (Pierce 
Biotechnology, Rockford, IL). 
The samples (25 μg of each as determined by the BCA assay) were mixed with 
2X Laemmli Sample Buffer containing fresh 5% β-mercaptoethanol. The samples were 
incubated at 65 °C for 20 min prior to being separated using SDS-polyacrylamide (7.5%) 
gel electrophoresis and transfer to polyvinylidene difluoride membranes. Membranes 
were incubated at room temperature for two hours in 5% milk. The transgene was 
detected with primary antibodies directed against the FLAG epitope (mouse, anti-FLAG 
M2, 1:15000, Sigma). Immunoreactive bands were visualized using horseradish 
peroxidase-conjugated secondary antibody (goat anti-mouse, 1:100000, Santa Cruz 
Biotechnology, Santa Cruz, CA), directed against the primary antibody, Super Signal 
West Femto Maximum Sensitivity Substrate (Pierce Biotechnology, Rockford, IL) 
incubation and Hypersensitive film detection.  
 
Results 
We optimized several conditions for recording from acutely isolated CA1 
hippocampal neurons. We used optimized conditions to record from neurons expressing 
the GAL879-881QQQ transgene in the B6.Q54 and F1.Q54 background strains to look 
for differences in sodium current. We also used western blot analysis of membrane 
preparations from whole brains to examine transgene expression of both background 
strains. 
Cell plating 
We began by performing hippocampal dissections on wild-type (WT) mice to 
optimize methods. We plated isolated neurons on 35 mm Corning dishes that were 
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uncoated, but the neurons would not adhere well. We next tried coating the dishes with 
poly-l-ornithine (PLO) in a borate buffer (0. 5 mg PLO per ml of buffer), but this proved 
difficult to standardize. We then used pre-coated dishes coated with collagen or poly-d-
lysine coating on a glass coverslip in the middle of the plastic dish from MatTek 
Corporation (Ashland, MA). We found that the MatTek dishes with the poly-d-lysine 
coating worked best and used them for subsequent experiments (including the majority 
of the experiments described below). 
We plated 250 μl of cell suspension in the center of the dish and filled the other 2 
ml of media within 10 minutes. The original plating method resulted in glial proliferation 
and a large amount of debris remaining on the dish. We found that performing the 
trituration in plating media and plating 250-275 μl in the center of the dish allowing 2 hrs 
for settling time and adherence was optimal (1 hr was too short for adherence and 3.5 – 
4 hrs was too long to remove most of the debris). After 2 hrs, 1 ml of maintenance media 
was used to wash the dish and then 2 ml of maintenance media were added to the dish. 
If the dishes were maintained longer than 48 hrs, then 1 ml of media was removed and 
replaced with 1 ml of fresh maintenance media. All dishes were used within 72 hrs of 
neuron plating. 
 
Optimization of pipettes 
During our initial recordings, we noticed that the opening of the pipette was too 
large and resulted in most of the neuron being drawn up into the pipette. This could be 
seen visually through the microscope or by measuring the capacitance of the neuron. 
We started performing whole-cell recordings using thin wall borosilicate glass we had 
previously used for our heterologous expression studies with pipette resistances of 
between 1.0 and 2.0 MΩ. We tried to increase the resistance and decrease the size of 
the pipette opening, but were unsuccessful in making the tip small enough. We tried four 
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different types of glass before settling on a custom patch glass from Warner Instruments 
with a resistance of between 2.0 and 4.0 MΩ as the optimal condition for all subsequent 
experiments. 
 
Time after dissection 
Based upon the literature, we began electrophysiological experiments 1 hr after 
plating neurons. At early time points after dissection, we saw either no or very small (≤ -
200 pA) inward voltage dependent currents (Figure 37A). We slowly lengthened the time 
between dissection and electrophysiological experiments. Prior to the Moticam 3000 
installation, we successfully obtained a recording from one WT neuron approximately 7 
hrs after dissection (Figure 37B). Other than the one recording presented in Figure 37B, 
no other neurons patched less than 48 hrs post dissection had inward voltage-
dependent current > -500 pA. Another difficulty with recording 1 to 24 hrs after plating 
was the spherical shape of the neurons that makes morphological identification of 
neurons difficult (Figure 38A). We found that after 48 hrs the morphology was no longer 
spherical and by 72 hrs there was extensive branching of the neurons (Figure 38B). 
Although we initially planned to record from CA1 pyramidal neurons, we decided to 
record from any healthy neurons because the NSE promoter used to drive the Scn2a 
transgene (Figure 46A) is expressed in all neurons. We recorded from neurons that had 
phase bright membranes without blebbing, and that had at least one intact process.  
 
 
Properties of B6.Q54 neurons 
After setting optimal conditions by using WT mice, we recorded from neurons 
isolated from B6.Q54 mice, the mice with the less severe seizure phenotype. We had 
difficulty discerning neuronal type by morphology, but chose neurons that looked healthy
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Figure 37. Representative whole-cell traces from WT neurons. (A) Typical recording from initial experiments when most of the 
neuron was drawn up into the pipette. The capacitance of this cell was 2 pF. (B) Best recording from a WT neuron collected 7 hrs 
post dissection. The neuron had a capacitance of 5.6 pF and a maximum inward peak current of -1.0 nA. The red trace indicates the 
step to -10 mV. 
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Figure 38. Representative neuronal morphologies. (A) Picture of a neuron about 20 hrs post dissection. The neuron had no 
voltage-gated inward current but highlights the rounded nature of neurons less than 48 hrs post dissection. (B) Picture of a neuron 
about 48 hrs after dissection which still has very little branching. The peak inward current was -100 pA. (C) Picture of a neuron 67 hrs 
post dissection showing extensive branching of processes. The neuron had a peak inward current of -300 pA. 
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and had at least one intact process. We obtained recordings of voltage-gated sodium 
channel currents from four B6.Q54 neurons that each had current ≥ -900 pA (Figures 39 
– 41). Representative traces are shown for each neuron in Figures 39C and 41. Based 
on earlier experiments, we used a holding potential of -100 mV to limit channel 
inactivation and maximize membrane potential stability. We ran standard protocols to 
look at current density-voltage relationships, voltage dependence of activation and fast 
inactivation (Figures 42, 43A and Table 17). For two of the neurons we also examined 
persistent current by recording a 200 ms test pulse in the absence and presence of TTX 
(Figure 43B and Table 17). Both B6.Q54 neurons examined had persistent current with 
a mean of 4.4 % of peak current. 
 
Properties of F1.Q54 neurons 
Since fewer F1.Q54 animals were available and there were time constraints, we 
performed fewer experiments on neurons isolated from F1.Q54 mice. We were only able 
to obtain recordings from one neuron (Figure 44A). The representative trace for this 
neuron is shown in Figure 44B. We examined the current density-voltage relationship 
and voltage dependences of activation and fast inactivation (Figure 45 and Table 17). 
More studies need to be performed before any conclusions can be drawn. 
 
Transgene protein expression levels 
We performed western blot analysis on membrane preparations from whole 
mouse brain of B6.Q54, F1.Q54, or WT littermates. The transgene contains a 
singleFLAG epitope at the N terminus of Scn2a (Figure 46A) (Kearney et al., 2001). We 
addressed the question of whether the transgene was expressed at different levels in
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Figure 39. B6.Q54 neuron. (A) A picture of a B6.Q54 neuron 48.5 hrs after dissection. (B) Picture of the same B6.Q54 neuron with 
pipette sealed onto neuron. (C) Representative trace from this neuron with the red line indicating the step to -10 mV. The 
capacitance of this neuron was 21 pF and the maximum peak current was -1.55 nA. The current density-voltage relationship and 
other biophysical parameters are presented in Figures 42 and 43. 
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Figure 40. Pictures of B6.Q54 neurons. (A) Picture of a B6.Q54 neuron 70 hrs after dissection. The capacitance of the neuron was 
18 pF and the maximum peak inward current was -2.0 nA. (B) Picture of a B6.Q54 neuron 71 hrs after dissection. This neuron had a 
capacitance of 21 pF and a maximum peak inward current of -900 pA. (C) Picture of a B6.Q54 neuron 69 hrs post dissection with a 
capacitance of 39 pF and a maximum peak inward current of -1.2 nA. The representative traces for each of these neurons are shown 
in Figure 41. The biophysical parameters of these neurons are shown in Figures 42 and 43. 
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Figure 41. Representative whole-cell traces from B6.Q54 neurons. Representative 
traces in response to 20 ms voltage steps from a holding potential of -100 mV to 
between -80 and +60 mV. The red line indicates the step to -10 mV. The scale bars are 
as shown for each panel. (A) Representative trace for neuron in Figure 40A with a peak 
current of -2.0 nA and a capacitance of 18 pF. (B) Representative trace for neuron in 
Figure 40B that has a capacitance of 21 pF with a peak current of -900 pA. (C) 
Representative trace for neuron in Figure 40C. This neuron had a capacitance of 39 pF 
and a peak current of -1.2 nA. 
 
  186
  187
  
 
 
 
 
 
 
 
 
 
 
 
Figure 42. Activation properties of B6.Q54 neurons. (A) Current density-voltage 
relationship for B6.Q54 neurons (n = 4, pictures of neurons and representative traces 
shown in Figures 39 – 41). (B) The normalized conductance-voltage curve shows the 
voltage dependence of activation for B6.Q54 neurons (n = 4 as described above). The fit 
parameters are shown in Table 17 and the voltage protocol is shown as panel inset. 
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Figure 43. Fast inactivation and persistent current of B6.Q54 neurons. (A) Voltage 
dependence of fast inactivation for B6.Q54 neurons (n =4). The fit parameters are shown 
in Table 17 and the voltage protocol is shown as panel inset. (B) Persistent current 
properties of B6.Q54 neurons (n = 2, neurons in Figures 39 and 40A). The TTX sensitive 
current is shown as a percentage of peak current over the 200 ms pulse duration. The 
mean persistent current is shown in Table 17. 
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Figure 44. F1.Q54 neuron. (A) ) A picture of one F1.Q54 neuron 45 hrs after dissection. (B) Picture of the same F1.Q54 neuron with 
pipette sealed onto neuron. (C) Representative trace from this neuron with the red line indicating the step to -10 mV. The 
capacitance of this neuron was 15 pF and the maximum peak current was -850 pA. The current density-voltage relationship and 
other biophysical parameters are presented in Figure 45. 
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Figure 45. Biophysical parameters for F1.Q54. (A) Current density-voltage relationship for the F1.Q54 neuron depicted in Figure 
44. (B) Voltage dependence of activation for the neuron in Figure 44. (C) Voltage dependence of fast inactivation for F1.Q54 neuron. 
The fit parameters are shown in Table 17 and the voltage protocols were the same as the inset in Figure 42B and 43A. 
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Persistent Current
 Mean (% of peak)         n 
Voltage dependence  
of fast inactivation 
V1/2 (mV)       k (mV)       n 
Voltage dependence 
of activation 
 V1/2 (mV)       k (mV)        n 
B6.Q54         -26.9 ± 1.7     6.6 ± 0.4      4     -66.4 ± 1.8     8.6 ± 0.8      4              4.4 ± 3.5                     2 
                        
 F1.Q54              -34.9              8.3          1           -70.4             8.1          1       
Table 17. Biophysical parameters of B6.Q54 and F1.Q54 neurons 
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two strains of mice.  We were able to detect the transgene in membrane preparations 
isolated from B6.Q54 and F1.Q54 (Figure 46B). The transgene was specifically detected 
because the WT littermate lacked a signal at the same molecular weight (Figure 46B). 
 
Discussion 
In this appendix, we described our attempts to record from acutely isolated 
neurons and study transgene expression levels from two transgenic mouse lines with 
differing seizure susceptibility. These studies were preliminary and need to be repeated 
but provided the infrastructure in the laboratory and setup optimal conditions for 
conducting these and future experiments. 
We found that B6.Q54 neurons have a current density-voltage relationship, 
voltage dependence of activation and fast inactivation similar to those reported in the 
literature (Figures 42, 43A). The recordings from F1.Q54 also appear similar to those 
reported in the literature (Figure 45) and to those from B6.Q54 (Figures 42, 43A). Based 
on the data we have collected, there seems to be a preliminary difference in the voltage-
gated sodium currents generated from neurons isolated from Q54 transgenic mice from 
the two background strains. The voltage dependences of activation and fast inactivation 
for the F1.Q54 neuron were both hyperpolarized in comparison to B6.Q54. If this holds 
true with increased replicates, then this may suggest that the modifier is altering the 
sodium channel directly. Increased persistent current was previously seen in the 
neurons isolated from Q54 animals of mixed background (Kearney et al., 2001). We 
examined the neurons isolated from B6.Q54 mice and found increased persistent 
current with a mean of 4.4% (Figure 43B) instead of the previously observed 2% of peak 
current (Kearney et al., 2001). Although more experiments need to be performed, the 
presence of increased persistent current in the mice with less severe seizures suggests 
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Figure 46. Transgene expression in B6.Q54 and F1.Q54 animals. (A) Schematic 
diagram showing the structure of the Q54 transgene. Key features include the NSE 
promoter, start site (ATG) for Scn2a, FLAG epitope, and Scn2a coding sequence. (B) 
Representative western blot analysis of membrane preparations probed with anti-FLAG 
antibody to examine transgene levels. Lane 1 was isolated from B6.Q54, lane 2 from a 
WT littermate control mouse, and lane 3 is isolated from F1.Q54. The arrows indicate 
transgene detection at ~260 kDa molecular weight. 
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that the genetic modifiers are not affecting the persistent sodium current caused directly 
by the mutant sodium channel. After confirmation of elevated persistent current and a 
more thorough examination of voltage dependent properties in neurons isolated from 
F1.Q54 mice, voltage clamp recordings isolating potassium current or current clamp 
recordings would aid in determining how the genetic modifiers are altering neuronal 
excitability. 
We performed western blot analysis to determine if the mutant Scn2a transgene 
was expressed at different levels in the two background strains. The western blot 
analysis of the membrane preparations from the whole brain of B6.Q54 and F1.Q54 
revealed no differences in the transgene expression (Figure 46B). Our detection may not 
be sensitive enough to pick up differences in the protein expression at this point, but 
perhaps more optimization could reveal differences. The protein samples were loaded 
based on concentration estimates from performing the BCA assay. The samples are 
probably not equally loaded as seen by nonspecific bands at lower molecular weights 
(Figure 46B). Future experiments need to load more equivalent amounts of each protein 
sample. We would also be interested to examine the transgene to endogenous NaV1.2 
expression ratio and see if the ratio differs between the two background strains. The 
data from these two experiments are another way to determine if the genetic modifiers 
directly modulate the sodium channel transgene. 
Ultimately animal models will help investigate defects in neuronal excitability in 
ways that other model systems cannot address. For example, animal models allow us to 
test physiological questions that cannot be assessed through in vitro studies. Though the 
findings presented in this chapter are preliminary results, they demonstrate avenues for 
further investigation with regards to genetic modifiers that may contribute to better 
understanding phenotypic variability in genetic forms of epilepsy. Animal models, 
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including the Q54 animals used in above experiments, can be useful tools for testing 
new therapeutic agents as treatment options for specific forms of epilepsy. 
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